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GENERAL INTRODuCTION
In the Netherlands the incidence of a first myocardial infarction is 20-30  per thousand 
annualy in people over 60  years of age. Forty percent of these people die before they 
reach the hospital and sixty percent is admitted to the hospital[1]. Plaque rupture with 
subsequent thrombus formation in one of the coronary arteries is the pathophysi­
ological mechanism most often responsible for myocardial infarction. The coronary 
thrombus obstructs the artery and compromises the oxygen supply of the myocar­
dium. Myocardial infarction occurs when the coronary artery is (sub) totally obstructed 
for a prolonged period of time leading to myocardial necrosis.
Acute coronary syndrome
Rapidly progressive exercise induced chest pain or pain in rest are symptoms which 
should raise suspicion of plaque rupture and potential subsequent myocardial infarc­
tion. Patients with these symptoms have an acute coronary syndrome. The challenge 
for physicians is to apply appropriate risk stratification and consequent treatment deci­
sions in patients with this syndrome.
The electrocardiogram (ECG) is of paramount importance for risk stratification in 
patients with an acute coronary syndrome. In patients with ST-segment elevation on 
the ECG a total occlusion is suspected and prompt re-opening of the occluded coro­
nary artery is the primary goal of therapy. In patients without ST-elevation plaque rup­
ture has, in general, not resulted in a complete coronary obstruction and for this type 
of acute coronary syndrome reperfusion therapy is not indicated. The cornerstone of 
therapy for all acute coronary syndrome patients is anti-thrombotic treatment with 
aspirin, a form of anticoagulation therapy and clopidogrel. W hether or not to perform 
an invasive procedure is based on clinical presentation (persistent pain, heart failure) 
and additional risk stratification. The current thesis pertains patients with an acute 
coronary syndrome with ST-elevation myocardial infarction treated with reperfusion 
therapy.
Reperfusion therapy
The goal o f reperfusion therapy is to achieve early and complete recanalization of the 
occluded infarct-related coronary artery to salvage the myocardium and preserve left
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ventricular function, the major determinant of long-term mortality. Reperfusion can be 
achieved with either fibrinolysis or primary angioplasty. For both strategies the degree 
of reperfusion (Table i; Figure 1) and the time to treatment (Figure 2) are related to the 
clinical outcome of the patient[2-4].
Table 1: T IM I flow grading system
TIM I 0 No perfusion:
No antegrade flow beyond the point of occlusion
T IM I 1 Penetration without perfusion:
The contrast material passes beyond the area of obstruction but "hangs up” 
and fails to opacify the entire coronary bed distal to the obstruction for the 
duration of the cineangiographic filming sequence.
T IM I 2 Partial perfusion:
The contrast material passes across the obstruction and opacifies the coronary 
bed distal to the obstruction. However, the rate of entry of contrast into the 
vessel distal to the obstruction and/or its rate of clearance from the distal bed 
are perceptibly slower than its entry into and/or clearance from comparable 
areas not perfused by the culprit vessel (e.g., the opposite coronary artery or 
coronary bed proximal to the obstruction).
T IM I 3 Complete perfusion:
Antegrade flow into the bed distal to the obstruction occurs as promptly as 
into the bed proximal to the obstruction and clearance of contrast material 
from the involved bed is as rapid as from an uninvolved bed in the same vessel 
or the opposite artery.
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Figure 1: Relation between patency and mortality after fibrinolysis and primary angioplasty
Figure 2: Hypothetical relationship between the time to treatment and the reduction in mortality and the 
extent of salvage in patients treated with reperfusion therapy
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Fibrinolysis
Since the introduction of fibrinolysis in the early 1980 's mortality has declined substan­
tially from ~10%  to ~ 6%  in case of contemporary fibrinolytic regimens[5]. Fibrinolytic 
therapy activates the endogenous fibrinolytic system. It converts the naturally occur­
ring plasminogen to plasmin, a non specific protease which lyses fibrin, the binding 
component of a thrombus. Streptokinase, one of the oldest drugs in its class is a 
non-fibrinogen specific fibrinolytic agent that activates plasminogen independent of 
its association with fibrin. Its efficacy is lower than the more recently developed fibrin 
specific fibrinolytic drug alteplase[6]. Both these drugs are administered by continu­
ous intravenous infusion. Successors of alteplase like tenecteplase and reteplase have 
similar efficacy but have the advantage of being a bolus drug[7,8]. The absolute mortality 
benefit o f alteplase is 1%  as compared to streptokinase and alteplase is associated with 
a significantly higher rate of complete reperfusion (T IM I 3 flow grade) 9 0  minutes after 
initiation of treatment; 54%  as compared to 32%  with streptokinase[3]. An infrequent 
(<1% )  but serious disadvantage of fibrinolysis is the risk of intracranial hemorrhage. 
Especially patients with older age (>75 years), female gender and low body weight 
(<67 kg) seem to be at increased risk for a bleeding event after fibrinolysis[9]. Early in 
the course of ST-elevation myocardial infarction the occlusive thrombus is smaller and 
lacks cross-linking of fibrin and is therefore more susceptible for fibrinolysis[10]. Pre­
hospital administration of fibrinolysis reduces treatment delay by 60 minutes which is 
associated with a 17%  relative risk reduction in mortality as compared to in-hospital 
fibrinolysis[11]. Routine early angioplasty after fibrinolysis has the potential to re-open 
persistently occluded infarct related arteries after failed fibrinolysis and prevent rein­
farction and reocclusion. This strategy has been associated with improved clinical out­
come as compared to a more conservative revascularization strategy after ST-elevation 
myocardial infarction. [12]
Primary angioplasty
In primary angioplasty reperfusion is achieved by crossing the occlusion of the coro­
nary artery with a wire and inflate a balloon to mechanically dilate the residual stenosis. 
The rate of procedural success and door-to-balloon time are strongly dependent on 
the expertise of the operator and the volume of patients treated in an intervention 
center[13]. In high volume centers the rate of patients with complete reperfusion is more
12
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than 9 0% .  Given this relation between expertise and outcome this procedure should 
only be performed in specially designated high-volume centers. A strong relation ex­
ists between the T IM I 3 flow rate before primary angioplasty and the rate of complete 
reperfusion after the procedure and outcome[14]. In addition high dose unfractionated 
heparin in patients presenting early seems to improve the patency before primary an­
gioplasty as compared to patients presenting late[15]. As a consequence the concept 
of pretreatment has emerged in which antithrombotic therapy is initiated as early as 
possible before primary angioplasty in order to improve the patency before the proce­
dure. Several pretreatment strategies have been tested; glycoprotein IIb/IIIa receptor 
blocker, combined therapy with half dose fibrinolysis and a glycoprotein IIb/IIIa recep­
tor blocker and full dose fibrinolysis. Although pretreatment improved the T IM I 3 flow 
rate before the intervention, the rate of brisk antegrade flow after the procedure was 
not significantly higer as compared to no pretreatment[16]. In case of fibrinolytic based 
pretreatment, the clinical outcome tended to be worse. Pretreatment with high-dose 
tirofiban early after symptom onset seemed to improve clinical outcome as compared 
to provisional tirofiban[17]. Simple passive thrombus aspiration before angioplasty is 
a promising new treatment strategy which improves the microcirculatory myocardial 
blood and tends to improve outcome but additional studies are needed to confirm this 
finding[18]. Numerous other promising adjunctive pharmacological agents designed to 
inhibit inflammation, prevent reperfusion injury, optimize myocardial metabolism, im­
prove oxygen delivery, restore intramyocardial hemodynamics or antagonize adverse 
neurohumeral mediators active in STEM I intended to reduce infarct size have failed to 
improve outcome in primary angioplasty[19]. Studies on the regeneration of myocardial 
cells after myocardial infarction using stem cell therapy have shown mixed results and 
this form of therapy cannot be recommended at this moment. The lack of an effect 
of these interventions designed to limit infarct size after reperfusion underscores the 
importance of the goal to establish early and complete recanalization. While primary 
angioplasty is highly effective in restoring the patency it is hampered by its limited 
availability and the inherent time delay before initiation of therapy as compared to 
fibrinolysis.
13
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Primary angioplasty versus fibrinolysis
In a large meta-analysis, primary angioplasty has been shown superior to fibrinoly- 
sis[20]. An additional 2%  absolute mortality reduction can be achieved if primary angio­
plasty is used instead of fibrinolysis. Importantly, the majority of these studies were 
done in high volume centers with experienced personnel. Primary angioplasty was not 
superior to fibrinolysis in less experienced centers[21].
In both primary angioplasty and fibrinolysis the time to treatment is related to 
clinical outcome. The impact of the incremental delay to PCI as compared to fibrino­
lysis remains a matter of debate. Initially it was suggested that the survival benefit of 
primary angioplasty is lost if the delay in addition to fibrinolysis exceeds 60  minutes[22].
Afterwards these results were contradicted and the superiority of primary angio­
plasty seemed independent of presentation and treatment delay[23]. Most recently it has 
been shown that the acceptable delay associated with primary angioplasty appears to 
depend on the time to presentation and the risk profile of the patient[24,25]. In high risk 
patients presenting early this acceptable delay is the shortest. The most recent STEM I 
guideline underscores the importance of treatment delays and states that primary an­
gioplasty should be performed in a high volume center with a median first-medical- 
contact-to-balloon time < 9 0  minutes with at least 75%  of patients treated within 90 
minutes of hospital presentation and fibrinolysis should be given if these criteria are 
not met[26]. For patients presenting in an intervention center, in hospital treatment 
delays are short and primary angioplasty is always the preferred treatment strategy. 
However, the majority of patients presents in a hospital without these facilities. The 
time delay until primary angioplasty in these patients is much longer as inter-hospital 
transport is necessary. Increasing the number of intervention centers will improve the 
availability of primary angioplasty and it has been shown that primary angioplasty can 
safely be performed in centers without on-site cardiac surgery[27]. However, too many 
intervention centers may reduce the volume and quality of these centers and negate 
the clinical benefit of primary angioplasty. Another way to increase the amount of pa­
tients eligible for primary angioplasty is to incorporate a system o f pre-hospital tri­
age and diagnosis of ST-elevation myocardial infarction. W hen opting for this strategy 
the question can yet again be raised whether primary angioplasty is superior to pre­
hospital, early fibrinolysis as the only study (CAPT IM ) performed in the pre-hospital 
setting did not show a mortality benefit of primary angioplasty[28]. Moreover in the
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meta-analysis o f primary angioplasty versus fibrinolysis patients treated with fibrino­
lysis often received streptokinase instead of alteplase, in-hospital fibrinolysis instead 
of pre-hospital fibrinolysis and no rescue angioplasty instead of an invasive approach 
after failed fibrinolysis[20]. Pre-hospital fibrinolysis is expected to save 16 lives per 10 0 0  
treated patients as compared to in-hospital fibrinolysis[11]. This is comparable to the 17 
lives per 1 0 0 0  treated patients that can be saved if primary angioplasty is the reperfu­
sion therapy of choice instead of fibrin-specific fibrinolysis[20]. Chapter 2 and 3 o f this 
thesis describe the rationale and results of the Holland Infarction Study (H IS ), which 
had a comparable design to the CAPT IM  study. Primary angioplasty was compared to 
“ the optimized fibrinolytic strategy” of early, preferably prehospital, fibrinolysis with 
a liberal invasive approach in patients presenting early with ST-elevation myocardial 
infarction. Due to funding problems this study was prematurely discontinued. The 
currently enrolling STREAM  trial studies the issue of the optimal reperfusion strategy 
in the particular group of patients presenting early after symptom onset. For coun­
tries with a prehospital diagnosis/fibrinolysis system and relatively high proportions 
of patients treated early, this is an important study, especially if the expected time to 
primary angioplasty is long.
Pre-hospital triage for primary angioplasty
In 1987 Nijmegen was the first city in the Netherlands and one of the first cities world 
wide to introduce pre-hospital fibrinolysis after pre-hospital diagnosis of ST-elevation 
myocardial infarction. The pre-hospital ECG was faxed to the Canisius W ilhelm ina Hos­
pital and the cardiologist on service decided whether pre-hospital fibrinolysis should 
be given. As a result of pre-hospital diagnosis two thirds of patients were treated with 
fibrinolysis within 2 hours of symptom onset[29]. After the results became available of 
the superiority of primary angioplasty over fibrinolysis it was decided to use the pre­
hospital system to triage for primary angioplasty. A registry was initiated to monitor 
the treatment delays proven to be so important in primary angioplasty. Moreover, in­
terventions known to be associated with reduced treatment delays were implemented 
as standard of care[30]. Previously it has been shown that treatment delays can be re­
duced in case of pre-hospital triage for primary angioplasty as compared to in-hospital 
triage and referral to an intervention center[31]. In chapter 4  o f this thesis we study the 
impact of direct transfer to an intervention center as compared to referral through a
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non-intervention center on time intervals, angiographic and clinical outcome in pa­
tients who presented in the prehospital setting.
The impact o f time intervals in pre-hospital triage for primary angioplasty
While there is general consensus about the detrimental effect of delay in time to treat­
ment on clinical outcome after primary angioplasty, the question remains which time 
interval is the main determinant of outcome. In a large scale multicenter registry per­
formed in the US with long in-hospital treatment delays the door-to-balloon time was 
an independent predictor of mortality[32]. In a small single center study performed in 
the Netherlands with short treatment delays not the door-to-balloon but the symptom- 
to-balloon time was an independent predictor of mortality[33]. In chapter 5 o f this thesis 
the impact of the respective time components that constitute the ‘treatment delay' 
are studied: all intervals that together form the symptom-to-balloon time are studied 
in relation to long-term mortality. This in the setting of optimized in- and prehospital 
treatment intervals of patients presenting with ST-elevation myocardial infarction in 
the ambulance.
Reinfarction and reocclusion
Despite the superiority of primary angioplasty, it is not always timely available and 
fibrinolysis is still the preferred reperfusion therapy in many parts of the world. Part 
of the initial benefit of success of fibrinolysis is offset by the occurrence of reinfarction 
and reocclusion. After successful fibrinolysis reinfarction is associated with a doubled 
risk of mortality[34]. The majority of reinfarctions occurs early after fibrinolytic therapy 
and is often attributed to reocclusion of the infarct related artery[35,36]. Reocclusion is 
a time dependent phenomenon and occurs in 10 %  of patients at discharge with an 
incidence of up to ~ 30 %  at one year after fibrinolysis despite anti-thrombotic treat­
ment with aspirin in case of a rather conservative ischemia-guided revascularization 
strategy[37,38]. Reocclusion is not widely studied as it requires the routine performance 
of follow-up angiography. Systematic angiographic studies have shown that reocclu­
sion occurs asymptomatic in about half of the cases[38,39]. Even in the absence of clinical 
reinfarction reocclusion has been associated with impaired recovery of left ventricular 
function[4° ]. In chapter 6 o f the current thesis the impact o f reocclusion on 10-year 
mortality is studied.
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Progression
In the late stable phase after myocardial infarction prevention of recurrent ischemic 
events, not necessarily related to the infarct-related artery, becomes the main goal of 
therapy. Aspirin, beta-blocker, statin and ace inhibitor therapy have all been proven ef­
fective in the prevention of late recurrent events[41-44]. After stenting at least 12 months 
of therapy with thienopyridines seems to improve outcome even further[45]. Given the 
low incidence of cardiovascular events in the stable phase after myocardial infarction 
surrogate endpoints have been used to study the impact of novel pharmacological reg­
imens. In the early statin trials progression o f coronary artery disease was a frequently 
used endpoint which required far less patients than in trials on clinical outcome. Se ­
rial angiography of patients with known coronary artery disease showed a tendency 
of coronary lesions to progress[46]. Statin therapy reduced the rate of progression and 
progression was shown to predict clinical events[46,47]. The impact of combined therapy 
with aspirin and dipyridamole on the progression of coronary artery disease in non­
infarct related arteries in the more stable phase after myocardial infarction has never 
been studied before and is the subject of chapter 7 o f the current thesis.
Conclusion
In this thesis the following questions will be addressed:
• W hat is the role of optimized fibrinolytic therapy as compared to primary angio­
plasty in ST-elevation myocardial infarction?
• W hat is the impact of direct transfer for primary angioplasty after prehospital diag­
nosis of ST-elevation myocardial infarction?
• W hat is the impact of the components of the treatment intervals in primary angio­
plasty after prehospital diagnosis of ST-elevation myocardial infarction?
• W hat is the impact of reocclusion after successful fibrinolytic therapy for ST-eleva- 
tion myocardial infarction on 10 year cardiac mortality?
• W hat is the impact of antithrombotic therapy on the progression of coronary ath­
erosclerosis after successful fibrinolytic therapy for ST-elevation myocardial infarc­
tion?
17
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SUMMARY
The latest meta-analysis comparing fibrinolysis with primary percutaneous interven­
tion (PCI) has fuelled the discussion regarding the best reperfusion therapy for acute 
ST-elevation myocardial infarction.[1] As far as patients presenting to centres with in­
tervention facilities are concerned, the superiority of primary PCI has been unequivo­
cally demonstrated.[2] However, only a small proportion of patients with ST-elevation 
myocardial infarction primarily present to an intervention centre, the majority go to a 
hospital without these facilities. The optimal reperfusion strategy for patients present­
ing to a nonintervention centre or for patients presenting in the prehospital setting has 
been studied less extensively and the question remains as to whether all these patients 
should be transferred to an intervention centre to undergo primary PCI.
The available data to date on interhospital transport for primary PCI do show a 
mortality benefit for primary PCI.[3] Yet, as far as inferences to clinical practice are con­
cerned, it remains to be seen whether these studies are truly representative: almost 
half of patients in the transportation trials received streptokinase, they were treated 
relatively late, and the subsequent revascularisation strategy was rather conservative.
The impact of primary PCI as compared with prehospital fibrinolysis in patients 
presenting in the prehospital setting has so far only been addressed in the randomised 
CAPT IM  trial, without significant differences in outcome.[4] Additional studies are war­
ranted, with early treatment as primary focus. For patients presenting to noninterven­
tion centres or prehospitally, the impact of triage, and of combined pharmaco-invasive 
reperfusion strategies are promising fields of further exploration.
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ST-ELEVATION MYOCARDIAL INFARCTION IN AN INTERVENTION 
CENTRE
Ever since the first comparisons of primary PCI and fibrinolysis early in the 19 9 0s, the 
attention for primary PCI has increased accordingly. A primary PCI results in higher 
epicardial reperfusion rates (T IM I-3 flow of 70  to 95%  versus 50 to 6 0%  at 90  minutes 
after fibrinolysis) and has the advantage of the potential early triage of patients with 
left main and/or multivessel disease.[2]
A recently published quantitative review of 23 randomised trials showed a significant 
3 0 -day mortality reduction from 7 to 5%  in favour of primary PC I .[1] Yet, this meta­
analysis also included patients presenting to hospitals without intervention facilities.
As early as in 1997 the randomised evidence already proved to be in favour of pri­
mary PCI for patients presenting to an intervention centre (table i) . [2] Including almost 
2 6 0 0  patients, the mortality benefit attained with an intervention is 21 lives saved 
per 1 0 0 0  treated patients. Over the years, several additional trials were performed in 
which accelerated tPA was used in the control arm.[5'7] Irrespective o f the use o f the 
type of agent, primary PCI is to be preferred, although the magnitude of benefit differs 
according to the pharmacological reperfusion strategy used, varying from 10 per 10 00 
with accelerated tPA to 50 per 1 0 0 0  with streptokinase.
W ith respect to inferences to clinical practice, it should be noted that the trial data 
stem from highly specialised, high-volume intervention centres, with a lot of experi­
ence. The impact of these aspects is illustrated by the outcome of the GUSTO-IIb trial, 
in which no difference in one-year outcome was observed between fibrinolysis with rt- 
PA and a primary PCI.[8] Yet, when data were broken down by the experience of the op­
erators, outcome in high-volume centres was significantly better than after fibrinolysis. 
Registry data corroborate with these findings, underscoring the importance of short 
door-to-balloon times and good operator experience.^ Guidelines from the American 
College of Cardiology and the European Society of Cardiology prescribe that a primary 
PCI is to be preferred, provided the above-mentioned conditions are met, and the 
procedure can be performed within 9 0  minutes after first medical contact. The impor­
tance of time delays in primary PCI was recently underlined in an overview of 23 ran­
domised trials, which demonstrated that the benefit of primary PCI on mortality and 
the combined endpoint of death, reinfarction and stroke may be lost if door-to-balloon
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times were delayed by more than 62 and 93 minutes, respectively, as compared with 
the door-to-needle time with fibrinolysis.[10]
The observed mortality benefit with primary PCI has fuelled the call for an increase 
in the number of intervention centres, but may pose logistic problems. Aspects of 
early triage, pretreatment, and the need for on-site surgery should therefore be studied 
more thoroughly. W hether or not all intervention centres need on-site cardiac surgery 
remains a matter of debate, although at present the number of intervention centres 
without on-site cardiac surgery but with surgical backup is growing. The C-PORT has 
shown safety and clinical superiority of primary PCI without on-site cardiac surgery 
compared with fibrinolysis.[7] Regarding the implementation in daily clinical practice, it 
is important to be aware of the logistic aspects involved and of the fact that preserva­
tion of the currently high level of interventional experience in the Netherlands should 
be the cornerstone in the further implementation of the plans.
Table 1: Short term mortality for primary PCI as compared to fibrinolysis depending 
on the site o f presentation
Presentation in intervention centre
21 per 1000 lives saved with primary PCI
Primary PCI Fibrinolysis p value
Mortality * 4.4 % 6.5 % 0.02
57/1290 86/1316
Presentation in nonintervention centre
28 per 1000 lives saved with primary PCI
Primary PCI Fibrinolysis p value
Mortality ** 6.8 % 9.6 % 0.01
84/1242 117/1224
* JAMA 1997:278:2093 - 2098, 30 days to 6 weeks; ** Eur Heart J 2003;24:21-23, 30 days to 6 weeks
27
C h a p te r  2
ST-ELEVATION MYOCARDIAL INFARCTION IN A NONINTERVENTION 
CENTRE
O f all hospitals in the Netherlands, -1 9  have facilities for primary PCI. Consequently, a 
significant proportion of patients with a myocardial infarction present to noninterven­
tion centres. Observational studies have shown the feasibility and safety of interhos­
pital transportation. To date, a mere 2466  patients have been randomised to either 
fibrinolysis in the nonintervention centre or to referral for a primary PC I .[3] The results 
suggest that transport for an intervention is more effective than fibrinolysis on the 
spot (table 1).
Interestingly, the benefit of a primary PCI seems even more outspoken, despite 
the potential delay associated with transportation. Yet, transfer time only accounted 
for an average of 39 minutes, with a median symptom-to-balloon time of about 100 
minutes. Critical appraisal as to how representative these trials are of the current clini­
cal situation is, however, warranted. The fact that about 4 0 %  of patients in the control 
arms of the trials received the moderately effective streptokinase may have overesti­
mated the benefit in the pooled analysis of referral for primary PC I.[11,12] Whereas the 
relative risk reduction in these trials was 24% ,  it was 14%  when compared with rt-PA. 
Moreover, the DANAMI-2 , using rt-PA, had a design that created a disadvantage for 
fibrinolytic therapy by including patients with prior stroke and advocating re-fibrinoly­
sis instead of angioplasty for an impending reinfarction.[13] A second aspect that may 
have contributed to an overestimation of the clinical benefit of primary angioplasty in 
the transportation trials is the fact that one of the transportation trials was limited to 
high-risk patients, in whom the most pronounced benefit can be obtained.[14] Includ­
ing these data (relative risk reduction 4 0 % ) ,  the benefit for primary PCI in the overall 
population is probably overestimated. These examples demonstrate that the trials in 
the metaanalysis are only partly representative of the current clinical situation and that 
the observed differences can not simply be translated into daily clinical practice in the 
Netherlands. In addition to the previously mentioned aspects, the reported small ad­
ditional time delays associated with interhospital transport in the randomised trials 
may not reflect daily clinical practice. Besides a combined pharmaco-invasive strategy 
to bridge potential time delays associated with inter-hospital transport, early treatment 
by means of prehospital triage or prehospital fibrinolysis with or without an additional
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intervention could be an attractive alternative treatment strategy which deserves fur­
ther investigation.
ST-ELEVATION MYOCARDIAL INFARCTION IN THE PREHOSPITAL 
SETTING
Prehospital fibrinolysis is often underappreciated. The clinical impact of pharmaco­
logical reperfusion is highest in patients treated early, and with prehospital initiation 
of fibrinolytic therapy about one hour is gained as compared with in-hospital initia­
tion in ST-elevation myocardial infarction. Meta-analysis of all randomised prehospital 
fibrinolysis trials reveals a benefit of 16 to 18 lives saved per 10 0 0  patients treated, a 
relative reduction of 17%  (figure 1) .[15] This benefit is of the same order as the difference 
achieved by primary PCI observed in the randomised trials in intervention centres 
when compared with in-hospital fibrinolysis. The CAPT IM  trial is the first multicentre 
trial in which primary PCI was compared with fibrinolysis in a prehospital setting.[4] A 
primary PCI after prehospital diagnosis, thus allowing the cath-lab to get ready (me­
dian door-to-balloon time: 4 0  minutes), was compared with prehospital fibrinolytic 
therapy with a liberal rescue angioplasty policy (26% ) .  All patients were transported 
to intervention centres. Mortality at 30  days was astonishingly low: 3.8 versus 4 .8%  
for pre-hospital fibrinolysis and primary PCI, respectively. The combined primary end­
point of death, reinfarction and stroke was not significantly different between groups, 
although it should be noted that the trial was stopped prematurely due to slow inclu­
sion and lack of finances rendering the study underpowered. An interesting substudy 
of the CAPT IM  showed that in patients treated within two hours of symptom onset a 
significant one-year mortality benefit was observed in favour of prehospital fibrinolysis 
(2.2 vs. 5.7 % ,  p=0 .058).[16]
The H IS  (Holland Infarct Study) was designed to compare rather similar strategies 
for the situation in the Netherlands: patients with a large ST-elevation myocardial in­
farction presenting in the ambulance or to a nonintervention centre were randomised 
to either a primary PCI with abciximab pretreatment or early (preferably prehospitally) 
initiated fibrinolysis, with a protocol-driven, liberal policy o f rescue angioplasty. Unfor­
tunately, the H IS was stopped prematurely due to logistic problems and a lower than
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anticipated recruitment rate. However, the scientific questions and the design of the 
study are still up to date and very relevant. W ith the promising CAPT IM  data on very 
early pharmacological reperfusion therapy, further prehospital studies are warranted, 
especially in view of the fact that 50 to 6 0 %  of the patients are treated within two hours 
o f symptom onset with prehospital fibrinolysis.[17-19]
Figure 1: Meta-analysis of all randomised trials of prehospital fibrinolysis for acute MI
FUTURE DIRECTIONS
Although the additional benefit of prehospital fibrinolysis compared with in-hospital 
fibrinolysis is undisputed, T IM I-3 flow will not be realised in a substantial number of 
patients. A meta-analysis of rescue angioplasty with angiographically documented 
failed reperfusion in patients with large infarctions demonstrated a significant rela­
tive one-year mortality reduction of 38% ,  equal to 50 lives saved per 10 0 0  patients 
treated as compared with a conservative strategy (figure 2). In addition, reductions
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in re-infarction and heart failure are impressive, with events saved per 10 0 0  treated 
patients of 70  and 8 0 , respectively.[20]
Randomised data from the Maastricht area have shown that a systematic strategy 
of early angiography with/without ‘rescue' angioplasty may result in similar T IM I-3 flow 
rates as achieved by primary PC I .[21] In spite o f this, the potential benefit of rescue an­
gioplasty is often questioned, although the (limited number) of randomised trials sug­
gest a clinically relevant benefit. O f  importance though, the CAPT IM  used noninvasive 
clinical grounds to perform rescue angioplasty, whereas in rescue angioplasty trials 
systematic angiography was performed to assess infarct-related artery patency. In the 
regions in the Netherlands adopting a policy of rescue angioplasty, a similar noninva­
sive approach is followed to triage patients.
W hen a primary PCI is the preferred reperfusion strategy, pretreatment with a gly­
coprotein IIb/IIIa receptor blocker or fibrinolysis could enhance pre-procedural T IM I-3 
flow and possibly improve clinical outcome.[22] From either perspective, different com ­
binations of pharmaco-invasive reperfusion strategies should become the subject of 
further study, preferably in a prehospital setting.
To reduce the bleeding risk associated with full-dose fibrinolysis, half-dose rt-PA 
pretreatment before rescue angioplasty was tested in the placebo-controlled PACT 
trial, achieving about 30%  T IM I-3 flow in the treatment arm at angiography at a median 
of 49 minutes after lysis.[23] Primary angioplasty trials using tirofiban or abciximab as 
pretreatment showed preprocedural T IM I-3 rates of 19 to 30% ,  sometimes superior 
and sometimes similar to aspirin and heparin alone.[24,25] None o f these trials were de­
signed to demonstrate clinical effect. Given the known 6 0 minute patency rate of TNK- 
tPA (6 0%  T IM I-3 flow), pretreatment with this agent before primary angioplasty might 
be expected to give the most pronounced benefit. This strategy will be compared with 
a standard primary angioplasty in the clinical A SSEN T -4 trial. Studies such as the FI­
N ESSE  (cath-lab initiated abciximab + primary PCI vs. abciximab pretreatment + PCI 
vs. 1/2 rPA + abciximab pretreatment + PCI), ADVANCE (eptifibatide + primary PCI vs. 
1/2 TNK + eptifibatide + primary PCI) and C ARESS (1/2 r-PA + routine PCI vs. 1/2 r-PA 
+ rescue PCI) will test other reperfusion strategies.
These trials will give insight into the magnitude of additional clinical benefit from 
more intensive anti-thrombotic pretreatment and whether this counterbalances the 
expected increase in bleeding risk. Moreover, C ARESSE might provide insight into
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whether routine angioplasty or clinically driven angioplasty should be opted for after a 
half-dose fibrinolytic pretreatment.
Figure 2: The impact of rescue PCI after fibrinolysis
In conclusion, the obtained overall benefit of primary PCI in an intervention centre is
21 lives saved per 10 0 0  treated patients and ranges from 10 per 10 0 0  with second-and 
third-generation fibrinolytics to 50 per 10 0 0  with streptokinase. Critical re-appraisal is 
warranted with respect to how representative the trials involving interhospital trans­
port for primary PCI are for the clinical situation in the Netherlands. On the one hand, 
data with respect to the mortality benefit for patients presenting to an intervention 
centre have been thoroughly tested and proven reproducible. Notably, this statement 
only holds true if the primary PCI can be initiated within 90 minutes of presentation. 
Moreover, the clinical outcome of a primary PCI has been shown to largely depend on 
the infrastructure of the intervention centre and operator experience. W ith the increas­
ing number of intervention centres, it is of paramount importance to guarantee the 
prerequisites with respect to logistics and operator experience, if the currently high 
standard of care is to be maintained.
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On the other hand, further research is warranted to address the issue of patients 
presenting to a nonintervention centre or prehospitally. W ith respect to transportation 
trials, almost half of the control arm data reflect outcome using first-generation, less 
potent, fibrinolytics and the subsequent revascularisation strategy was rather conser­
vative. Prehospital fibrinolysis, as well as prehospital diagnosis and triage for a primary 
PCI have been implemented in a growing number of regions in the Netherlands, but 
trials addressing the influence on outcome of these strategies are lacking. Future tri­
als should therefore focus on early treatment, prehospital triage and the impact on 
pharmacological pretreatment, whereas in daily clinical practice all efforts should be 
made to improve our logistics and infrastructure, not only at the level o f the hospital 
itself, but also at a regional level to further improve the treatment of acute ST-elevation 
myocardial infarction.
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T ra n sp ort f o r  a b c ix im a b  fa c ilit a t e d  p r im a ry  a n g io p la sty  versus on -site  th ro m b o ly sis
ABSTRACT
Aims: As of to date, the only large transportation trial comparing on-site fibrin-specific 
thrombolysis with transfer for primary angioplasty in patients presenting in a referral 
centre is the D A N A M I-2 trial, with only 3%  rescue angioplasty. The Holland Infarc­
tion Study (H IS) compared abciximab facilitated primary angioplasty (FP) with on-site 
fibrin-specific thrombolytic therapy (TT) with a liberal protocol-driven rescue angio­
plasty (transport to intervention centre in case < 50%  ST resolution at 60  min).
Methods and Results: Patients in a referral centre without shock and < 4.5 h of chest 
pain presenting with ST-elevation having > 12 mm ST-segment shift were randomised 
to either strategy. O f the originally planned 9 0 0  patients only 48 were included due to 
suspension of financial funding. Death, recurrent MI and stroke at one year was 8%  
for the FP-group and 22%  for the TT-group (p = 0 .2). Two hours after randomisation 
the rates of complete ST-segment resolution ( > 7 0 % )  were 52%  and 35% ,  respectively
(p = o.2).
Conclusion: This prematurely discontinued randomised transportation trial shows fa­
vorable trends with respect to long-term clinical outcome and early ST-resolution for 
abciximab facilitated primary angioplasty. In view of the real world delays associated 
with interhospital transport for primary angioplasty, treatment strategies focusing on 
early fibrin-specific lysis with a liberal selective rescue policy are warranted.
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in t r o d u c t io n
In randomised trials, primary angioplasty has been shown superior to thrombolysis for 
the treatment of patients with ST-elevation myocardial infarction (STEM I) presenting 
in an intervention centre[1]. As a consequence the amount of intervention centres has 
increased and mounting numbers of patients who present prehospitally are directly 
transported to an intervention centre. Nevertheless, most patients first present in a 
hospital without intervention facilities. In the studies of interhospital transport com ­
paring primary angioplasty with on-site thrombolysis, more than 4 0 %  of the 2,466 ran­
domised patients received streptokinase[2]. The only large randomised trial comparing 
on-site fibrinspecific thrombolysis with interhospital transport for primary angioplasty 
is the DANAMI-2 [3]. This trial demonstrated superiority of referral for primary angio­
plasty with a median first door-to-balloon time of 112 min. However, the patients ran­
domised to on-site thrombolysis were treated rather conservatively, with rescue angio­
plasty performed in only 3%  of patients and mandated re-thrombolysis for impending 
reinfarction. Therefore, the Holland Infarction Study (H IS ) was specifically designed to 
compare a modern primary angioplasty strategy with a more optimised thrombolytic 
strategy in patients with large STEM I presenting early after symptom onset in a refer­
ral centre: abciximab facilitated primary angioplasty was compared to on-site fibrin- 
specific thrombolysis with a liberal protocol-driven rescue policy. Patients allocated to 
primary angioplasty received abciximab which has been shown to improve one-year 
mortality in high risk patients[4]. Moreover, abciximab was initiated before interhospital 
transport because pretreatment has been demonstrated to improve pre-intervention 
patency[5], which is a predictor of improved clinical outcome[6]. As for patients allo­
cated to thrombolysis, a protocol-driven liberal rescue strategy was pursued, as rescue 
angioplasty after failed thrombolysis has been shown to improve clinical outcome, 
especially in high risk patients with large infarction[7].
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METHODS 
Study design
Patients with a large STEM I presenting in a referral centre were randomly assigned to 
abciximab facilitated primary angioplasty or on-site thrombolysis with a liberal proto­
col driven rescue policy. From January 2003 to January 2 0 0 4 , four intervention centres 
and eight referral centres in the Netherlands participated in the HIS-trial. The protocol 
was approved by the institutional review board at each participating centre and written 
informed consent was obtained from all patients.
Criteria for eligibility
The criteria for inclusion were:
1. age > 21 years,
2 . the presence o f typical chest pain for at least 20  min but less than 4 n/2 h not re­
sponding to sublingual nitroglycerin,
3 . ST-elevation with a cumulative ST-segment deviation of at least 12 millimetres 
(measured 60  ms after the J-point on a standard 12-lead electrocardiogram).
The criteria for exclusion were Killip class II or more; known contraindication to throm ­
bolytic therapy; previous CABG; pulseless femoral arteries; known allergy or hypersen­
sitivity to aspirin, clopidogrel, enoxaparin or abciximab; coma or severe concomitant 
disease with a life expectancy of less than 12 months. Patients were randomised in per­
muted blocks stratified per centre by a central 24  h computerised telephone service.
Abciximab facilitated primary angioplasty
Patients randomly assigned to abciximab facilitated primary angioplasty received at 
least 3 0 0  mg of aspirin, an 0.75 mg/kg i.v. bolus of enoxaparin and an 0.25 mg/kg i.v. 
bolus of abciximab before transport to an intervention centre for primary angioplasty. 
Abciximab infusion was started either at the referral centre or in the intervention cen­
tre at a rate of 0.125 mg/kg/min up to a maximum of 10 mg/min for 12 h. Angioplasty 
with stenting of the culprit lesion had to be performed if the procedure was technically 
feasible, the infarct related artery was occluded (T IM I 0,1 or 2) or had T IM I-3 flow with 
a >50%  stenosis. During angioplasty the use of additional heparin was at the discre­
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tion of the operator. All patients preferably received a Rithron stent (Biotronik Gm bH, 
Berlin Germany) followed by standard treatment with clopidogrel. After the interven­
tion, all clinically stable patients were transported back to the referral hospital as soon 
as possible. Aspirin was continued according to local standard procedures (8 0 -1 0 0  
mg/day). Enoxaparin 1 mg/kg s.c. twice daily had to be continued for at least 48  h after 
angioplasty. The administration of other pharmacologic agents was at the discretion 
of the attending physician or cardiologist.
On-site thrombolysis with a liberal rescue policy
For patients randomly assigned to thrombolysis the protocol mandated at least 30 0  
mg of aspirin and a 30 mg i.v. bolus of enoxaparin for patients < 75 yrs (patients > 75 
yrs received no bolus of enoxaparin) before administration of fibrin-specific throm bo­
lytic therapy. Aspirin was continued according to local standard procedures (8 0 -1 0 0  
mg/day) and enoxaparin was continued at a dose of 1 mg/kg s.c. twice daily for pa­
tients < 75 years and 0.75 mg/kg s.c. twice daily for patients older than 75 years for at 
least 4 8  h. Patients remained at the referral centre until sixty minutes after initiation 
of thrombolysis when a new ECG was recorded to evaluate the ST-segment resolution. 
W hen the cumulative resolution was less than 50% ,  transport to an intervention centre 
was advised for immediate angiographic evaluation. The protocol mandated additional 
angioplasty with stenting of the culprit lesion if the procedure was technically feasible, 
if the infarct-related artery was occluded (T IM I 0,1 or 2) or had T IM I-3 flow with > 9 0%  
stenosis. In the case of additional angioplasty standard treatment with clopidogrel was 
initiated. The administration of other pharmacologic agents was at the discretion of 
the attending physician or cardiologist.
Endpoints and definitions
Primary endpoint: the composite of death, recurrent MI and stroke at 30  days. The HIS- 
trial was designed as a superiority trial expecting a relative reduction of 42% [3] in the 
primary endpoint from 15%  for on-site thrombolysis to 8 .7%  for referral for primary an­
gioplasty. To achieve a power of 8 0%  with an alpha-level of 5%  a total of 9 0 0  patients 
was required. Clinical endpoints were assessed according to the TIMI-definitions[8]. 
Unfortunately, the trial was prematurely stopped because of slow patient recruitment 
leading to withdrawal of funding from one of the main contributing organizations.
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Secondary endpoint: after premature discontinuation, the predefined ancillary anal­
ysis on the rate of ST-segment resolution in time between treatment groups was con­
sidered as a secondary endpoint. According to protocol a standard 12-lead ECG had to 
be performed every hour in the first 4  h after randomisation. Analysis of the cumulative 
ST-segment elevation resolution was performed according to the Schroder-criteria[9]: 
the sum of the ST-elevation was measured from leads I, aVL, and V 1-6 for anterior MI 
and leads II, III, aVF and V 5-6 for non-anterior MI. For each patient the ECGs at ran­
domisation and two and four hours thereafter were used for analysis of ST-segment 
resolution and were analysed in pairs, unaware of the treatment assignment.
Angiographic definitions: a successful coronary intervention was defined as T IM I-3 
flow in the infarct-related artery with <50%  residual stenosis of the culprit lesion after 
angioplasty and was evaluated by an angiography committee (M AB, W R M A , FWAV) 
unaware of the initial treatment assignment. In case of disagreement between MAB 
and W R M A , FW AV evaluated the angiogram. T IM Iflow  assessment was done by the 
operator at the time o f angiography.
Meta-analysis and statistics
A meta-analysis including the HIS-trial was performed of all randomised trials[3,10-13] 
comparing interhospital transport for primary angioplasty versus on-site thromboly­
sis. The meta-analysis was performed using the relative risk as the parameter o f ef­
ficacy with a random effect model and the appropriate tests for association and het­
erogeneity. The probability value for significance of association and heterogeneity test 
was set at 0 .0 5 . Normally distributed continuous variables are expressed as means 
and standard deviations and were compared using an independent T-test. Continuous 
variables not normally distributed are expressed as medians and inter-quartile ranges 
(IQR) and were compared using non-parametric tests. Proportions were compared by 
chi-square and Fisher's exact tests whenever appropriate.
r e s u lt s
In this trial 48  patients were included: 25 were assigned to transfer for primary angio­
plasty and 23 to on-site thrombolysis. The baseline characteristics are shown in Table 1.
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Table 1: Baseline characteristics at randomization and treatment intervals
N (% ) Primary PCI
n = 25
Thrombolysis
n = 23
Age (yrs, mean, SD) 61 ± 13 66 ± 16
Male 18 (72% ) 13 (57%)
Systolic BP < 100 mmHg 1 (4%) 1 (4%)
Heart rate > 100/min 0 1 (4%)
Both 0 0
Cum. ST-deviation (mm, median, IQR) 20 24
( i 6 -2 7) (1 9 -3 4 )
Anterior MI 12 (48% ) 8 (35%)
Prior MI 0 3 03%)
Diabetes 2 (8%) 1 (4%)
Hypertension 6 (24% ) 6 (26% )
Peak CK (U/l, median, IQR) 2091 2582
( 9 1 4 - 3 0 0 5 ) (1 3 2 7 - 3 3 6 9 )
Time to peak CK (hours, median, IQR) 15 11
(11-18) (9 -13)
Pain to randomization (min, median,IQR) 130 150
(8 1 -1 4 6 ) (115-181)
Pain to medication* (min, median,IQR) 145 170
(9 5-155) (1 2 3-1 9 1 )
Pain to angioplasty (min, median,IQR) 230 -
(1 9 5 -2 5 0 )
PCI = percutaneous coronary intervention; yrs = years; SD = standard deviation; BP = blood pressure; 
Cum. = cumulative; mm = millimeter; IQR = interquartile range; MI = myocardial infarction;
CK = creatine kinase; min = minutes; * abciximab or thrombolysis
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Abciximab facilitated primary angioplasty
All 25 patients allocated to primary angioplasty received the abciximab bolus in the 
referral centre. In 56%  of patients bolus plus infusion was initiated before transferral 
to an intervention facility. The median duration of abciximab pretreatment was 85 min 
(interquartile range: 71- 104). One patient did not undergo immediate angiography be­
cause of relieve of symptoms and complete normalisation of the ECG at arrival in the 
intervention centre. At preprocedural angiography, 17%  (4 /24) o f patients had T IM I-3 
flow and 33%  (8/24) had T IM I-2 or 3 flow. One patient did not undergo angioplasty 
because the culprit lesion was unsuitable for intervention. The procedural success rate 
was 83%  (19/23) and the post-procedural T IM I-3 flow rate was 8 7%  (20/23).
On-site thrombolysis with a liberal rescue policy
All 23 patients allocated to thrombolysis received fibrinspecific therapy: 43%  (10/23) 
reteplase, 35%  (8/23) tenecteplase and 22%  (5/23) front-loaded alteplase. One hour 
after initiation of thrombolysis 35%  (8/23) had > 50%  ST-resolution. O f  the remaining 
15 patients (65% )  without ST-resolution, 12 patients were transported to an interven­
tion centre and 11 o f the 15 patients (73% )  underwent immediate angiography at a 
median time o f 166 min (IQR: 132- 2 0 7 ) after randomisation. Three patients without 
ST-resolution at one hour remained in the referral centre because the responsible car­
diologist deemed rescue angioplasty not necessary. One patient without ST-resolution 
underwent immediate transport but did not undergo angiography because o f relieve 
of symptoms and complete ST-resolution upon arrival at the intervention centre. O f 
the eleven patients who underwent immediate angiography, 6 underwent additional 
angioplasty at a median of 302  minutes (IQR: 245- 384) after symptom onset. These 
angioplasties were performed according to protocol in all but one patient who had 
preprocedural T IM I-3 flow and <9 0 %  stenosis. Upon arrival at the intervention centre 
5 (45% )  patients had > 50%  ST-resolution. The procedural success rate was 50%  (3/6) 
and 50%  (3/6) had post-procedural T IM I-3 flow. In total, 26%  (6/23) o f the patients 
treated with thrombolysis underwent immediate angioplasty.
Clinical outcome
The one-year combined endpoint of death, recurrent MI and stroke tended to occur 
less frequently in the facilitated primary angioplasty group as compared to the throm ­
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bolysis group (8%  vs. 22% ,  p = 0 .2), Table 2 . One 88-year old patient (not to be re­
suscitated) randomised to primary angioplasty died because of shock four days after 
a rebleed of an infected puncture site. Three patients randomised to thrombolytic 
therapy died: two patients died from cardiogenic shock and one patient with one- 
vessel disease and a good left ventricular function died unwitnessed and unexpectedly 
141 days after anterior MI successfully treated with a rescue angioplasty. No major 
bleedings occurred in patients allocated to thrombolysis.
Table 2 : Clinical outcome
3 0 -days, n (% )
Primary PCI
n = 25
Thrombolysis
n = 23
p-value
Combined endpoint*
• Mortality
• Reinfarction
• Stroke
1 (4%) 
1 (4%)
3 (13%) 
2 (9%)
1 (4%)
0.3
1-year, n (% )
Combined endpoint*
• Mortality
• Reinfarction
• Stroke
2 (8% ) 
1 (4%) 
1 (4%)
%) 
%) 
%) 
2
3
%
u-\ 
CT\ 
CM
0.2
Revascularization, n (% )
One-year revascularization 23 (92% ) 12 (52% ) <0.01
• PCI (including primary PCI)
• CABG
23 (92% ) 
1 (4%)
10 (43%) 
2 (9%)
• Randomization to Discharge
- related to acute reperfusion strategy
- recurrent ischemia
• Discharge to One-year
) 
) 
) 
%
%
2 
2 
%
3 
3 
1
2
2
) 
%) 
) 
) 
%
%
%
0 
VO 
CM
PCI = percutaneous coronary angioplasty; CABG = coronary artery bypass grafting; 
* mortality, reinfarction and stroke
46
T ra n sp ort f o r  a b c ix im a b  fa c ilit a t e d  p r im a ry  a n g io p la sty  versus on -site  th ro m b o ly sis
ST-segment resolution
In both groups, ST-resolution was assessed at two and four hours after randomisa­
tion. At two hours, the intervention was completed in all patients allocated to pri­
mary angioplasty, in the patients allocated to thrombolytic therapy no angioplasties 
had yet been performed. The proportions o f patients with complete, partial and no 
ST-segment resolution for both treatment groups are shown in Fig. 1. In the primary 
angioplasty group median time from randomisation to ECG was 134 min (interquartile 
range; 117- 166) and median time from angioplasty to ECG was 37 min (13- 57). In the 
thrombolytic group median time from randomisation to ECG was 130 min (108- 147) 
and median time from treatment to ECG was 110 min (75- 137). Four hours after ran­
domisation all immediate angioplasties in the thrombolytic group were completed. 
The proportion of patients with complete ST-segment resolution at that time was 68%  
in the primary angioplasty group and 7 0 %  in the thrombolytic group (p = 0 .9).
Figure 1: Distribution of ST-segment resolution two hours after randomisation: abciximab facilitated 
primary angioplasty versus thrombolysis and a liberal rescue policy
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Meta-analysis
The mortality results from the HIS-trial were added to the five randomised trials com ­
paring interhospital transport for primary angioplasty with thrombolysis. The results 
from this meta-analysis are shown in Fig. 2. Transport for primary angioplasty was as­
sociated with a mortality rate of 6 .7%  as compared to 9 .6%  for on-site thrombolysis. 
This difference was significant with a relative risk of 0.70  (95%  CI; 0 .54- 0 .92). The test 
for heterogeneity was not significant.
Figure 2: Meta-analysis of trials comparing transport for primary angioplasty with on-site thrombolysis on 
30-42-day mortality, (p PCI = primary percutaneous coronary intervention; lysis = thrombolysis)
d is c u s s io n
The Holland Infarction Study is a modern randomised transferral trial of abciximab 
facilitated primary angioplasty as compared to on-site fibrin-specific thrombolysis with
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a liberal rescue policy in patients with large STEM I presenting in a referral centre. 
The one-year composite endpoint o f death, recurrent MI and stroke seemed lower in 
patients treated with primary angioplasty as compared to patients treated with throm ­
bolysis. Despite the fact that the rate of early ST-resolution is a strong prognosticator 
after both thrombolysis and primary angioplasty[9'14'15], this is the first direct compari­
son on this endpoint, which tended to occur more frequently in patients transferred 
for primary angioplasty. Although prematurely discontinued, this trial contributes to 
the randomised data of fibrin-specific thrombolysis as compared to referral for primary 
angioplasty in the large population of patients with ST-elevation presenting in a non­
intervention centre.
Transfer for primary angioplasty versus on-site thrombolysis
For patients who present in a high volume intervention centre with experienced opera­
tors timely performed primary angioplasty has been shown superior to thromboly- 
sis[16]. Despite an increase in the amount of intervention centres, a substantial num­
ber of patients first present in hospitals without these facilities. In our meta-analysis 
of randomised trials comparing interhospital transport for primary angioplasty with 
on-site thrombolysis (Fig. 2), a significant mortality benefit of primary angioplasty is 
demonstrated (relative risk 0 .7 0 : 95%  CI; 0 .54- 0 .92). Yet, streptokinase was used in 
more than 4 0 %  of the total study population and rescue angioplasty was used in a mi­
nority of patients treated with thrombolysis. Compared to streptokinase, fibrin-specific 
thrombolytic therapy is associated with a 14%  relative risk reduction for mortality[17]. 
Moreover, rescue angioplasty is likely to be effective in reducing mortality as compared 
to a more conservative strategy, especially in large infarctions[7,18]. In view of the above, 
and combined with the fact that real world delays for referral for primary angioplasty 
are about 180 m in[19], further reperfusion trials are warranted. W herever possible these 
trials should concern the field of prehospital diagnosis, given the 17 per 10 0 0  lives 
saved with ambulance initiated thrombolysis as compared to inhospital thromboly- 
sis[20] and the advantage of prehospital notification of the catheterisation laboratory in 
case of primary angioplasty[21]. Additional prehospital trials like C A PT IM [22], should set 
the stage for further research.
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Rescue angioplasty
Rescue angioplasty of an occluded infarct-related artery within a timeframe of expect­
ed myocardial salvage has been shown to improve clinical outcome, especially in high 
risk patients with large infarction[7]. Moreover, rescue angioplasty in patients with non­
invasive signs of failed thrombolysis (predominantly, persistent ST-elevation) seems 
to be more effective than a conservative strategy in a recently performed clinical tri- 
al[23]. To reduce the burden on intervention centres patients in the H IS trial were only 
transported to an intervention centre if ST-elevation persisted one hour after initiation 
of thrombolysis. Despite this early triage for rescue angioplasty, the median pain-to- 
balloon time exceeded five hours. A strategy of immediate transport to an intervention 
centre after initiation of thrombolysis may reduce this delay and has been shown safe 
and feasible in the PRAG U E and LIM I trials[10,11] and successful in the CAPTIM  trial[22]. In 
contrast to the H IS and CAPTIM  trials, all thrombolytic treated patients in the PRAGUE 
and LIM I trials underwent immediate angiography and in most cases subsequent an­
gioplasty. Given the disappointing results of routine immediate angioplasty (median 
104 min) after facilitation with full-dose thrombolysis in the recent A SSEN T -4 trial[24], 
further study is warranted addressing the timing and selection of patients for routine 
angiography and subsequent angioplasty after thrombolysis.
Facilitated primary angioplasty
In view of the delays associated with referral for primary angioplasty and the observa­
tion that higher preintervention patency is associated with improved clinical outcome, 
pretreatment with various antithrombotic regimens is a rapidly moving field of re­
search. In the H IS trial the observed rate o f preintervention T IM I-3 flow was 17% ,  which 
is lower than the observed rate of T IM I-3 flow in the pretreatment trials of abciximab, 
but comparable to the 20%  in the meta-analysis of any glycoprotein IIb/IIIa blocker as 
pretreatment before primary angioplasty[5]. Although pretreatment strategies with a 
glycoprotein IIb/IIIa inhibitor[5] or half dose alteplase[25] are safe and have been shown 
to modestly improve preintervention patency[6], the clinical efficacy in case of pretreat­
ment has yet to be demonstrated. In the recent A SSEN T -4 trial, pretreatment with full- 
dose thrombolysis has been shown to improve preintervention patency but failed to 
demonstrate a mortality benefit as compared to primary angioplasty[24]. W hether this 
apparent disconnect between preintervention patency and clinical outcome is due to
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studied pretreatment regimen or due to inclusion of patients with a disadvantageous 
risk profile, may be further elucidated in the ongoing F IN ESSE  trial studying pretreat­
ment with half-dose lysis in combination with abciximab.
Limitations
Enoxaparin was chosen as the adjuvant anticoagulant in both treatment strategies of 
our trial. After thrombolysis enoxaparin has been shown more effective in reducing 
ischemic events than unfractionated heparin for 4 8 -7 2  h[26]. As a result o f the increased 
risk of ICH associated with this enoxaparin regimen in patients over 75 years of age 
in the A SSEN T -3 PLUS trial[27], we have adopted the age adjusted dosage regimen of 
the TIM I-EXTRACT trial[28]. Enoxaparin in combination with abciximab has never been 
tested in primary angioplasty. However, the combination has been shown feasible and 
safe in conjunction with elective PCI in the N IC E -4  study[29]. The continuation of enoxa­
parin for at least 48  h has arbitrarily been chosen as no clear consensus exists about 
the duration of anticoagulation therapy after primary angioplasty. For practical reasons 
4 4 %  of patients only received an abciximab bolus before transferral for angioplasty. 
Although the anti-aggregatory effect of a single bolus is maximal after two hours and 
measurable for 2 4  h thereafter, the impact of a delay in the initiation of infusion is 
uncertain and might be less efficacious if transferal times are long. Patients in the HIS 
trial randomised to thrombolysis did not receive clopidogrel routinely as the results 
of the C LAR ITY [3° ] and C O M M IT [31] trial became only known after termination of our 
study. Administration of (a high-loading dose of) clopidogrel as pretreatment in pa­
tients undergoing primary PCI was not a part of the H IS protocol. Although efficacious 
in patients undergoing PCI for non-ST-elevation MI, the impact of pretreatment with (a 
high loading dose of) clopidogrel has not yet been addressed in primary angioplasty.
Conclusion
In this randomised transportation trial in patients presenting in a referral centre with 
large ST-elevation myocardial infarction, transfer for abciximab facilitated primary an­
gioplasty tended to improve clinical outcome and to be associated with more complete 
early ST-resolution as compared to on-site fibrin-specific thrombolysis with a liberal 
rescue strategy. Although meta-analysis demonstrated a 1 .9%  absolute mortality ben­
efit for transport for primary angioplasty, streptokinase was used as the comparator
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in 4 0 %  of patients. Given the real world delays for patients referred for primary an­
gioplasty, further studies using early fibrin-specific lysis with a liberal rescue policy 
as comparator are warranted for patients with large ST-elevation MI presenting in a 
referral centre.
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Prehospital Triage for Primary Angioplasty
ABSTRACT
Objective: To study the impact of direct referral to an intervention center after prehos­
pital diagnosis of STEM I on treatment intervals and outcome.
Background: Primary angioplasty has become the preferred reperfusion strategy in ST- 
elevation myocardial infarction. Ambulance diagnosis and direct referral to an interven­
tion center is an attractive treatment option which has not been studied extensively.
Methods: Consecutive prehospital patients with STEM I who were referred to our in­
tervention center for primary angioplasty between 20 0 5  and 2 0 0 7  were studied. After 
prehospital diagnosis patients were either directly transported to our center or referred 
through a non-intervention center. The cath lab was activated before transport to the 
intervention center.
Results: O f the 581 patients referred 454  (78% )  came with direct transport and 127 
(2 2 % )  through a non-intervention center. Direct transport was associated with a higher 
proportion of patients treated within the 9 0 -minute time window of the STEM I guide­
lines: 82%  vs. 23%  (p<0 .0 1). Patients directly transported had a significantly shorter 
median symptom-to-balloon time 149  minutes (118 -19 7 ) vs. 219  (178-315), p<0 .0 1 , a 
higher postprocedural T IM I -3 flow rate (9 2%  vs. 84% ,  p=0 .03) and lower one-year 
mortality (7%  vs. 13% ;  p=0 .03). Direct transport to the intervention center was inde­
pendently associated with the symptom-to-balloon time, which in turn was an inde­
pendent predictor of postprocedural T IM I -3 flow, a strong prognosticator of outcome.
Conclusions: After ambulance based diagnosis of STEM I direct transport to an inter­
vention center with prehospital notification of the catheterization laboratory more than 
triples the proportion of patients treated within the guidelines time window. Time to 
balloon was an independent predictor of post procedural T IM I grade 3 flow, which 
underscores the need to reduce treatment delays.
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in t r o d u c t io n
Primary angioplasty is the preferred reperfusion therapy in ST-elevation myocardial 
infarction (STEM I) if performed within 90  minutes of first medical contact by an expe­
rienced team of personnel in a high-volume center[1]. In real world practice only ~10 %  
of patients in the United States meet the current time goal in case of referral for pri­
mary angioplasty[2]. Strategies to reduce treatment delays in primary angioplasty are a 
subject of interest. It was shown that early activation of the catheterization laboratory 
is associated with a reduced door-to-balloon tim e[3]. Prehospital diagnosis, notification 
and direct referral to an intervention center is a promising strategy associated with a 
significant reduction in treatment delays[4,5]. This strategy was associated with better 
left ventricular function and a lower risk of death or M I[6] as compared to a strategy 
of referral from a non-intervention center. Although most studies using prehospital 
triage were performed in Europe, data from the US confirm the feasibility and im­
pact of the prehospital electrocardiogram in managing patients with S T EM I[7'9]. In the 
Netherlands, where distances between hospitals are much smaller and patients with 
suspected STEM I usually bypass the emergency physician and are immediately triaged 
by a cardiologist, a higher proportion of patients is treated within the time goal of 
the guideline. In the Nijmegen area (The Netherlands) a system of prehospital triage 
of STEM I has been used for over 15 years, initially designed to triage for prehospital 
fibrinolysis[10]. This same system now serves for the triage for primary coronary inter­
vention. In contrast to previous studies in which prehospital triage was compared with 
in-hospital triage, the current study focuses on prehospital triage and compares direct 
transport to an intervention center to referral through a non-intervention center. The 
aim of our study is to further elucidate the impact of direct transport to the interven­
tion center on treatment intervals, procedural and clinical outcome.
METHODS
Patients
Consecutive patients with a prehospital diagnosis of ST-elevation myocardial infarc­
tion (STEM I) referred for primary angioplasty to the catheterization laboratory of the
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Radboud University Medical Center in Nijmegen, the Netherlands were included in a 
registry from January 20 0 5  until December 2 0 0 7 .
Intervention Center
The Radboud University Medical Center Nijmegen, Netherlands is a University Hos­
pital and tertiary referral center. It is a high-volume center performing > 10 0 0  angio­
plasty procedures per year, with 3 catheterization laboratories, surgical back-up and a 
team of experienced personnel with around the clock service. All operators perform 
>150  procedures per year. Before 20 0 5  primary angioplasty was only performed in 
a selected group of patients (late MI, shock and in case of a contra-indication for 
fibrinolysis) due to a successful prehospital fibrinolysis program with two thirds of 
patients receiving fibrinolysis within 3 hours of symptoms[10,11]. Rescue angioplasty was 
performed in more than 10 0  patients per year.
Patients
From the beginning of 2 0 0 5 , in agreement with the referral sites (ambulance services 
and local hospitals), all prehospital patients with large infarctions (>15 mm cumula­
tive ST-segment deviation), were referred for primary angioplasty. Prehospital patients 
with smaller infarctions (< 15 mm ST-segment deviation) were treated either with pre­
hospital fibrinolysis or primary angioplasty depending on local agreements. Regular 
evaluation of the protocol demonstrated the feasibility and success of this primary 
angioplasty strategy, and prehospital fibrinolysis for smaller infarcts gradually de­
creased. Over time primary angioplasty became the reperfusion strategy of choice for 
all patients. All patients who were presented to our intervention center were accepted 
for primary angioplasty. In case of an eligible patient the resident of the intervention 
center was contacted either directly from the ambulance by paramedics or by the phy­
sician on call in the referral center. After acceptance the catheterization laboratory per­
sonnel was directly activated to prepare the catheterization laboratory. If possible the 
emergency room of the intervention center was bypassed and the patient was directly 
transported to the catheterization laboratory.
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Referral region
The referral region is located in the east of the Netherlands and covers parts of the 
provinces of Gelderland and Brabant. It has a radius of about 48  miles with about 
1 ,0 0 0 ,0 0 0  inhabitants. Five referral hospitals and 4  regional ambulance services are 
located in the referral region. Patients presenting with ST  elevation MI in a non-in­
tervention center were treated with primary angioplasty, but were excluded from the 
current analysis of prehospital patients.
Ambulance Protocol
All ambulances in the region were equipped with the Lifepak-12  system. Specially 
trained paramedics made a 1 2 -lead electrocardiogram (ECG) in all patients with chest 
pain for less than 12  hours of duration, not resolving after sublingual nitroglycerin. This 
1 2 -lead prehospital ECG was interpreted by the paramedics with the help of a com ­
puter algorithm. In case of a clear cut case of a patient with a large STEM I (> 15 mm) 
paramedics contacted the cardiology resident of the intervention center to notify the 
cath lab before transportation. In other cases prehospital fibrinolysis or primary PCI 
was chosen, often after initial contact with the cardiologist of the nearest hospital. All 
patients who were suspected of STEM I were given a loading dose of aspirin, clopido­
grel and unfractionated heparin before transport according to the prevailing guidelines 
at the time of inclusion.
Definitions
Symptom time: time o f symptom onset. 911 call time: time of 911 call. Diagnosis time: = 
First Medical contact time = time of first ECG on which ST-elevation MI was diagnosed. 
Door time: time of arrival at the intervention center. Balloon time: time of first balloon 
inflation or first device insertion. Total distance: The total distance was calculated with 
the use o f an internet route planner using postal codes. Direct transport: the distance 
between the pick-up address and the intervention center. Interhospital transport: the 
distance between the pick-up address and referral hospital plus the distance between 
the referral hospital and the intervention center.
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Endpoints
Postprocedural TIMI-flow: TIMI-flow after the procedure was assessed by two expe­
rienced angiography analysists blinded to the study group of the patient. In case of 
discrepant findings, TIMI-flow was determined by a third angiography analysist[12].
Long-term mortality: Information about the survival status of the patients was as­
sessed on the 19 th and 23th of March 2 0 0 8  for the patients included in 20 0 5  and 
2 0 0 6 , and on 5th of May 2 0 0 9  for patients included in 2 0 0 7  using the Municipal Per­
sonal Records Database.
Statistical analysis
Categorical variables are expressed as numbers with percentages and were compared 
by Pearson's chi-square and Fisher's exact test whenever appropriate. Normally dis­
tributed continuous variables are expressed as means with standard deviations and 
were compared using an independent T-test. Continuous variables not normally dis­
tributed are expressed as medians with interquartile ranges (IQR) and were compared 
using the Mann-Whitney-U test. Multivariable binary logistic regression using forward 
stepwise inclusion was used to assess the relation between direct transport to the 
intervention center and the symptom-to-balloon time (divided at the median). Entered 
in the model were those variables (listed in Table 1) with a univariate association with 
the median symptom-to-balloon time (p < 0 .10 ), and the baseline variables that dif­
fered (p < 0 .10 ) between direct transport to the intervention center and interhospital 
transport. The symptom-to-911 call time was prospectively chosen to be included in 
the model. To assess the relation between direct transport to the intervention center 
and the postprocedural T IM I -3 flow binary logistic regression was used with similar 
methodology as described above. Long-term survival analysis was performed accord­
ing to Kaplan and Meier, using the log-rank test for a univariate comparison between 
patients directly transported to the intervention center and patients referred through 
a non-intervention center. Multivariable Cox-regression analysis using forward step­
wise inclusion was used to determine the association between direct transport to the 
intervention center and survival. Baseline characteristics (listed in Table 1) studied 
had a univariate association with survival (p < 0 .10 ) or differed (p < 0 .10 ) between di­
rect transport and referral through a non-intervention center. The symptom-to-balloon
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time and door-to-balloon time were prospectively chosen to be included in the multi­
variable models of postprocedural T IM I-3 flow and mortality.
r e s u l t s
In total 581 prehospital patients with ST-elevation were referred for primary angioplas­
ty to the catheterization laboratory of the Radboud University Medical Center between 
January 20 0 5  and the end of December 2 0 0 7 . All but one patient with ST-elevation on 
the prehospital ECG had ST-elevation myocardial infarction. The other patient had an 
aortic dissection type A and died after the catheterization (direct transportation to the 
intervention center). During transport no patient died. Between first presentation and 
primary angioplasty 14%  of patients had an episode of ventricular fibrillation.
Direct transport to intervention center versus interhospital transport
O f  the patients who first presented in the ambulance 454  (78% )  were directly trans­
ported to our intervention center and 127  (2 2 % )  were referred through a non-inter­
vention center. The baseline and angiographic characteristics are shown in Table 1 . 
O f  the patients directly transported to the intervention center 82%  had a first-med- 
ical-contact-to-balloon time of less than 90  minutes and adhered to the time goal 
of the STEM I guidelines as compared to 23%  of patients who were referred through 
a non-intervention center (p<0 .0 1) The corresponding median symptom-to-balloon 
times were 149  minutes (IQR: 118 -19 7 ) versus 219  m in.(IQR: 178 -315), p<0.01 (Figure 1). 
The symptom-to-911 call (A 7 minutes), 911 call-to-diagnosis (A 3 minutes) and the 
diagnosis-to-balloon time (A 49 minutes) were significantly shorter in patients who 
were directly transported to the intervention center. The door-to-balloon time was sig­
nificantly longer in patients directly transported to the intervention center, 32 m in­
utes (IQR: 2 0 -45) vs. 2 4  minutes (IQR: 17-36), p<0 .0 1 . Patients directly transported 
to the intervention center more often had post procedural T IM I -3 flow (9 2%  vs. 84% , 
p=0 .03) and had lower mortality at one year (7%  vs. 13% ,  p=0 .03) as compared to 
patients after interhospital transport (Figures 2 and 3).
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Table 1 : Baseline characteristics o f prehospital patients referred for primary pci
Direct
transport
n=454
Interhospital
transport
n= 12 7
p-value
Age, yrs, mean, SD 63 ± 12 65 ± 13 0.05
Age > 75 years 76 07% ) 33 (26%) 0.02
Male 323 (71% ) 92 (72%) ns
Diabetes 38 (8% ) 14 (11%) ns
Hypertension 162 (36% ) 36 (28% ) ns
Previous MI 49 (11% ) 19 (15%) ns
Previous revascularization (CABG/PCI) 35 (8% ) 13 (10% ) ns
Killip class I 382 (84% ) 99 (78%) ns
Cardiogenic shock (Killip IV) 39 (9%) 12 (9%) ns
Anterior MI 164 (36% ) 56 (44%) 0.10
>15 mm ST deviation 291 (64% ) 53 (42% ) <0.01
Presentation during office hours 181 (40% ) 49 (39%) ns
Total distance, km, median, IQR 13 (5-24) 23 (10 -47) <0.01
Infarct related artery:
- LAD 160 (36% ) 58 (47%) 0.03
- non-LAD 294 (64%) 69 (53%)
Single vessel disease 199 (45%) 54 (43%) ns
Preprocedural TIMI-flow:
TIM I-3 flow 66 (15% ) 16 (13% ) ns
TIMI-2/3 flow 126 (28% ) 30 (24%) ns
Yrs = years; SD = standard deviation; MI = myocardial infarction; mm = millimeters; km = kilometers; 
IQR = interquartile range; LAD = left anterior descending artery; ns = not significant; CABG = coronary 
artery bypass grafting; PCI = percutaneous coronary intervention
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Figure 1: Median symptom-to-balloon times in prehospital patients referred for primary angioplasty.
All time intervals are represented as medians and differ significantly (p<0.05) between direct 
transport to the intervention center and interhospital transport.
Figure 2: Pre- and postprocedural TIMI-3 flow rates in prehospital patients referred for primary angio­
plasty.
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Figure 3: Impact of direct transport to the intervention center on one-year survival in prehospital patients 
referred for primary angioplasty.
Predictors o f the symptom-to-balloon time
The symptom-to-balloon time was dichotomized at the median and was available in 
all patients. The univariable (p<o.io) and multivariable characteristics associated with 
increased (above the median) symptom-to-balloon times are listed in Table 2 .
Predictors o f postprocedural T IM I-3 flow
Postprocedural T IM I-3 flow was available in all patients. The univariable (p<o.io) and mul­
tivariable characteristic associated with post procedural T IM I-3 flow are listed in Table 3 .
Long-term mortality
Follow-up at one year was complete for all but one patient (9 9 .8% ) .  The median total 
follow-up duration was 596 days (IQR: 496  -  7 2 6 ). During follow-up 64  patients (11% )  
had died. Univariable (p<o.io) and multivariable predictors o f long-term mortality are 
shown in Table 4 .
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Table 2 : Variables associated with the symptom-to-balloon time*
Variable
Univariable analysis
O R  (95%  CI) Wald x2 p-value
Symptom-to-911 call time (minute) 1.05 (1.04 - 1 .06 ) 117 <0.01
Direct transportation 0.15 (0.09 - ° . 24) 58 <0.01
Total covered distance (km) 1.02 (1.01 - ■L°4 ) 11 <0.01
Age (year) 1.02 (1.00 - 1 .03) 9 <0.01
>15 mm ST-deviation 0.67 (0.48 - 0.93) 6 0.02
Previous revascularization 1.76 (0.96 - 3.23) 3 0.07
Multivariable analysis
Symptom-to-911 call time (minute) 1.06 (1.05 - 1.08) 58 <0.01
Direct transportation 0.29 (0.01 - 0 .11) 42 <0.01
Total covered distance (km) 1.03 (1.00 - 1 .0 5) 5 0.03
* = dichotomized at the median; OR = Odds ratio; CI = confidence interval; km = kilometers
Table 3 : Variables associated with post procedural timi flow grade 3
Variable
Univariable analysis
O R  (95%  CI) Wald x2 p-value
Symptom-to-Balloon time (hour) 0 8 7 (0 .78 - 0 .95) 9 <0.01
Pre-procedural TIMI-flow 1.60 (1.16 - 2 .20) 8 <0.01
Single vessel disease 2 .18 (M 9 - 3 .97) 6 0.01
Direct transportation 2.04 (1.14 - 3.64) 6 0.02
Killip class I 1.95 (1 0  - 3.52) 5 0.03
Door-to-Balloon time (minute) 0.99 (0.99 - 1 .01) 0 0.7
Multivariable analysis
Pre-procedural TIMI-flow 1.43 (1.14 - 1 .80) 9 <0.01
Symptom-to-Balloon time (hour) 0.87 (0.80 - 0 .96) 8 <0.01
Single vessel disease 1.89 (1.19 - 3 .01) 7 0.01
OR = Odds ratio; CI = confidence interval
68
Prehospital Triage for Primary Angioplasty
Table 4 : Variables associated with long-term mortality
Variable
Univariable analysis
O R  (95%  CI) Wald x2 p-value
Age (year) 1.08 (1.05 - 1 .10 ) 42 <0.01
Post-procedural T IM I-3 flow 0.22  (0.13 - 0 .37) 31 <0.01
Killip I 0.36 (0.22  - 0 .59) 16 <0.01
Symptom-to-Balloon time (hour) 1.13 0 .°4  - 1 .24) 8 <0.01
Single vessel disease 0.48 (0.28 - 0 .82) 7 <0.01
Hypertension 1.89 O.M - 3.14) 6 0.01
Direct transportation 0.55 (0.33 - 0.93) 5 0.03
Previous revascularization 1.95 (°.9 6 - 3.95) 3 0.06
>15 mm ST-deviation ^6°  (°.94 - 2 .74) 3 0.09
Door-to-Balloon time (minute) 1.00  (0.99 - 1 .01) 0 1.0
Multivariable analysis
Age (year) 1.08 (1.05 - 1 .10 ) 36 <0.01
Post-procedural T IM I-3 flow 0 2 5 ( °.M  - °4 4 ) 23 <0.01
Killip I 0.47 (0.28 - 0 .81) 8 0.01
HR = Hazard Ratio; CI = confidence interval; MI = myocardial infarction
DISCUSSION
To our knowledge, this is the largest prospective cohort o f patients after prehospital di­
agnosis of STEM I comparing direct transport to an intervention center with interhospi­
tal transfer, and the first to suggest an effect of direct transport on long-term survival. 
Compared to interhospital transport, the rate of patients treated within the 9 0 -minute 
time frame of the guidelines more than tripled. Moreover, direct transport resulted in 
higher rates of postprocedural T IM I-3 flow, a strong prognosticator of improved long­
term survival. This was observed in a unique setting of a more than 1 0 -year experience 
with prehospital diagnosis of STEM I by trained paramedics, computerized ECG inter­
pretation and telephone consultation with a physician.
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The observed time benefit of direct transportation is in concordance with previous 
reports showing comparable benefits with regard to improved time delays [4,5]. Given 
the higher postprocedural T IM I -3 flow rate and the fact that guideline adherence has 
been associated with clinical outcome[13], this infrastructure should further improve 
outcome after STEM I. Several studies showed that prehosital diagnosis is associated 
with a greater use of reperfusion therapy[8], with a substantial reduction of treatment 
intervals and with improved outcome in fibrinolysis[14] and primary angioplasty[4'6,8]. In 
addition, in the current study several interventions proven to be effective in reducing 
treatment intervals[3] are part of standard of care. Examples of these interventions are 
a single call from the ambulance to activate the catheterization laboratory, activation 
of the catheterization laboratory while the patient is en route and the fact that the 
intervention team had to be present within 20  minutes after being paged. Previous 
studies compared patients who presented at the referral center with patients directly 
transported to the intervention center after prehospital diagnosis. In contrast, all pa­
tients in our study underwent prehospital diagnosis of STEM I. The results of our study 
therefore underline the importance of direct referral to an intervention center, com ­
pletely bypassing the emergency department if possible.
W ith regard to the safety, our data concur with CAPT IM  and DANAMI-2 , that showed 
a low mortality rate during ambulance transport[15,16]. Although not available in the 
current analysis, the reported sensitivity and specificity of a computer algorithm (of­
ten used in the prehospital setting) to detect ST-elevation myocardial infarction are 
5 0 -60%  and 9 6 -10 0 %  respectively[17]. The relatively high mortality rate and the high 
prevalence o f ventricular fibrillation in the current study is probably a reflection of the 
inclusion of substantial amount of older patients and patients presenting with large 
infarction. The apparent selection bias for older patients to be transferred through 
a referral hospital may be a consequence of the absence of an age limit for primary 
angioplasty. Doubt in the prehospital setting about the indication for primary angio­
plasty may have caused the preference for transport to the nearest referral center for 
additional evaluation. Moreover, patients may have been considered to sick for direct 
transport and may therefore have been presented at the nearest hospital.
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Shorter symptom-to-balloon times were independently associated with higher rates of 
post procedural T IM I-3 flow and patients directly transported to the intervention cen­
ter had improved long-term survival. Direct transportation to the intervention center 
was independently associated with a shorter symptom-to-balloon time, a strong pre­
dictor of procedural success, which in turn is a prognosticator of long-term mortality.
In the current analysis well known independent predictors of outcome were con­
firmed. Preprocedural T IM I flow and symptom-to-balloon time are well established 
predictors of procedural success[18,19] and underline the importance of studies on anti­
thrombotic pretreatment and reducing treatment delays. Age, Killip class and proce­
dural outcome were confirmed to be independent prognosticators of long-term mortal- 
ity[2° '21]. As procedural outcome is the only modifiable predictor efforts should be made 
to perform primary angioplasty in high volume centers with experienced personnel[22]. 
In previous transportation studies the observed differences and sample sizes were too 
small to state conclusions with regard to clinical outcome. Our cohort study supports 
the previously observed trends of improved clinical outcome after direct transport to 
the intervention center. The fact that we observed higher postprocedural T IM I -3 flow 
rates after direct transport to the intervention center, provides a plausible mechanistic 
explanation for the higher survival rate in this group.
Limitations
Results from the current analysis are from an observational study in which the referral 
strategy for smaller infarctions was not uniform between referral sites and tended to 
change over time. Inherently, bias has been introduced with regard to the selection 
between direct transport to the intervention center or interhospital transport.
This may have affected the observed clinical outcome differences, but the time in­
tervals from 911 call to balloon inflation will be merely unaffected. Although multivari­
able analysis was used confounding of unknown and/or uncorrectable factors can not 
be excluded. Although only established predictors of outcome were found in the cox 
analysis the model is overfit and should be interpreted conservatively.
Conclusions and implications
Prehospital diagnosis of STEM I with direct notification of the cath lab and subsequent 
transportation to the intervention center is an attractive treatment strategy. It results
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in a more than tripling of the rate of patients treated within the 9 0 -minute timeframe 
of the STEM I guideline compared to interhospital transport. Direct transportation to 
the intervention center resulted in a reduction of about 50 minutes in the diagnosis-to- 
balloon time. In case of uncertainty with regard to the diagnosis of STEM I or indication 
for reperfusion therapy, valuable time can be saved by direct transportation and evalu­
ation in the intervention center, in stead of opting for presentation at the nearest non­
intervention center. W ith the symptom-to-911 call time representing one third o f the 
symptom-to-balloon time, renewed efforts should be made for patients' awareness [23]. 
Time-to-balloon was an independent predictor of post procedural T IM I 3 flow, which 
underscores the need to reduce treatment delays in order to further improve clinical 
outcome after STEM I. O ur data underscore that efforts should be made to organize 
a large scale implementation of an infrastructure of prehospital diagnosis and direct 
transport to the intervention center, with early notification o f the cath lab from the 
ambulance.
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The impact of treatment intervals in pre-hospital initiated primary angioplasty
ABSTRACT
Background: Pre-hospital diagnosis of ST-elevation myocardial infarction (STEM I) and 
immediate cath lab notification markedly reduces delays until primary angioplasty. The 
impact of treatment intervals in this setting has not been studied extensively.
Methods: Consecutive patients with a pre-hospital diagnosis of STEM I who were re­
ferred to the Radboud University Medical Center in Nijmegen, the Netherlands for 
primary angioplasty between 20 0 5  and 2 0 0 7  were followed for 1 year.
Results: 547 patients had complete data on time intervals and during follow-up (me­
dian 593 days; IQR: 4 9 3-732 ) 60  patients had died. The median symptom-to-balloon 
time was 16 2  minutes (IQR: 12 6 -218 ), with 6 0%  treated within 3 hours of symptom 
onset. The median first medical contact (FMC)-to-balloon time was 82 min. (IQR: 
6 6 -10 7 ), with 61%  treated within 90  minutes after EM S arrival. The median door-to- 
balloon time was 31 min. (IQR: 19 -4 4 ), with 97%  treated within 90  min. of hospital 
arrival. Neither the door-to-balloon time nor the FMC-to-balloon time (per 30  minutes) 
was significantly associated with long-term mortality, HR 1 .0 9 , 95% C I 0 .85-1 .4 0 , p=0.5 
and HR 1 .0 7 , 95% C I 0 .95-1 .2 1 , p=0 .3 , respectively. The symptom-to-balloon time was 
an independent predictor o f long-term mortality, HR 1.0 7  (95% C  1: 1 .0 1-1 .12 ), p=0 .0 2 , 
together with age and Killip class.
Conclusions: In this series of pre-hospitally diagnosed STEM I with subsequent primary 
angioplasty, the symptom-to-balloon time is an independent predictor of mortality. In 
a setting with very short door-to-balloon times, and with good first-medical-contact- 
to-balloon times with only modest variation, these intervals were not associated with 
mortality. In an infrastructure with increasing optimization of intervals after patient 
presentation, efforts to try and reduce patient delays will become more and more 
important.
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INTRODUCTION
Primary angioplasty is the preferred reperfusion therapy in ST-elevation myocardial 
infarction (STEM I) if performed within 90  minutes of first medical contact by an expe­
rienced team of personnel in a high-volume center[1]. The guidelines state that if this 
time limit cannot be met fibrinolysis should be considered as alternative. A large scale 
multicenter US registry has demonstrated that only one third of patients had a door- 
to-balloon time of less than 9 0  minutes and that a prolonged door-to-balloon time was 
independently associated with increased in-hospital mortality[2]. This registry referred 
to patients who presented in a hospital, either at an intervention center or in a center 
without intervention capabilities. Pre-hospital triage of STEM I with direct transport to 
an intervention center and pre-hospital notification of the catheterization laboratory 
has been associated with a significant reduction in treatment delays. W ith this strategy 
>7 0%  of patients can be treated within the time window of the guidelines[3'5]. Addition­
ally, the time from symptom onset to presentation is about 60  minutes shorter in case 
of pre-hospital triage[3]. Given the improvement in treatment delays, a process of pre­
hospital identification and activation with destination protocols for patients with ST E ­
MI is advocated in the most recent update of the guidelines[1]. In case of a system with 
pre-hospital diagnosis of STEM I, patients should be treated with angioplasty within 
9 0  minutes of EM S arrival at the scene (first medical contact-to-balloon time), and the 
door-to-balloon time should be reserved as marker for STEM I patients presenting at 
an intervention center. The prognostic impact of the different treatment delays in pa­
tients presenting in the pre-hospital setting has not been studied extensively and will 
be addressed in the current study of primary angioplasty.
METHODS
Patients
Patients with a pre-hospital diagnosis of ST-elevation myocardial infarction (STEM I) 
referred for primary angioplasty to the catheterization laboratory of the Radboud Uni­
versity Medical Center in Nijmegen, the Netherlands, were included in a registry from 
January 20 0 5  until December 2 0 0 7  and followed for one year.
78
The impact of treatment intervals in pre-hospital initiated primary angioplasty
Ambulance Protocol
All ambulances in the region were equipped with the Lifepak-12  system. Specially 
trained paramedics made a 1 2 -lead electrocardiogram (ECG) in all patients with chest 
pain for less than 12  hours of duration, not resolving after sublingual nitroglycerin. This 
1 2 -lead pre-hospital ECG was interpreted by the paramedics with the help of a com ­
puter algorithm. In case of a clear cut case of a patient with a large STEM I (> 15 mm) 
paramedics contacted the cardiology resident of the intervention center to notify the 
cath lab before transportation. In other cases pre-hospital fibrinolysis or primary PCI 
was chosen, often after initial contact with the cardiologist of the nearest hospital. All 
patients who were suspected of STEM I were given aspirin, clopidogrel and unfraction­
ated heparin before and/or during transport according to the prevailing guidelines at 
the time of inclusion.
Intervention Center
The Radboud University Medical Center Nijmegen, Netherlands is a University Hos­
pital and tertiary referral center. It is a high-volume center performing over 10 0 0  an­
gioplasty procedures per year, with 3 catheterization laboratories, 2 4 /7-surgical back­
up and a team of experienced personnel with around the clock service. All operators 
perform more than 150 procedures per year. All patients presented by the ambulance 
to our intervention center with a suspected ST-elevation myocardial infarction were 
accepted for primary angioplasty. After acceptance the catheterization laboratory per­
sonnel was directly activated to prepare the catheterization laboratory for the arrival of 
the patient. If possible, the emergency room of the intervention center was bypassed 
and the patient was directly transported to the catheterization laboratory.
Definitions
Symptom time: time of symptom onset. 9 11call time: time of 911 call. First Medical 
contact time = time of arrival of the EM S personnel at the scene[1]. Door time: time of 
arrival at the intervention center. Balloon time: time of first balloon inflation or first 
device insertion.
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Endpoint
Long-term mortality: Information about the survival status of the patients was as­
sessed on the 19 th and 23th of March 20 0 8  for the patient included in 20 0 5  and 2 0 0 6 , 
and on 5th of May 2 0 0 9  for patients included in 2 0 0 7  using the Municipal Personal 
Records Database.
Statistical analysis
Categorical variables are expressed as numbers (% ) and were compared by Pearson's 
chi-square and Fisher's exact tests whenever appropriate. Normally distributed contin­
uous variables are expressed as means with standard deviations and were compared 
using a one-way analysis of variance. Continuous variables not normally distributed 
are expressed as medians with interquartile ranges (IQR) and were compared using 
the Kruskal-Wallis test. According to the time from symptom onset to the first balloon 
inflation patients were divided into three groups (< 3 hours, 3-6  hours and > 6 hours). 
For the time from EM S arrival to balloon inflation patients were divided into 3 three 
groups (< 1 hour, 1 -2  hours and > 2 hours). Several subgroups (1 . high risk patients; 2 . 
presentation delay < 2 hours; 3 . no flow at first injection) were studied in particular, to 
allow comparisons with previous reports[7'12]. Patients were considered at high risk if at 
least one the following criteria was present; age > 70  years, Killip class > 2 or anterior 
myocardial infarction[7].
Predictors of long-term mortality were assessed with Cox-regression analysis. For­
ward stepwise inclusion of variables was used to determine the independent associa­
tion between the predictors and survival. Baseline characteristics listed in table 1 were 
studied and included in the model if a univariate association with survival (p < 0 .10 ) 
was present. The TIMI-flow after the procedure was not included in the model as this 
variable is available after balloon inflation and therefore is an outcome variable with a 
known relation with time intervals and mortality[13,14].
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RESULTS
In total 581 patients with pre-hospital diagnosis of ST-elevation were referred for pri­
mary angioplasty. Data on the time intervals was complete in 547 patients. The median 
time intervals are depicted in figure 1 . The median total follow-up duration was 593 
days (IQR: 493 -  732). In total 60  patients had died. One year follow-up was complete 
in all but one patient (9 9 .8% ).
Figure 1: Median time intervals from symptom onset to balloon inflation in patients referred for primary 
angioplasty after pre-hospital diagnosis of STEMI.
Symptom-to-Balloon time
The median symptom-to-balloon time was 16 2  minutes (IQR: 12 6 -218 ) and 60%  of 
patients were treated within 3 hours of symptom onset. Demographic, clinical and 
angiographic characteristics according to the symptom-to-balloon time are listed in 
table 1 . The impact of the symptom-to-balloon time on one-year mortality is shown 
in figure 2 . Per 30  minutes the symptom-to-balloon was significantly associated with 
long-term mortality, hazard ratio (HR) 1.0 8  (95%  CI: 1 .0 3-1 .13), p=0 .0 0 1 .
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Table 1 : Baseline and angiographic characteristics according to the symptom-to- 
balloon time
0 -3  hours
n=329
3 -6  hours
n=173
> 6  hours
n=45
p-value
Age (years, mean, SD) 61 ± 12 65 ± 13 66 ± 14 0.01
Male 239 (73%) 119 (69% ) 29 (64% ) ns
Diabetes 22 (7%) 18 (10% ) 7 (16%) 0.08
Hypertension 100 (30% ) 64 (37%) 20 (44%) 0.09
Current smoking 188 (57% ) 79 (46%) 18 (41% ) 0.01
Previous revascularization 24 (7%) 18 (10% ) 5 (11% ) ns
Previous aspirin use 48 (15%) 36 (21%) 14 (32% ) 0.01
Killip class I 279 (80% ) 135 (78%) 36 (80%) ns
>15 mm ST deviation 209 (64%) 89 (51%) 22 (49%) 0.01
Anterior MI 123 (37%) 66 (38% ) 19 (43%) ns
Single vessel disease 153 (47%) 73 (42% ) 14 (31% ) ns
Pre-procedural TIMI 3 flow 51 (16% ) 18 (10% ) 8 (18% ) ns
Post-procedural T IM I-3 flow 305 (93%) 153 (88% ) 37 (82% ) 0.02
Symptom-to-Balloon time 
(min, median, IQR)
134 (111-154) 222 (198-266) 500 (419-606) <0.01
Symptom-to-911 call time 
(min, median, IQR)
38 (19-62) 107 (67-151) 359 (274-459) <0.01
911-call-to-FMC time 
(min, median, IQR)
11 (8-14) 11 (9-14) 5)9­12 ns
FMC-to-Balloon time 
(min, median IQR)
76 (63-90) 100 (74-138) 109 (74-169) <0.01
SD=standard deviation; MI = myocardial infarction; ns = not significant (p > 0.10); FMC = first medical 
contact; min=minutes; IQR=interquartile range
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Figure 2: One year mortality for the symptom-to-balloon time and the first-medical-contact-to-balloon 
time in patient referred for primary angioplasty after pre-hospital diagnosis of STEMI.
First-medical-contact-to-balloon time
The median first medical contact (FMC)-to-balloon time was 82 minutes (IQR: 6 6 ­
10 7 ), 61%  of patients were treated within 90  minutes after EM S arrival. Demographic, 
clinical and angiographic characteristics according to the symptom-to-9 11-call time are 
listed in table 2 . The FMC-to-balloon time (per 30 minutes) was not significantly asso­
ciated with long-term mortality, HR 1.0 7  (95%  CI: 0 .95-1 .21), p=0 .3 . Neither in patients 
at high-risk (HR 1 .0 8 ; 95%  CI: 0 .9 4-1 .2 4 ; p=0 .3), with a symptom-to-911 call time < 2 
hours (HR 1 .13 ; 95%  CI: 0 .98-1 .31; p=0 .1), nor in patients with pre-procedural T IM I 0 or 
1 flow (HR 1 .1 0 : 95%  CI: 0 .9 6 -1 .2 6 ; p=0 .2), the FMC-to-balloon time was significantly 
associated with long-term mortality.
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Table 2 : Baseline and angiographic characteristics according to the first medical 
contact-to-balloon time (ems arrival)
0 -1  hour
n=83
1 -2  hours
n=368
> 2  hours
n=95
p-value
Age (years, mean, SD) 61 ± 11 63 ± 12 66 ± 13 <0.01
Male 62 (75%) 266 (72% ) 59 (62% ) ns
Diabetes 3 (4%) 33 (9%) 11 (12% ) ns
Hypertension 27 (33%) 127 (35%) 30 (32%) ns
Current smoking 47 (57%) 198 (54%) 40 (42%) 0.08
Previous revascularization 6 (7%) 26 (7% ) 15 (16% ) 0.02
Previous aspirin use 13 (16% ) 62 (16% ) 22 (23% ) ns
Killip class I 71 (86% ) 295 (80%) 68 (72%) 0.06
>15 mm ST deviation 51 (61% ) 228 (62%) 40 (42%) <0.01
Anterior MI 37 (45%) 131 (36% ) 39 (42%) ns
Total covered distance 
(km, median, IQR)
6 (4-14) 15 (6-28) 23 (11-49) <0.01
Single vessel disease 35 (42%) 168 (46%) 36 (38% ) ns
Pre-procedural TIMI 3 flow 13 (16% ) 54 (15%) 10 (11%) ns
Post-procedural T IM I-3 flow 74 (89%) 341 (93%) 79 (83%) <0.01
Symptom-to-Balloon time 
(min, median, IQR)
126 (90-183) 152 (126-196) 244 (198-343) <0.01
EMS=emergency medical system; SD=standard deviation; MI = myocardial infarction; ns = not signifi­
cant (p > 0.10); min=minutes
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Door-to-Balloon time
The median door-to-balloon time was 31 minutes (IQR: 19 -4 4 ), 97%  of patients were 
treated within 90  minutes. The door-to-balloon time (per 30  minutes) was not signifi­
cantly associated with long-term mortality, HR 1.0 9  (95%  CI: 0 .85-1 .4 0 ), p=o.5.
Multivariable predictors o f long-term mortality
Variables associated with long-term mortality are listed in table 3 . The symptom-to- 
balloon time was an independent predictor of long-term mortality, HR 1.0 7  (95% C I: 
1 .0 1-1 .12 ), p=0 .0 2 , together with age and Killip class.
Table 3 : Variables associated with long-term mortality
variable H R  (95% C I) Wald x2 p-value
Univariable analysis
Age (per year) 1.08 (1.05 - 1 .10) 39 <0.01
Killip class I °.33 (0.20 - 0 .55) 18 <0.01
Previous aspirin use Lnvq(N 3).54.-5.5 13 <0.01
Symptom-to-balloon time (per 30 min) 1.08 (1.03 - 1 .13) 11 <0.01
Current smoker °.44 (0.26 - 0 .76) 9 <0.01
Single vessel disease 0.52 (0.30 - 0 .90) 6 0.02
Previous revascularization 2.04 (1.00 - 4 .15) 4 0.05
Hypertension 1.63 (0.98 - 2 .71) 4 0.06
> 15 mm ST-deviation 1.48 (0.86 - 2 .56) 2 0.2
Anterior MI 1.41 (° . 85 - 2 .34) 2 0.2
Diabetes mellitus 1 52 (0.69 - 3.35) 1 0.3
Multivariable analysis
Age (per year) 1.°7 (1.04 - 1 .09) 28 <0.01
Killip class I 0.38 (0.22 - 0 .64) 13 <0.01
Symptom-to-balloon time (per 30 min) 1.07 (1.01 - 1 .12) 6 0.02
HR = Hazard Ratio; CI = confidence interval; min = minutes; MI= myocardial infarction
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DISCUSSION
Recent studies have reported on the positive impact of pre-hospital diagnosis of ST- 
elevation MI with regard to the reduction of treatment delays for primary PC I[3"6]. How ­
ever, to our knowledge this is the first study on the assocation of the different time 
intervals on patient outcome in this setting. W ith an overall median symptom to bal­
loon time of 16 2  minutes - of which patient delay accounted for 60  minutes- every 30 
minute increase was associated with a relative increase of 7%  in mortality. Almost all 
patients were treated within the 9 0 -minute door-to-balloon interval and in about two 
thirds of patients first medical contact-to-balloon time was less than 90  minutes. This 
infrastructure with rather fast treatment times, and the little variation in these times, 
may explain why the latter two intervals were found not be associated with outcome.
Symptom-to-balloon time
The aim of reperfusion therapy is to restore brisk antegrade coronary and myocardial 
blood flow as soon as possible in order to salvage jeopardized myocardium and im­
prove survival. W hile  the prognostic impact of time to therapy is well established in 
patients treated with fibrinolysis[15], conflicting data are reported for patients treated 
with primary angioplasty. This is the case, despite the fact that there is a clear rela­
tion between the time to treatment and the rate of successful reperfusion in primary 
angioplasty[13,14]. Two European studies have reported a relation between the total isch­
emic time and mortality. One study described this association in high risk patients[9]. 
The other performed a thorough analysis of allcomers and demonstrated that per 30 
minutes delay one-year mortality increased with 7% [16]. Our results concur with these 
latter findings and a comparable magnitude of increase in relative risk per 30 minute 
delay was observed for the symptom-to-balloon time. In contrast, several large US 
registries failed to demonstrate a relation between the symptom-to-balloon time and 
mortality[2,12]. An interesting difference between studies that demonstrated a relation 
between the symptom-to-balloon time and mortality and those without a clear asso­
ciation is the proportion of patients with a total ischemic time of less than 3 hours. In 
studies with an established relation between the total ischemic time and mortality the 
proportion with a symptom-to-balloon time of less than 3 hours is between 5 0-6 0%  
whereas in studies without this relation, the proportion is about 30% .
86
The impact of treatment intervals in pre-hospital initiated primary angioplasty
Another difference between the studies with and without a relation of the symp- 
tom-to-balloon time and mortality is the proportion o f patients with a door-to-balloon 
time of more than 2 hours. In the studies without a relation the proportion of patients 
with a door-to-balloon time of more than 2 hours is 4 0 -50%  whereas the studies with 
a relation this proportion is less than 2 0 % .  Another potential source for the observed 
difference in the impact of the symptom-to-balloon time may be related to selection 
bias as a result of differences in presentation delay. Late presenters have survived the 
first hours of myocardial infarction which is known to be the highest risk period of 
death. Unfortunately, the presentation delay and the proportion of patients presenting 
late is not consistently reported in all studies.
First medical contact-to-balloon time
To our knowledge this is the first pre-hospital registry to study the impact of the first 
medical contact-to-balloon time on mortality. In the current study about 60%  of pa­
tients had a first medical contact-to-balloon time of less than 90  minutes and this 
time interval was not associated with long-term mortality. Large scale registries from 
the US of patients presenting in-hospital have demonstrated that a prolonged door-to- 
balloon time is independently associated with increased mortality[2]. In these registries 
around 30%  of patients are treated within the time limit of the guidelines. The lack of 
impact of the fist medical contact to balloon time in our study may be related to the 
fast treatment times with only little variability. O ther studies in which the majority of 
patients are treated within the time limit of the guidelines also failed to demonstrate 
an impact on mortality[1°'11]. Several studies have compared pre-hospital initiated pri­
mary PCI to in-hospital initiation with regard to the impact on the treatment intervals 
and have used the door-to-balloon time as the primary endpoint. However the impact 
of the door-to-balloon time on clinical outcome in the setting of pre-hospital initiated 
primary PCI is unknown and may be different to the impact in the in-hospital setting. 
Potentially important time intervals like the time from presentation to diagnosis and 
the time from diagnosis to clinical decision making is not a part of the door-to-balloon 
time in the pre-hospital setting. The first medical contact-to-balloon time seems there­
fore the better comparator in pre-hospital initiated primary PCI. The definition of the 
first medical contact time differs in the European guidelines and ACC/AHA guidelines. 
In the European guidelines it is defined as the time of diagnosis o f ST-elevation myo­
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cardial infarction. This time point probably stems from the data studying the accept­
able delay to primary angioplasty as compared to fibrinolysis. The ACC/AHA guidelines 
define the first medical contact time as the time of emergency medical system arrival 
which facilitates the comparison with door-to-balloon times in patients presenting in a 
hospital. Given the known relationship between the door-to-balloon time and mortal­
ity we have chosen to use the latter definition in the current study. O f  note no relation 
could be substantiated between the diagnosis-to-balloon time and long-term mortality 
in the current study (data not shown).
Pre-hospital diagnosis: time intervals and quality improvement
In the current study with pre-hospital diagnosis of STEM I and notification of the cathe­
terization laboratory for primary angioplasty 60%  of patients has a total ischemic time 
of less than 3 hours and this time interval is an independent predictor of mortality. A 
pre-hospital strategy is associated with shorter treatment intervals after first medical 
contact, with not only a reduction in the door-to-balloon time but also in the time from 
presentation to diagnosis[17]. Importantly, also the time from symptom onset to pre­
sentation is about one hour shorter as compared to patients presenting in-hospital[3-6]. 
Although no relation was demonstrated between the first medical contact-to-balloon 
time and mortality in the current study, previous studies have unequivocally proven 
that in the real world long delays are associated with worse outcome[2'10]. Therefore, it is 
important to keep this time interval as short as possible. After pre-hospital diagnosis 
of STEM I direct transport to an intervention center instead of through a non-inter­
vention center is associated with an additional reduction of the time from diagnosis 
to balloon of 50 minutes[5]. Clear regional agreements and unambiguous pre-hospital 
protocols should be developed to transport all patients with ST-elevation myocardial 
infarction directly to the nearest intervention hospital. In view of the limited sensitivity 
of the pre-hospital computer algorhythms to detect ST elevation myocardial infarc­
tion^ , telefax options should be made available or at least a low acceptance policy 
should be adopted by the intervention centers in case of doubt about the diagnosis. 
As the delay from symptom onset to presentation is also an important part of the total 
ischemic time effort should be made to reduce this delay. Although results from past 
trials have been disappointing[19], media campaigns specifically designed to target pa­
tients groups known to present late might reduce time delays even further.
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Limitations
The current study is relatively small and may not detect all specific predictors of mor­
tality. Unfortunately no data is available with regard to the infarct size and left ventricu­
lar function. This would have provided the opportunity to further unravel the relation­
ships between treatment delay, post procedural T IM I flow, infarct size, left ventricular 
function and long term mortality.
Conclusions and implications
In this single center registry of pre-hospital diagnosis with subsequent primary angio­
plasty for ST  elevation myocardial infarction almost all patients are treated within the 
9 0 -minute time door-to-balloon interval and about two thirds of patients is treated 
within the 9 0 -minute first medical contact-to-balloon interval. In this well-organized 
infrastructure treatment times are rather fast and show little variation, which may ex­
plain the lack of an association between these intervals and outcome. However, the 
symptom to balloon time did show an association with outcome. Importantly, with in­
creasing optimization of time intervals after presentation, reduction of patient delays 
becomes more and more important. Efforts should be made to reduce both the time 
interval from first medical contact-to-balloon time as well as the interval from symp­
tom onset to presentation.
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Sustained coronary patency after fibrinolytic therapy
ABSTRACT
Background: W hether late coronary patency after myocardial infarction has prognostic 
impact independent of left ventricular function remains a matter of debate. Reocclu­
sion rates in the first year after fibrinolysis vary between 2 0 %  and 30% .  O f  all reocclu­
sions, about 30%  present as clinical reinfarction, associated with a 2 -fold-increased 
risk of mortality. The clinical impact of reocclusion that presents without reinfarction 
has not been studied; but an association has been demonstrated with impaired con­
tractile recovery of left ventricular function, the strongest prognosticator of long-term 
outcome. W e therefore studied the impact of 3-month coronary patency after success­
ful fibrinolysis on 1 0 -year cardiac survival.
Methods: In the APR ICO T -1 trial, 24 8  ST-elevation myocardial infarction patients with 
an open infarct artery 2 4  hours after fibrinolysis had 3-month repeated angiography. 
Ten-year clinical follow-up was complete in 9 9 .6% .
Results: The reocclusion rate was 29%  (7 1/2 4 8 ). O f  these reocclusions, 2 4 %  presented 
as clinical reinfarction (17/71). Cardiac survival at 10  years was 73%  in patients with a 
reoccluded infarct artery and 88%  in patients with sustained patency (P < .01). This dif­
ference was also present in patients in whom reocclusion was only detected as a result 
of systematic repeated angiography, that is, in the absence of reinfarction or ischemic 
symptoms between angiograms (70%  vs 86% ,  P < .03). Multivariable analysis identi­
fied sustained patency at 3-month angiography as independent predictor of 1 0 -year 
cardiac survival (hazard ratio 2 .1 0 , 95%  CI 1 .1 0 -4 .0 2 ) together with left ventricular ejec­
tion fraction.
Conclusions: Sustained infarct artery patency in the first 3 months after successful fibri­
nolysis is a strong predictor of 10 year cardiac survival, independent of left ventricular 
function. Notably, this also holds true when reocclusion occurs without signs of clini­
cal reinfarction or recurrent ischemia. Therefore, future preventive strategies should 
also focus on “ clinically silent” reocclusions. Additional studies on better antithrom­
botic regimens and the combination with a routine invasive strategy early after suc­
cessful fibrinolysis are warranted.
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INTRODUCTION
Late coronary patency after myocardial infarction, and its potential prognostic impact 
independent of left ventricular (LV) function, remains an issue of ongoing debate. Af­
ter primary percutaneous coronary intervention, reocclusion is infrequent, especially 
after the introduction of stenting.[1] However, many patients with ST-elevation myo­
cardial infarction are treated with fibrinolytic therapy; and reocclusion rates vary from 
5%  to 10 %  before hospital d ischarge^  to 2 0 %  to 30%  in the subsequent year when 
adopting a conservative revascularization strategy.[5'7] About 30%  of these reocclusions 
result in clinical reinfarction. The incidence of clinical reinfarction is about 5%  at 30 
days, o f which half occur within 48  hours after fibrinolysis.[8] These early symptomatic 
reocclusions are associated with a 2 -fold increase in mortality.[4,8,9] Notably, system­
atic angiographic follow-up has revealed that about half of reocclusions occur w ith­
out overt ischemic symptoms.[10,11] W hen reocclusion occurs in the absence of clinical 
reinfarction, impaired LV contractile recovery has been demonstrated.[12] In contrast, 
patients with sustained patency showed improvement in LV function, a key correlate 
of both short-and long-term outcomes.[13]
To date, only one study after fibrinolysis demonstrated the adverse prognostic 
consequences of late reocclusion over a 6 -year follow-up period, independent of LV 
function. Reocclusion was assessed 6 months after routine angioplasty, performed 
10  days after fibrinolysis.[11] O ther studies on the impact of an open infarct artery re­
ported contradicting findings and included a heterogeneous population of patients 
with persistently occluded and reoccluded infarct arteries, both with and without prior 
reperfusion therapy.[14]
In light of the continuing interest in the concept of late coronary patency,[14,15] we 
sought to assess its impact on 1 0 -year cardiac survival in a well-defined population of 
myocardial infarction patients with a patent infarct artery 2 4  hours after fibrinolysis in 
whom a conservative ischemia-guided revascularization strategy was adopted.
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METHODS
The APR ICO T -1 study protocol has been reported in detail previously.[5] In brief, 300 
patients < 71 years old with chest pain lasting > 30  minutes and < 4  hours and with 
0 .2 -mV ST-segment elevation in at least 2 contiguous leads on the electrocardiogram 
received fibrinolysis for suspected acute myocardial infarction followed by 2 0 ,0 0 0  U 
of intravenous heparin per 2 4  hours. In the case of clinical and/or electrocardiographic 
signs of reperfusion, clinically stable patients were asked informed consent to undergo 
coronary angiography within 48  hours after fibrinolysis. Patients with a patent infarct 
artery, defined as grade 1 to 3 stenosis according to the European Cooperative Study 
Group (ECSG ) criteria (Table 1), were eligible for the study. Sixteen patients were ret­
rospectively excluded for not having a patent infarct artery at baseline angiography 
according to the blinded angiography committee.
The 28 4  patients with a patent infarct artery were randomly allocated to one of 3 
arms: blinded treatment with either 325 mg of aspirin or placebo, or open-label couma­
din including continued heparinization until the target International Normalized Ratio 
(2 .8-4 .0 ) was reached.
By protocol, revascularization was only to be performed in case of spontaneous 
or inducible recurrent ischemia refractory to maximal anti-ischemic medication. The 
protocol recommended a predischarge stress test.
After follow-up angiography, the study medication was discontinued; and all pa­
tients received aspirin based on the IS IS -2  results,[16] which became available shortly 
after initiation of the trial.
At the time of completion of the angiographic main trial, the investigators decided 
to perform 3-year clinical follow-up to study the long-term impact of reocclusion.[10] In 
view of the low 3-year mortality rates, follow-up was extended to 10  years to study the 
impact of reocclusion on long-term survival.
97
Chapter 6
Table 1 : Classification o f coronary artery patency according to the european coopera­
tive study group
Stenosis grade
0 Normal
1 < 50%  diameter stenosis
2 50%  to 90%  diameter stenosis
3 91%  to 99%  diameter stenosis, complete filling within 3 cycles
4 91%  to 99%  diameter stenosis, no complete filling within 3 cycles
5 100%  diameter stenosis
Cardiac catheterization
The primary end point of the APR ICO T study was reocclusion of the infarct artery, 
defined as ECSG grade 4  or 5 stenosis (Table I), at follow-up angiography scheduled 
at 3 months. If coronary angioplasty was performed before this planned follow-up 
angiography, the patency status of the infarct artery before dilatation was scored as 
study end point.
Left ventricular ejection fraction was calculated from the 30 ° right anterior oblique 
ventriculogram by the area-length method. One of the participating centers did not 
routinely perform ventriculography. In 36 cases, ejection fractions at angiographic 
follow-up were not available. In 15 o f these, data were retrieved and/or retrospectively 
assessed (M . B./F. W . A. V.); information from the medical chart and ejection fractions 
determined otherwise (echocardiography, nuclear imaging) were used in case angio­
graphic data could not be retrieved.
Clinical follow-up
Ten-year survival data were collected from medical charts, from municipal registries, 
or by telephone contact with the patient, relatives, or general practitioner. Cardiac 
mortality was defined based on the information of the treating physician and only in 
the case of a confirmed cardiac diagnosis. An instantaneous death for which the cause 
could not be determined with certainty was scored as a death of cardiac origin. Con­
firmed vascular deaths (strokes, aneurysms, dissections, pulmonary embolisms) were
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not considered as cardiac death. If the cause was unknown/uncertain and death did 
not occur instantaneously, it was classified as “ cause undetermined.”
Statistics
Statistical analysis was performed with SPSS  11.0  (2 0 0 1 ; S PSS  Inc, Chicago, IL). Dif­
ferences between continuous variables were compared using the Student t test and 
Mann-Whitney U test whenever appropriate. Comparisons of proportions between 
groups were performed with the %2-test. Long-term survival analysis was performed 
according to Kaplan and Meier, using the log-rank test for a univariable comparison 
between patients with coronary patency at follow-up angiography and those with a 
reoccluded infarct artery. Statistical significance was defined as a 2 -sided P value < .0 5 . 
Multivariable Cox regression analysis using forward logistic regression was used to 
determine the association between infarct artery patency at follow-up angiography and 
1 0 -year cardiac survival. Variables studied were baseline characteristics that were im­
balanced between the study groups (P < .1 0 , Results) and variables with a univariable 
association with 1 0 -year cardiac survival (P < .1 0 , Results). Infarct artery, LV function, 
and age were prospectively chosen to be included, irrespective of the corresponding 
P value.
RESULTS
O f the 28 4  patients who had a patent infarct artery 2 4  ± 14  hours after fibrinolytic 
therapy, 248  (87% )  underwent follow-up angiography performed 75 ± 31 days later. 
Refusal to undergo the second angiography was reported in 28 o f 36 cases; 2 patients 
died, and the other 6 patients had coronary bypass surgery. Patients without follow-up 
angiography were more often female (31%  vs 17% ,  P < .05) and older (60 ± 7 vs 56 ± 
9 years, P < .0 1) and more often had a history of myocardial infarction (17%  vs 6% ,  P 
< .°3)-
Reocclusion was observed in 29%  of patients, dividing the present study popula­
tion into 177  with sustained infarct artery patency and 71 with reocclusion at follow-up 
angiography. Patients' characteristics at the time of follow-up angiography are listed 
in Table 2 .
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As a consequence of recurrent ischemic symptoms and/or reinfarction, second 
angiography was performed earlier than scheduled in 26 patients (10 % )  with subse­
quent revascularization. Fourteen patients had a reoccluded infarct artery: all under­
went successful recanalization. At the time of elective follow-up angiography, none of 
the patients was revascularized.
Table 2 : Clinical and angiographic characteristics at follow-up angiography
Sustained Patency
n = 177
Reocclusion
n = 71
Men 144 (81% ) 62 (87% )
Age (years) <Ti+1VDLn 9+175
History of MI# 11 (6%) 4 (6% )
Anterior MI 7 ° (4 °% ) 34 (48%)
Peak CK, median, IQR 1065 (561-1983) 1143 (515-2150)
Antithrombotic therapy:
• Aspirin 70 (40%) 23 (32%)
• Coumadin 57 (32% ) 24 (34%)
• Placebo 5 0 2 00 ) 24 (34%)
Clinical status:
• Symptomatic* )%18CM3 38 (53%)
• Asymptomatic 145 (82% ) 33 (47%)
Infarct related artery:
• LAD 71 (40%) 34 (48%)
• LCx 2 00 6 ) 11 (15%)
• RCA 78 (44%) 26 (37%)
Single vessel disease 106 (60% ) 36 (51% )
Ejection fraction % * 8)5(n+155 51 ± 12 (n=69)
< 40% 17 (11% ) 14 (20% )
%Ln4< 31 (20%) 20 (29%)
< 5 0 \P os 51 (32%) 31 (45%)
Data are presented as the number (%) of subjects for discrete variables, and as mean ± SD for continu­
ous variables. MI = myocardial infarction ; CK = creatine kinase ; IQR = interquartile range ; LAD = left 
anterior descending artery ; LCx = left circumflex coronary artery ; RCA = right coronary artery ; # = 
prior to inclusion in the APRICOT-1 trial ;* = p < 0.10.
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Long-term survival
During follow-up, a total number of 59 deaths were observed, 4 0  o f which were car­
diac, 18 were noncardiac, and 1 was unclassifiable (sustained patency). In all but one 
of the surviving patients, >1 0 -year follow-up was available (9 9 .6% ) .  Median survival 
follow-up was 10 .8  years.
Figure 1: Ten-year cardiac survival and the impact of sustained coronary patency versus reocclusion.
Late infarct artery patency and long-term cardiac survival
Overall, 21 deaths were observed in the group with reocclusion and 38 in the sustained 
patency group. Overall 1 0 -year survival did not differ significantly: 70 %  versus 79%  
(P = .16 ). In the 71 patients with reocclusion, 19 cardiac deaths were observed as com ­
pared with 21 cardiac deaths in the 177  patients with sustained patency. Cardiac 1 0 -year 
survival rates were lower in patients with reocclusion: 73%  versus 88% ,  respectively 
(Figure 1)(log-rank P < .0 1).
Cardiac survival in the 14  patients with reocclusion who were successfully recana­
lized (see above) did not differ from patients without reopening of the reoccluded 
infarct artery: 64%  versus 75%  (P =not sign ificant). If these 14  patients were classified 
as having a patent infarct-related artery (instead of having reocclusion), the 1 0 -year 
cardiac survival rate was 73%  for patients with a reoccluded infarct artery as compared
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with 86%  for patients with a patent infarct artery after the second angiography (log­
rank P = .0 2 ).
Figure 2: Ten-year cardiac survival and the impact of sustained coronary patency versus symptomatic
(reinfarction, recurrent ischemia or angina with positive stress testing) and asymptomatic reoc­
clusion. SP vs. SR: p = 0.05; SP vs. AR: p < 0.01; SR vs. AR: p = 0.6
O f the 71 patients with reocclusion, 38 (53% )  were classified as symptomatic between 
the 2 angiograms: 17  (2 4 % )  had reinfarction, 19 (2 7% )  had unstable angina, and 2 
(3% )  had angina with positive stress testing. The remaining 33 (4 7% )  were classified as 
asymptomatic. The 1 0 -year cardiac survival in both patients with symptomatic reocclu­
sion and patients with asymptomatic reocclusion is depicted in Figure 2 . The 1 0 -year 
cardiac survival was 70%  in patients with asymptomatic reocclusion as compared with 
86%  in patients with sustained patency (Figure 2 ) (log-rank P < .03). There were no 
differences in the nature of death between patients with an open or reoccluded infarct 
artery: sudden death accounted for half of all cardiac causes in both groups.
102
Sustained coronary patency after fibrinolytic therapy
Revascularization
During long-term follow-up after the repeated angiography, 28%  (69/2 4 8 ) o f patients 
underwent revascularization of the infarct artery. Revascularization rates did not differ 
between patients with sustained patency and patients with reocclusion: 2 7%  (47/177 ) 
versus 31%  (2 2 /71), P = not significant.
Prognostic impact o f infarct artery patency and LV function
By univariable comparison, age, previous myocardial infarction,multivessel disease, 
and LV ejection fraction were associated (P < .10 ) with lower 1 0 -year cardiac survival 
(Table 3). To assess the potential independent prognostic impact of late infarct artery 
patency, these variables were included in a multivariable Cox regression model. On 
clinical grounds, the infarct-related artery was included as well, although not meeting 
the prespecified P value (P = .13) (Table 3). The clinical status at the time of repeated 
angiography (symptomatic/asymptomatic) was also part of the model, given its asso­
ciation with reocclusion (Table 2).
Table 3 : Univariable associations with 1 0 -year cardiac death
Cardiac Death
(n = 4 0)
No Cardiac Death
(n = 2 0 8 )
p-value
Age (years) 5 00 ± 9 56 ± 9 0.09
History of MI* 13% 5 % 0.02
Multivessel disease
O
NLn
L
n 40% 0.06
Infarct Artery
• LAD 53% 40% 0.13
• Left 68% %6Ln 0.16
Reocclusion 48% %Ln2 < 0.01
Ejection Fraction (%) 5 0 ± 4 II 3 ) 55 ± 11 (n = 190) 0.05
• < 40% 24%  (n = 9) 12%  (n = 22) 0.08
• < 45% 38%  (n =14) 20%  (n = 37) 0.02
• < 50% 49%  (n = 18) 34%  (n = 64 ) 0.10
LAD = left anterior descending artery ; Left= LAD and left circumflex coronary artery; 
MI = myocardial infarction; * prior to inclusion in the APRICOT-1 trial.
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Table 4 : Independent predictors o f 1 0 -year cardiac death
1 0 -Year cardiac death
Multivariable analysis
Hazard Ratio 95%  CI P-value
Age per yr 1.04 0.99 - 1.08 0.06
Ejection Fraction %  (continuous) °-97 °.94 - °.99 0.03
Reocclusion 2.10 1.10 - 4.02 0.03
Reocclusion predicted 1 0 -year cardiac death (hazard ratio [HR] 2 .1 0 , 95%  CI 1 .1 0 -4 .0 2 ), 
independent of LV function, which turned out to be the only other independent prog­
nostic variable (Table 4 ). W hen including ejection fraction as dichotomous variable, 
the corresponding HRs for 1 0 -year cardiac death were 2.21 (95%  CI 1 .14 -4 .30 ) for ejec­
tion fraction < 45%  and 2 .2 4  (95%  CI 1 .18 -4 .28 ) for reocclusion.
The relation between coronary patency and cardiac survival was studied in several 
subgroups (Table 5). No significant interaction was observed between the various sub­
groups.
Table 5: Prognostic impact o f late coronary patency for infarct site and left ventricular 
function
Coronary patency and 1 0 -year cardiac survival in subgroups
Variable Patency Reocclusion p-value Interaction
(n = 177) (n=7i) P
Infarct Artery
• LAD (n=105) %Ln
00 68% 0.03 ns
• nonLAD (n=143) %<Ti
00 78% 0.09
• Left (n=144) 85% 71% 0.04 ns
• Right (n=104) 91% 77% 0.06
Ejection Fraction
• < 45%  (n=51) 83% 55% 0.01 ns
• > 45%  (n=176) 89% 81% 0.27
Survival percentages as determined by Kaplan and Meier, compared by log-rank.
LAD = left anterior descending artery ; Left = LAD and left circumflex coronary artery ; 
Right = right coronary artery
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DISCUSSION
This 1 0 -year clinical follow-up report shows that sustained coronary patency in the 
subsequent 3 months after fibrinolysis for ST-elevation myocardial infarction is an im­
portant predictor of long-term cardiac survival, independent of LV function, even in a 
rather low-risk population of patients. Notably, we demonstrated the impact of reoc­
clusions that occur without signs of recurrent ischemia and clinical reinfarction: even 
these reocclusions, detected as a result o f protocol-driven second angiography, proved 
to be associated with adverse long-term outcome.
Late infarct artery patency and long-term survival
Although the prognostic consequences of early infarct artery patency[2] and early rein­
farction and reocclusion are undisputed,[4,8,9] conflicting studies have been reported 
regarding the independent impact of late coronary patency after myocardial infarc­
tion. [14] When restricted to studies after reperfusion therapy, data corroborate, sup­
porting the importance of late patency.[10,11,17'19] Notably, these studies often had paired 
angiography[10'1n'19] and reflected the impact of sustained patency versus reocclusion.
The first study after fibrinolysis that addressed the independent predictive value 
of late coronary patency was a 6 -year follow-up report on consecutive patients with 
routine angioplasty about 10  days after reperfusion therapy.[11] The prognostic impact 
of infarct artery patency at routine 6 -month angiography was found to be independent 
of LV function. Our findings are in line with these results and demonstrate that late 
reocclusion independently doubles the risk of long-term cardiac mortality, with the 
most pronounced effects in patients with anterior infarction and/or impaired LV func­
tion. W ith respect to the revascularization strategy after fibrinolysis, the studies dif­
fer. Instead of routine angioplasty, the APR ICO T study adopted a rather conservative, 
ischemia-guided revascularization strategy, with an overall 3-month revascularization 
rate of only 10 % .  The present findings therefore merely reflect the “ natural course” 
after fibrinolysis.
After fibrinolysis, reocclusion occurs in up to 30%  of patients within a year. The mi­
nority results in clinical reinfarction,[9,11,12] of which the adverse impact has been dem ­
onstrated before.[8'20] However, about 50%  of reocclusions occur “ clinically silent,” that 
is, in the absence o f clinical reinfarction or ischemic symptoms. The present report
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is the first to demonstrate the adverse clinical impact of these “ silent reocclusions.” 
Previously, we showed that reocclusion in the absence of clinical reinfarction has been 
associated with LV dilatation at 5-year follow-up echocardiography.[21] The question re­
mains whether other (yet unknown) factors may attribute to the observed independent 
relation of reocclusion with survival.
Until now, new treatment regimens have primarily focused on the reduction of 
clinical events, that is, reinfarction and recurrent ischemic events. New antithrombotic 
therapies and revascularization in case of recurrent ischemia have reduced the inci­
dence of reinfarction.[22,23] Our findings suggest the need to expand our focus toward 
the prevention of reocclusion in the absence of overt ischemic symptoms; that is, pre­
ventive strategies targeted against the whole spectrum of reocclusion are warranted.
Prevention o f reinfarction and reocclusion: antithrombotic strategies
Antithrombotic treatment plays a prominent role in the prevention of reocclusion. A 
meta-analysis on long-term combined antiplatelet and moderate-intensity anticoagu­
lant therapy reported a ~ io %  reduction in death or reinfarction.[24] Administration of 
low-molecular-weight heparins until discharge also reduces recurrent events.[25] Fur­
thermore, promising short-term results have been reported with clopidogrel on top 
of aspirin.[26] In view of the favorable short-term results with fondaparinux,[27] trials on 
long-term treatment with new oral anticoagulants are eagerly awaited.
Prevention o f reinfarction and reocclusion: revascularization strategies
Stenosis severity has been consistently reported to be associated with reocclusion. 
[3,4,28] Yet, no reduction in death and/or reinfarction was observed with a strategy of 
routine revascularization in a review of trials from the 19 9 0 s, which was attributed to 
high periprocedural event rates.[29] These studies do not represent modern cardiol­
ogy with improved angioplasty techniques, stenting, and glycoprotein I Ib/I I la receptor 
blockers. More recent i-year data from the GRACIA-i trial showed higher patency rates 
and improved LV function with a modern routine invasive strategy within 2 4  hours 
after fibrinolysis.[3° ] In aggregate, the data of several feasibility trials conducted in the 
“ stent era” demonstrated a 2 -fold reduction in the rate of death or reinfarction with an 
early routine invasive strategy as compared with a delayed or ischemia-guided revascu­
larization strategy.[31] Importantly, in contrast to APRICOT, the above-mentioned trials
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on routine revascularization also included a substantial proportion of patients with 
occluded infarct arteries, which results in a population with a higher a priori risk of 
both mortality and (re)occlusion.[2,9] This may have contributed to the observed results. 
Demonstration o f an effect in a population like in APR ICO T will require long-term 
follow-up or a large study population.
Late opening o f (re)occluded arteries
Potential mechanisms of the expected benefit of late recanalization include better 
electrical stability, the possibility of collateral supply to another coronary territory, and 
assumed beneficial effects on LV function.[14] The Occluded Artery Trial is the first 
properly sized randomized trial to address the clinical implications of late recanaliza­
tion, performed a median o f 8 days after myocardial infarction.[15,32] Although long­
term patency was significantly higher, recovery of LV function was not better than after 
medical therapy; and 3-year clinical outcome was similar. A reduced risk of LV dila­
tion was observed after routine intervention, achieved at the expense of an increased 
risk of reinfarction. Importantly, this trial mainly addressed patients with persistently 
occluded infarct arteries, without prior fibrinolysis. W hether these findings also hold 
true for patients with a reoccluded infarct artery after initially successful fibrinolysis 
is uncertain. In the 14  patients with reocclusion that underwent recanalization in our 
study, we did not observe a higher survival rate when compared with those without an 
intervention for reocclusion.
Limitations
Our findings refer to a well-defined but selected group o f rather low-risk patients (all 
fibrinolysis, open infarct artery, and angiographic follow-up).[5] In the present study, a 
conservative ischemia-guided revascularization strategy was adopted, whereas nowa­
days, a more aggressive revascularization strategy is common.
In most patients, ejection fraction was calculated from the right anterior oblique 
projection alone at ventriculography. Although the accuracy of this method to deter­
mine LV ejection fraction has its limitations, it was also used in other reports.[19]
W ith regard to the clinical follow-up, the cardiovascular risk profile and medication 
were not routinely scored; and thus, differences between groups cannot be excluded. 
Furthermore, despite a strict definition of cardiac mortality and detailed information
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about the circumstances of death in all deceased patients, the adjudication of mortal­
ity was sometimes limited by the recollection of patients' relatives and general practi­
tioners. Finally, notwithstanding the hypothetical advantages of prevention of reocclu­
sion, it should be realized that reocclusion could only be a marker of poor prognosis 
and not have a direct causal relationship with outcome.
Conclusions and implications
The present report fuels the interest in the concept that late infarct artery patency is 
an important prognostic factor for long-term cardiac mortality after fibrinolysis for 
ST-elevation myocardial infarction, independent of LV function. These findings refer 
to a well defined population of patients with an initially open infarct artery after fibri­
nolysis. Most importantly, we demonstrated that outcome is also negatively affected 
in case reocclusion occurs in the absence of clinical reinfarction or recurrent ischemic 
symptoms. This calls for preventive strategies aimed at both symptomatic and asym p­
tomatic reocclusions. Randomized clinical trials are warranted to determine whether 
optimized antithrombotic strategies and early routine revascularization will reduce the 
incidence of reocclusion and if this translates into improved long-term clinical out­
come.
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Antiplatelet therapy and progression of coronary artery disease
ABSTRACT
Introduction: In patients after ST-elevation myocardial infarction (STEM I), antiplatelet 
therapy reduces subsequent cardiac events, which are often attributed to recurrent 
throm bosis with (sub)total occlusion in the infarct-related artery. W hether antiplatelet 
therapy influences the often subclinical process of coronary disease progression in 
noninfarct arteries has not been reported.
Methods: Quantitative coronary angiography of noninfarct arteries was performed on 
paired cine-angiogram s of 149 patients from fibrinolytic trials who had a patent infarct- 
related artery 3 to 4 weeks following STEM I and who were randomized to either con­
tinue the daily combination of 50-m g aspirin and 4 0 0 -m g  dipyridam ole or to matching 
placebo. Follow-up angiography was scheduled at 1 year.
Results: On a per-patient basis, the change in m inim al lum inal diameter (MLD) was 
0.0 0 mm in the aspirin/dipyridam ole group (n =  76) and was 0.01 mm in the placebo 
group (n =  73). There was no difference between these groups in the changes in MLD 
(-0.02 mm; 9 5 %  CI -0.09 to 0.05), neither were there significant differences in mean 
lum inal diameter and diameter stenosis. Progression (1 segm ent/patient with >0 .4 0  
mm decrease in MLD) was seen in two thirds of patients and did not independently 
predict long-term death and/or reinfarction.
Conclusion: In this placebo-controlled trial after STEM I, the combination of aspirin and 
dipyridam ole did not affect noninfarct artery disease progression. Progression did not 
predict long-term clinical outcome.
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INTRODUCTION
Antiplatelet therapy has been shown to reduce early and late mortality and reinfarction 
after ST-elevation myocardial infarction (STEM I).[1] H a lf of reinfarctions occur within 
48 hours of fibrinolytic therapy for STEM I and are often associated with reocclusion of 
the infarctrelated artery (IRA).[2,3] Aspirin has been associated with a 5 0 %  reduction in 
reocclusion of the IRA during hospitalization.[4] However, in patients who survive the 
acute phase, antiplatelet therapy has not been shown to reduce late reocclusion up to 
1 year.[5,6]
Nevertheless, a large m eta-analysis demonstrated that aspirin still confers clinical 
benefit when treatment is initiated a month or more after an acute coronary syndrome, 
albeit with a less pronounced relative risk reduction.[1] As the likelihood of infarct artery 
related events decreases over time, this finding suggests that aspirin may alter the 
frequency of the development of clinical events subsequent to throm bosis associated 
with plaques in the noninfarct arteries. Importantly, the clinical m anifestations of coro­
nary throm bosis may only represent the “tip of the iceberg” of all throm botic processes 
in the coronary arteries. In the absence of clinical ischem ic events, serial angiographic 
studies have demonstrated that coronary artery disease progression is a phasic rather 
than a linear process.[7] It is postulated that clinically silent repeated plaque rupture 
and fissuring with mural throm bus formation and subsequent reorganization may lead 
to progression of coronary atherosclerosis.[8] Moreover, at the time of an acute event, 
nonocclusive throm bus formation has also been demonstrated in noninfarct arteries 
in up to 2 0 %  of patients.[9] Given its inhibitory effect on platelet aggregation, aspirin 
might influence this more subtle, often subclinical process of progression.
Despite many angiographic follow-up studies evaluating the effects of lip id -m o d i­
fying therapy, data on the impact of aspirin on coronary artery disease progression are 
sparse.[10] With the introduction of intravascular ultrasound (IVUS), our understanding 
of plaque progression has evolved and has lead to renewed interest in progression, 
which is often considered a surrogate marker for clinical outcomes. In this report, we 
describe the impact of antiplatelet therapy on angiographic coronary progression and 
the relation between progression and clinical outcomes.
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METHODS 
Study patients
The study group com prised consecutive consenting patients with STEM I, who pre­
sented within 4 hours of the onset of ischem ic chest pain, were enrolled in 2 random ­
ized trials of fibrinolytic therapies from 1984 to 1988,[11,12] and had TIM I grade 2 or 3 flow 
in the IRA at 3 to 4 weeks. These patients were then randomized to continue an oral 
combination of 50-m g aspirin and 4 0 0 -m g  dipyridam ole daily (Asasantin, Boehringer 
Ingelheim G m b H , Germany) or to receive matching placebo until follow-up angiogra­
phy, which was scheduled at 1 year.[6] In this angiographic trial, a conservative approach 
to revascularization was adopted,[6] and over the year, only 5 %  of patients underwent 
percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).
Coronary angiography
Sublingual nitroglycerin was given before coronary angiography, which was to be per­
formed via the femoral artery with contrast manual injection. Cine-angiography was 
recorded at 25 frames per second.[6] Blood flow in the IRA was assessed as previously 
described; patency was defined as TIM I flow grade 2 or 3.[6] The culprit stenosis in 
the IRA was defined as the stenosis with angiographic thrombus, or the one that best 
correlated with the regional wall and/or electrocardiographic abnorm alities.[6] Coro­
nary artery stenoses, the num ber of diseased vessels and the coronary segments were 
determined according to the Coronary Artery Surgery Study criteria.[13] Left ventricu­
lography and calculation of end-systolic volum e index were performed as previously 
described.[14]
Quantitative coronary angiography
Analysis was performed on 154 paired cine-angiogram s with comparable coronary ar­
tery views. Suitable segments were assessed irrespective of stenosis severity by an 
experienced quantitative coronary angiographer (BJW) at our angiographic laboratory. 
The analysis of each pair of angiogram s was performed in one session to avoid tim e- 
related changes and was undertaken blinded to treatment allocation and the order of 
film s. Analysis of cine frames was performed in end diastole, free of superimposed 
structures and foreshortening. Quantitative coronary angiography (QCA) analyses
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were performed using the Cardiovascular Measurement System (CM S-M ED IS Medical 
Imaging System s, Leiden, The Netherlands), and the 1-cm  grid was used for calibra­
tion; although in some patients, a nontapering portion of an angiographic catheter 
was used. The reproducibility of the Q C A  analysis in our laboratory has previously 
been reported.[15] For m inim al lum inal diameter (MLD), the standard deviation for re­
peat measurem ent was 0.17 mm from pairs of angiogram s at an interval of 2 months.
Definition of progression. We prospectively defined a decrease in M LD of > 0 .4 0  mm 
as progression of a coronary lesion over a 1-year period for consistency with previous 
reports.[16,17]
Angiographic end point
Quantitative analysis. The angiographic end points were the 1-year changes in MLD, 
mean luminal diameter, and diameter stenosis on a per-patient basis in non-IRA seg­
ments. The changes in these Q C A  measures between angiogram s (angiogram 2 -  
angiogram  1) were compared between the aspirin/dipyridam ole and placebo groups. 
To calculate the average changes on a per-patient basis, the differences in the respec­
tive Q C A  parameters observed in the paired coronary segments were added for each 
patient individually and subsequently divided by the number of contributing segments.
Semiquantitative analysis. Patients with a new occlusion in the non-IRA or at least 
one lesion worsening > 0 .4 0  mm in M LD were defined as showing progression (pro- 
gressors) and all other patients were prespecified as nonprogressors. Patients with 
new lesion formation had at least one segment with a diameter stenosis < 2 0 %  at base­
line, worsening > 0 .4 0  mm in MLD to a > 2 0 %  diameter stenosis at follow-up angio­
graphy. Semiquantitative analysis defining the proportion of progressors and nonpro­
gressors was also used to compare randomized treatment allocations.
Per-segment analysis. To assess the aspirin/dipyridam ole therapy at the level of indi­
vidual coronary segments, analyses on a per segment basis were performed.
Progression and long-term clinical follow-up
Late follow-up was performed by recall to the outpatient clinic, by the fam ily doctor, by 
telephone, or by mail. The cause of death was considered cardiac in case of death with 
a confirmed cardiac diagnosis or in case of sudden death. Reinfarction was defined as 
an adm ission for prolonged ischem ic chest pain and a creatine kinase level >2 times
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the upper lim it of the reference range and/or development of new Q waves. All events 
were verified by source docum ents by physicians.
The impact of progression on late clinical outcomes after the second angiogram 
was studied using the sem iquantitative dichotom ous definition. In addition, the long­
term clinical impact of progression was assessed with progression (1) as a continuous 
variable and (2) divided into quartiles of the 1-year changes in MLD.
Statistical analyses
Statistical analysis was performed SPSS version 12.0 software package (SPSS Inc, C h i­
cago, IL). N orm ally distributed continuous variables are expressed as means and SDs, 
and these were compared using a paired or an independent t test for within group dif­
ferences and between-group differences, respectively. Continuous variables not nor­
mally distributed are expressed as m edians and interquartile range (IQR). These were 
compared using nonparam etric tests. Proportions were compared by %2 and Fisher ex­
act tests. Survival curves were constructed using the Kaplan-M eier method and com ­
pared using the log-rank test. A 2-sided P < .05 for all hypothesis tests was considered 
to be significant.
To explore possible associations between angiographic progression and clinical 
outcomes, a multivariable analysis was performed by Cox proportional hazards regres­
sion m odeling using forward and backward regression analysis. Included were vari­
ables that significantly differed or tended to differ between progressors and nonpro- 
gressors ( P < .10) and the variables known to be associated with clinical outcom es.[14,18]
RESULTS 
Study population
O f  215 patients with TIM I grade 2 or 3 flow (patency) in the IRA at a median of 25 days 
(IQR 21-32) after STEM I, 10 patients died and 51 patients did not undergo follow-up an­
giography because of patient or physician refusal (Figure 1). There were no differences 
in baseline characteristics and clinical outcomes between the 51 patients with a single 
angiogram and the 154 patients with paired angiogram s. Clinical and angiographic 
baseline characteristics of the treatment and placebo groups are shown in Table 1.
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aspirin/dypridamole placebo
n = 76 n = 73
732 segments 704 segments
Figure 1: Flow chart showing the number of patients and segments suitable for QCA -analysis. 
IRA=infarct-related artery; MI=myocardial infarction; IQR=Inter quartile range.
The use of lipid-m odifying drugs was 5 %  in both groups. Thirteen patients had a non­
fatal reinfarction before the planned follow-up angiogram, 7 patients in the aspirin/ 
dipyridam ole group and 6 patients in the placebo group. O ne of these 13 patients had 
a nonfatal reinfarction in a n o n -IR A  (placebo group). Nine revascularizations were 
performed before elective follow-up angiography, 5 in the treatment group (3 CABG  
and 2 PCI) and 4 in the placebo group (1 CA B G  and 3 PCI).
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Table 1: C lin ical and angiographic baseline characteristics: aspirin/dipyridam ole ver­
sus placebo
Aspirin/D ipyridam ole
n =  79
Placebo
n =  75
Age (years) 55 ± 9 56 ± 8
Male 8 2% 76%
Smoking 4 8 % 48%
Diabetes 10 % 5%
Hypertension 30% %52
Total Cholesterol (mmol/l) ±
V
O ±
V
O
History of MI 6 % 8 %
CTFC (of IRA) 26 (18 -  41) 31 (20 -  48)
Peak CK (U/l) 2300 (1033 -  3258) 2196 (1700 -  3525)
Infarct-related artery :
• LAD 33% 43%
• RCA 56% 43%
• LCX 11% 14%
Vessel disease (CASS):
• 0 vessel 2 7 % 32%
• 1 vessel 48% %54
• 2 vessels 14% 12 %
• 3 vessels 11% 11%
LV-function
• ESVI (ml/m2) 31 (16) 33 (14)
• EF (%) 59 (12) 56 (11)
Data are presented as a percentage for discrete variables (%), as mean ± SD for continuous variables 
and as median (interquartile range) for continuous data not normally distributed. A/D = aspirin/dipyri­
damole ; P = placebo ; MI = myocardial infarction ; CTFC = corrected TIMI frame count ; CK = creatine 
kinase ; IRA = infarct-related artery ; LAD = left anterior descending artery ; RCA = right coronary artery 
; LCX = left circumflex coronary artery ; CASS = coronary artery surgery study[,4]; LV = left ventricular ; 
ESVI = end systolic volume index ; EF = ejection fraction
Angiographic changes over 1 year: im pact o f antiplatelet therapy
Per-patient analysis. Data suitable for analysis on noninfarct arteries was available in 
149 patients (Figure 1). The Q C A  values according to treatment assignm ent on a per­
patient basis are shown in Table 2 and Figure 2. Patients in the aspirin/dipyridam ole 
group did not have a significantly different change in Q C A  parameters over 1 year, as
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compared to the placebo group. The respective between group differences in the 1-year 
changes were (1) M LD -0 .0 2  mm (9 5 %  CI -0 .09 to 0.05); (2) mean lum inal diameter 
0.02 m m  (9 5 %  CI -0 .06 to 0.11); and (3) diameter stenosis 1 .3 %  (9 5 %  CI -0 .2  to 2.8).
Table 2: Quantitative coronary angiography m easurem ents: per patient analysis o f 
non-infarct arteries
A spirin/D ip yrid am ole Placebo p-value
n =  76 n =  73
Minimal Luminal Diameter, mm
• Baseline 1.92 M 5 -  1 .99) 1.97 (1.88 -  2.06) 0.4
• Follow-up 1.91 (1.84 -  1.98) 1.98 (1.89 -  2.07) 0.2
• Change -0.00 (-0.05 -  0.05) 0.01 (-0.04 -  0.06) 0.6
Mean Luminal Diameter, mm
• Baseline 2.60 9).62.-.51(2. 2.65 (2.55 -  2 .75) 0.4
• Follow-up Ln.62. 3).72.-7.5(2. 7.62. (2.57 -  2 .77) 0.7
• Change 0.05 (-0.01 -  0.11) 0.02 (-0.04 -  0.08) 0.5
Diameter Stenosis, %
• Baseline 33.7 5.3-.32.3 33.5 (32. °  -  35.°) 0.8
• Follow-up 352 (33.7 -  36.7) 33.7 3 0 - 3 4) 0.2
• Change 1.5 .5)2.-.5(0. 0.2 (-0.9 -  1.3) 0.08
Reference Diameter, mm
• Baseline 2.81 (2.72 -  2.90) 7.82. (2.75 -  2.99) 0.4
• Follow-up 2.86 (2.77 -  2 .95) 9.82. (2.78 -  3.00) 0.6
• Change 0.05 (0.00 -  0.10) 0.02 (-0.04 -  0.08) 0.6
• Progression 68% 64% 0.7
• New lesion 17 % 2 2 % 0.5
Data are presented as the per patient mean of QCA parameters of non-infarct artery segments, be­
tween brackets the 95% Confidence Interval.
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Figure 2: Mean changes with 95% CIs in quantitative coronary angiographic parameters of non-infarct
artery segments at one-year follow-up angiography on a per patient basis: aspirin/dipyridamole 
versus placebo.
Semiquantitative analysis. No treatment effect could be demonstrated on sem iquanti­
tative analysis: 6 8 %  of patients allocated to aspirin/dipyridam ole therapy and 6 4 %  in 
the placebo group were progressors ( P =  .6). Two patients, one in each group, had a 
silent occlusion of an initially patent noninfarct artery at follow-up angiography; both 
patients had reocclusion of the IRA as well. New lesion formation was present in 1 7 %  
of the patients in the aspirin/dipyridam ole group and 2 2 %  of the patients in the pla­
cebo group ( P =  .5).
Per-segment analysis. A total of 1436 paired non-IRA coronary segments were avail­
able for analysis, 732 in the aspirin/dipyridam ole group and 704 in the placebo group; 
baseline characteristics on a per-segment basis were sim ilar between groups. Q C A  
analysis by treatment allocation on a per segment basis showed no differences be­
tween the aspirin/dipyridam ole and placebo group in any Q C A  parameter (Table 3). 
However, there were significant within group differences over 1 year in the mean lu m i­
nal diameter, diameter stenosis, and the reference diameter in the aspirin/dipyridam ­
ole group (all with P < .01). In the placebo group, the within group differences were 
significant for mean lum inal diameter and reference diameter (both P < .05).
123
Chapter 7
Table 3: Quantitative coronary angiography m easurem ents : per segm ent analysis of 
non-infarct arteries
A spirin/D ip yrid am ole Placebo p-value
n =  732 n =  704
Minimal Luminal Diameter, mm
• Baseline 1.90 (1.83 - 1.97) 1.94 (1.86 - 2.02) 0.5
• Follow -up 1.92 (1.85 - 1 .99) 1.97 (1.89 - 2.05) 0.4
• Change 0.02 (-0.01 -  ° . ° 5) 0.03 (-0.01 -  0.07) 0.6
Mean Luminal Diameter, mm
• Baseline 2. 5 00 (2 .51 - 2.65) 2.62 (2.54 - 27 °) 0.5
• Follow -up
vq2. (2.57 - 2.71) 5.62. 2. 5 ''-J - 3).72. 0.8
• Change 0.06 3.0(0. 0.09) 0.03 (0.00 -  0.06) 0.2
Diameter Stenosis, %
• Baseline 33.5 -.52.3 34.5) 33.3 (32.2 -- 34.4) 0.8
• Follow -up 3 (33.7 - .7)5.3 33.6 (32.5 - 34.7) 0.1
• Change 1.2 (°.4 - 1.8) 0.2 (-0.7 - 1.1) 0.1
Reference Diameter, mm
• Baseline 2.78 2. 7 0 - 2.86) 2.83 -5.7(2. 2.91) 0.4
• Follow -up 3.82. -5.7(2. 2.91) 7.82. 9.7(2. 2.95) 0.6
• Change 6.00. 3.0(0. 0.09) 0.04 (0.00 -  0.08) 0.5
Data are presented as the average QCA parameters of non-infarct artery segments, between brackets 
the 95% Confidence Interval.
Late prognostic significance o f progression
There were 99 patients with angiographic progression and 50 patients without pro­
gression at 1 year; their clinical and dem ographic baseline characteristics including 
treatment assignm ent did not differ (no variables with P < .10). At first angiography, 
significantly wider baseline m inim al and mean lum inal diameters were found for pro- 
gressors as compared to nonprogressors (2.03 mm ± 0.34 vs. 1.77 mm ± 0.33 and 2.72 
mm ± 0.39 vs. 2 .4 4  mm ± 0.35, respectively).
The 149 patients were followed up for a median of 99 months (IQR 86-113) after 
follow-up angiography. Cardiac death occurred in 20 patients (13%), cardiac death and/ 
or myocardial infarction (MI) occurred in 31 patients (2 0 % ). The long-term survival, 
free from the combined end point of cardiac death and MI in progressors compared to 
nonprogressors, is shown in Figure 3. Progressors had a survival rate free from cardiac
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death and reinfarction of 7 9 % , as compared to 7 1 %  for nonprogressors (P =  .3). When 
progression was assessed based on changes in all coronary arteries, including the IRA, 
progression was seen in 8 7 %  of patients (aspirin/dipyridam ole 8 4 %  vs placebo 8 9 % , 
P =  .4). In addition, event-free survival did not differ between progressors and nonpro­
gressors (7 6 %  vs 7 7 % ,  respectively, P =  0.9).
Figure 3: Long-term survival free from cardiac death and non-fatal myocardial infarction: progressors 
versus non-progressors in non-infarct related arteries. ReMI=recurrent myocardial infarction; 
Progressors=patients with a new occlusion or at least one lesion worsening 20.40mm in M LD.
M ultivariable analysis was performed to assess the impact of angiographic progres­
sion and other variables on clinical outcome (see Methods). The model also included 
the average m inim al and mean lum inal diameter at baseline angiography (see above). 
O ne independent predictor of long-term cardiac m ortality and reinfarction was identi­
fied: end-systolic volum e index (HR 1.02, 9 5 %  CI 1.00-1.05, P =  .04). Neither changes 
in M LD (continuous/quartiles) were independently associated with long-term out­
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come (cardiac m ortality or the combined end point cardiac death and/or reinfarction), 
nor was progression as a dichotom ous variable.
DISCUSSION
To our knowledge, this is the first randomized placebo-controlled angiographic follow- 
up study to examine the influence of antiplatelet therapy on the progression of coro­
nary artery disease as assessed by Q C A  in noninfarct artery segments in the first year 
after STEM I. Progression, observed in two thirds of our patients, was not significantly 
affected by a combined antiplatelet regimen of aspirin and dipyridam ole. Neither Q C A  
analysis on a per-segment basis nor a sem iquantitative analysis demonstrated a sig­
nificant treatment effect. Because the patients in this study were recruited from 1984 
to 1988, and only 5 %  of patients received lipid-m odifying therapy, confounding of our 
results by these drugs is unlikely. The increase in the diameter stenosis in patients allo­
cated to combined antiplatelet therapy was unexpected and may be related to vasodila­
tation caused by dipyridam ole or neurohumoral effects on coronary arteries after MI.
Effect o f antiplatelet therapy on clinical and angiographic outcomes
The clinical benefit of aspirin after MI is undisputed.[1] M eta-analysis has demonstrated 
no significant difference in the observed risk reduction conferred by a daily dose of 
<75 or >75 mg.[1] The combination of aspirin 50 mg and dipyridam ole 4 0 0  mg, which 
we used in this analysis, has not been investigated extensively. Although a combined 
antiplatelet regimen was found to result in risk reductions in clinical end points at least 
as large as those occurring with aspirin alone,[1] the efficacy of aspirin/dipyridam ole has 
never been firm ly established after MI. In patients after stroke or transient ischem ic 
attack, dipyridam ole 4 0 0  mg is effective in preventing recurrent stroke, and its sepa­
rate effect is additive to that of 50-m g aspirin.[1] The lack of clinical benefit observed in 
our study cannot be used as indicator of its clinical efficacy.[6] Importantly, this study 
was designed and powered to address angiographic end points only in a moderately 
sized population with an open infarct artery 1 month after STEM I. With respect to the 
efficacy o f aspirin/dipyridam ole on long-term angiographic outcomes, the results are 
generally disappointing.[6,19] O nly a subgroup of patients from the CA B A D A S trial with
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saphenous vein grafts and small caliber distal arteries had a lower 1-year occlusion rate 
than patients randomized to aspirin alone.[20]
Lack o f benefit o f antiplatelet therapy: methodological considerations
In our analysis of angiographic progression in noninfarct arteries, no treatment effect 
of aspirin/dipyridam ole could be demonstrated. In spite of the relatively short follow- 
up duration, the small changes in Q C A  measures in our study were of the sam e order 
of magnitude as those shown in trials of lipid-m odifying therapies, which enrolled 
patients with stable coronary artery disease and with longer tim e intervals between 
angiogram s.[17] Moreover, our analysis in patients after acute MI showed higher rates 
of patients with at least one progressing lesion compared to the rates in studies of 
clin ically stable patients. The rates of progression we observed were comparable to the 
single angiographic trial of lipid-m odifying therapy starting 6 to 9 months after acute 
M I.[21] Thus, in spite of the high-risk population for progression studied, no treatment 
effect of aspirin/dipyridam ole was demonstrated.
Lack o f benefit o f antiplatelet therapy: m echanistic considerations
There are several potential explanations for the lack of a dem onstrable effect of anti­
platelet therapy on progression in our study. A ssum in g that antiplatelet therapy might 
affect coronary artery disease progression, angiography may not be a sensitive enough 
im aging modality. Although other angiographic trials studying lipid-m odifying therapy 
showed significant changes on the coronary lum inal diameter, the changes were sub­
tle, whereas the changes observed with IVUS showed marked reductions in atheroma 
volum e expansion.[22] These findings caused a shift in our perception of progression 
from the coronary lumen to the entire vessel wall, from throm bus consolidation to lipid 
pools and intimal hyperplasia.
With respect to antiplatelet therapy, IVUS studies on coronary disease progression 
are lacking, only one prelim inary angiographic follow-up study has been reported,[10] 
and few experimental studies have addressed the im pact of aspirin on throm bus con­
solidation or plaque/lipid pool com position. The available clinical studies have sug­
gested that aspirin m ainly exerts an antithrombotic effect, in terms of a reduction of 
the incidence of (sub)acute recurrent throm botic events, which is supported by the 
prevention of coronary occlusion observed in angiographic studies.
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W ith regard to the often subclinical, nonocclusive process of plaque mural throm ­
bus formation, anim al studies suggest an incomplete inhibitory effect of aspirin in this 
milieu, and it has been postulated that to decrease the superficial deposition of plate­
lets, antithrombin therapy is required to counteract the strong thrombin mediated 
aggregatory effect on platelets.[10] These findings of an incomplete effect of antiplatelet 
agents on mural platelet aggregation provide m echanistic support for the observed 
lack of a dem onstrable effect in our study. The only other study describing the impact 
of aspirin on angiographic progression did not find a treatment effect either.[10] Another 
potential m echanism  through which aspirin could influence coronary progression is 
its anti-inflam m atory effect, but this is likely to require higher doses than those often 
prescribed after MI. W hether aspirin influences the size of the lipid pool remains to 
be determined.
Correlation o f angiographic observations and clinical outcome
Angiographic progression has been reported as a predictor of future cardiac events. [23] 
However, there is no uniform ity in the definition of progression, with one study cor­
relating the per patient average decrease in M LD as a continuous variable with out- 
com e,[24] whereas another described progression in a sem iquantitative dichotom ous 
com parison.[23] In this study, we used both definitions, including a prespecified 0 .4 0 ­
mm change in MLD to assess this end point. Although progression was frequent, no 
association with future ischem ic events was found.
Thus, caution should be taken to make inferences from reported effects on sur­
rogate end points in angiographic trials, such as progression, to the potential impact 
in daily clinical practice. Clinical trials of angiotensin-converting enzym e (ACE) inhibi­
tors and polyunsaturated fatty acids have demonstrated a reduction of MI in patients 
with stable angina[25] and of sudden death after M I,[26] whereas in angiographic trials, 
these agents did not modify progression of atherosclerosis.[27,28] This incongruity be­
tween angiographic and clinical efficacy seem s to hold true for (combined) antiplate­
let therapy as well. Currently, IVUS is used to measure coronary disease progression, 
and atheroma volum e is regularly used as a surrogate endpoint in trials studying new 
treatment strategies. Although IVUS is precise and highly reproducible, it cannot reli­
ably discern a vulnerable plaque from a stable one, and it remains an open question 
as to whether atheroma volum e is associated with clinical outcomes. In this context,
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validation of atheroma volum e as a surrogate end point is warranted, and imaging 
end points should be uniform ly and prospectively defined. Even in case of a potential 
association, agents with proven impact on such end points should still be tested in a 
clinical trial
Limitations
In contrast to IVUS, angiography only yields information about the coronary lumen, 
and during the progression of atherosclerosis, vessel dilatation may occur.[29] In ad­
dition, vessel tortuosity, overlap of structures, and effects of lumen shape may con­
found the assessm ent of progression. Therefore, a treatment effect might have gone 
undetected due to a lack of sensitivity of Q C A . As the patients in this trial were treated 
before the widespread use of statins and A CE inhibitors, these drugs were rarely pre­
scribed and not routinely recorded in the database. Notably, this trial was designed to 
study angiographic and not clinical end points, and the event rates observed should be 
interpreted in the context of the medication and revascularization strategy used in the 
late 1980s. Although our data do not suggest an association between progression and 
late clinical outcome, an effect may have gone undetected because of differences be­
tween progressors and nonprogressors in the rates of variables that were not routinely 
assessed such as lesion complexity,[3°] statin and ACE-inhibitor therapy, and/or differ­
ences in the development of other adverse prognostic factors such as left ventricular 
dysfunction.
Conclusion
In this randomized placebo-controlled angiographic follow-up trial in patients with a 
patent IRA 3 to 4 weeks after STEM I, the combination of aspirin and dipyridam ole did 
not affect 1-year coronary artery disease progression in noninfarct artery segments, as 
assessed by quantitative angiography. Progression, present in two thirds of patients, 
was not validated as a surrogate end point for long-term clinical events.
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SUMMARY
In the Netherlands the incidence of a first myocardial infarction is 20-30 per thousand 
annualy in people over 60 years of age. Forty percent of these people die before they 
reach the hospital and sixty percent are admitted to the hospital. In the past decades 
the outcome of patients with this syndrome has improved dramatically. Many large- 
scale clinical trials studying a broad spectrum  of therapeutic options have contributed 
to this benefit. Particularly studies on early reperfusion and prevention of rethrombo­
sis have been shown to improve outcome in this field of study. Both patients treated 
with fibrinolysis and prim ary angioplasty are studied in the current thesis. Although 
fibrinolysis remains the best available reperfusion strategy in large parts of the world, 
over the years prim ary angioplasty has become the preferred treatment of choice. This 
shift in preference of reperfusion therapy is reflected in the current thesis. Importantly 
while the choice of reperfusion strategy may have changed the goals remain the same: 
early and complete reopening of the occluded artery and the prevention of reocclu­
sion. A central theme in the current thesis is the relation between angiographic and 
clinical outcome in the different phases after ST-elevation myocardial infarction. In the 
acute phase the impact of time and different reperfusion strategies has been studied. 
The long-term clinical effects of angiographic reocclusion are reported in the sub acute 
phase. In the more stable phase after myocardial infarction coronary progression has 
been the subject of interest.
In the general introduction of chapter 1 background information is given about the 
basic principles of reperfusion therapy, reocclusion and progression. A general outline 
is given about the rationale for the different studies in the current thesis.
In chapter 2 of this thesis the rationale for the randomized multicenter Holland In­
farction Study (HIS) is described. In this study prim ary angioplasty is compared to ear­
ly preferably pre-hospital fibrinolysis with a liberal rescue policy. At the time of the in i­
tiation of the HIS in 2002, prim ary angioplasty was superior to in-hospital fibrinolysis 
in patients presenting in an intervention center. However, the m ajority of patients do 
not present in an intervention center and the am ount of benefit of prim ary angioplasty 
in this case seems less. In addition, in the randomized studies prim ary angioplasty 
was usually compared with a “sub-optim al” fibrinolytic strategy. Often a non-fibrin 
specific fibrinolytic drug was used instead of fibrin specific fibrinolysis. Most patients
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received fibrinolysis in-hospital instead of the more effective pre-hospital fibrinolysis. 
Finally, patients were treated conservatively instead of with rescue angioplasty in case 
of failed fibrinolysis. In the HIS, prim ary angioplasty was compared with early initiated 
preferably pre-hospital fibrinolysis with a liberal rescue strategy in patients presenting 
with ST-elevation myocardial infarction. Unfortunately, the HIS was stopped prem a­
turely due to funding problem s. O f  the originally planned 900 patients only 48 were 
included. In chapter 3 the results of these 48 patients are reported. The rate of the 
com posite endpoint of death, recurrent myocardial infarction and stroke at one year 
was 8 %  for patients treated with prim ary angioplasty and 2 2 %  in case of fibrinolysis. 
Given the lack of power no clinical inferences can be drawn from this study.
Primary angioplasty is the preferred reperfusion strategy if it can be performed within 
90 minutes after presentation by an experienced team of personnel. The guidelines 
describe a time lim it for primary angioplasty due to the strong relation between the 
time from presentation to balloon inflation (door-to-balloon time) and the in-hospital 
mortality. Longer door-to-balloon times have been associated with increased mortality. 
It is therefore essential to reduce this delay as much as possible. Several strategies like 
a single call to activate the catheterization laboratory, activation of the catheterization 
laboratory while the patient is en route and the expectation that the crew has to arrive 
within 20 minutes after being paged, have been shown to reduce this delay. In chapter 4 
of this thesis we describe the results of a prospective registry of 581 pre-hospital pa­
tients treated with prim ary angioplasty in the Radboud University Medical Center from 
2005 until 2007. We demonstrate that ~  50 minutes of time can be gained if patients 
are directly transferred to an intervention instead of through a non-intervention center 
after pre-hospital triage. In addition we demonstrate that a shorter symptom-to-balloon 
time is independently associated with a higher rate of TIM I-3 flow after the procedure, 
an important independent determinant of long-term mortality. O ur results suggest that 
direct referral to an intervention center might improve long-term mortality.
In Chapter 5 we study the im pact of the treatment intervals on long-term mortality in 
patients who present in the pre-hospital setting and are treated with prim ary angio­
plasty for STEM I. After the introduction of pre-hospital initiated prim ary angioplasty 
the guidelines introduced a new time window (first medical contact to balloon time)
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within which prim ary angioplasty should be performed. The impact of this tim e inter­
val on long-term m ortality has never been studied in the pre-hospital setting. In chap­
ter 5 we study the impact of the different time intervals in 547 patients with complete 
data on the time intervals from our prospective registry of prim ary angioplasty. In our 
study, the sym ptom -to-balloon time was an independent predictor of long-term mor­
tality; HR 1.07 (9 5 %  CI:1.0 1-1.12, p=0.02) together with age and Killip class. The first- 
m edical-contact-to-balloon time was not associated with m ortality HR 1.07 (9 5 %  CI: 
0.95-1.21, p=0.3). In contrast to our finding, previous studies m ainly from the US study­
ing patients presenting in a hospital demonstrated a clear relation between the time 
from presentation to balloon inflation and in-hospital mortality. The fact that both the 
total ischem ic time as the time from presentation to balloon inflation are substantially 
shorter in our study probably contribute to observed differences in outcome between 
studies. In an infrastructure with increasing optim ization of intervals after patient pre­
sentation, efforts to try and reduce patient delays will become more important.
The initial benefit of reperfusion therapy is offset by the occurrence of reinfarction and 
reocclusion. After prim ary angioplasty with stent placement reocclusion is infrequent 
and occurs in 3 -6 %  of patients at 6-7 months. However after fibrinolysis reocclusion 
occurs in up to - 3 0 %  of patients at one year. Although reocclusion has been associat­
ed with an increased rate of reinfarction and revascularization and less recovery of left 
ventricular function, the impact on long-term cardiac m ortality after fibrinolysis has 
not been studied extensively. Chapter 6 of the current thesis describes the outcome af­
ter 10-year follow-up of the 248 patients with paired angiography from the randomized 
APRICO T-1 study. Patients in this study had ST-elevation myocardial infarction and 
were successfully treated with fibrinolysis. After an ischem ia guided conservative re­
vascularization strategy reocclusion occurred in 2 9 %  of patients at 3 months and was 
associated with a 10-year cardiac survival rate of 7 3 %  as compared to 8 8 %  in patients 
without reocclusion. Importantly, this relation was independent from left ventricular 
ejection fraction and was seen in both patients with a sym ptom atic reocclusion and in 
patients in whom reocclusion was merely detected as a result of systematic follow-up 
angiography.
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In stable patients angiographic follow-up studies have shown that lipid-m odifying 
drugs reduce rate of progression and that progression is associated with future c lin i­
cal events. Progression usually occurs phasic and sub-clinically. Mural non-occlusive 
throm bus formation is assum ed to be a part of the multi-factorial process of plaque 
progression. Although aspirin is associated with a reduced rate of ischem ic events 
early and late after myocardial infarction, the impact of aspirin on the more subtle 
process of progression is unknown. Chapter 7 describes the results of a randomized 
placebo-controlled study with one-year angiographic follow-up. The effect of dual anti­
platelet therapy with aspirin and dipyridam ole on progression in non-infarct related 
coronary arteries was studied. O ne month after fibrinolytic therapy 154 patients with 
an open infarct related artery were randomized to continue with dual anti-platelet ther­
apy or placebo. In total 1436 non-infarct related coronary segments were available for 
analysis. Several quantitative coronary angiography measures were used and no differ­
ences in mean changes in diameter could be observed between the treatment groups. 
Neither was there a difference in the proportion of patients with progression using a 
sem i- quantitative method. After long-term clinical follow-up, progression did not pre­
dict future clinical events. O ur results substantiate previous observations from animal 
studies that aspirin only prevents clinical events related to (sub) occlusive thrombus 
formation.
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EPILOGUE 
Reperfusion therapy
As prim ary angioplasty has been shown superior to fibrinolysis if performed timely 
in experienced hands, the availability of prim ary angioplasty should be increased. Ex­
pansion of the am ount of intervention centers is the first step to achieve this goal 
but strict regulation will be necessary to guard the volume, experience and thus the 
quality of prim ary angioplasty in individual intervention centers. W hile total coverage 
of tim ely high-quality prim ary angioplasty in the Netherlands should not be an is­
sue, coverage in less densely populated countries with long transportation distances 
may be a problem. Anti-throm botic pretreatment with full-dose fibrinolysis, half dose 
fibrinolysis with a glycoprotein IIb/IIIa blocker or a glycoprotein IIb/IIIa blocker alone 
seemed to be a prom ising strategy which could bridge the gap of time between the 
diagnosis of ST-elevation myocardial infarction and prim ary angioplasty. However, the 
large-scale clinical trials failed to demonstrate a clinical benefit of this strategy de­
spite an increased rate of open infarct-related arteries before the procedure and higher 
rates of ST-segm ent resolution after the procedure. A trend towards improved clinical 
outcome was seen in patients who received pre-treatment within two hours of sym p­
tom onset. Pre-hospital triage for ST-elevation myocardial infarction has been shown 
to effectively reduce the delay to treatment with ~  1 hour in prehospital fibrinolysis. 
Substantial time can be gained if prim ary angioplasty is performed after pre-hospital 
triage and direct transportation to an intervention center. W hile pre-hospital triage 
for prim ary angioplasty is already com m on practice in the Europe, legislative mat­
ters ham per the introduction of a prehospital triage system in the US. If a prehospital 
system is available uniform protocols are necessary to m inim ize the delay associated 
with making the proper diagnosis and choosing the optimal referral strategy. Given the 
limited sensitivity of the pre-hospital com puter algorhythm to diagnose ST-elevation 
myocardial infarction, intervention centers need to accept all patients with suspected 
myocardial infarction even in case of doubt about the diagnosis. W hether extensive 
training of param edics, a physician on the am bulance or faxing and evaluating the 
pre-hospital ECG by a cardiologist in the hospital improves the rate of patients with 
a definite pre-hospital diagnosis of myocardial infarction remains to be determined. 
Despite the potential of pre-hospital triage to improve the rate of patients treated with
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prim ary angioplasty, this reperfusion strategy will not be tim ely at hand in a substan­
tial proportion of patients who m ainly live in remote areas. In these cases, fibrinolysis 
(preferably prehospitally initiated) is the reperfusion therapy of choice. Recently, the 
90-m inute delay to intervention within which prim ary angioplasty is described to be 
superior to fibrinolysis is debated and longer intervals to prim ary angioplasty may be 
acceptable. These findings have resulted in a renewed interest for the com parison of 
prim ary angioplasty to an optimal fibrinolytic strategy with pre-hospital fibrinolysis 
with an early liberal invasive strategy in patients with long expected treatment intervals 
to prim ary angioplasty. Strategies aimed to lim it infarct size after reperfusion therapy 
or regenerate myocardial cells after myocardial infarction have failed to show an un­
am biguous treatment effect. Prompt and complete recanalization of the infarct-related 
artery in patients with ST-elevation myocardial infarction remains therefore the main 
goal of therapy.
It has been shown that substantial improvement in the time intervals can be ac­
com plished if patients are treated after prehospital diagnosis and notification of STEM I 
and direct referral for prim ary angioplasty. Further improvement in treatment delays 
may be associated with efforts to reduce the delay between symptom onset and pre­
sentation. Media cam paigns targeting patients at high risk for late presentation may 
be a way to reduce this delay. Importantly, - 3 0 %  o f patients with ST-elevation myocar­
dial infarction do not receive reperfusion therapy at all. The outcome of ST-elevation 
myocardial infarction could be improved substantially if these patient would be treated 
with reperfusion therapy as well.
Prevention o f reinfarction and reocclusion
W hile restoration of early and brisk antegrade flow is im portant in the acute phase of 
ST-elevation myocardial infarction, keeping the artery open is the challenge for the 
sub-acute phase after myocardial infarction. Both after fibrinolysis and prim ary angio­
plasty reocclusion has been associated with adverse long-term prognosis independent 
of left ventricular function. Routine reopening of occluded infarct-related arteries late 
(> 24  hours) after myocardial infarction does not improve long-term clinical outcome. 
Prevention of reocclusion and reinfarction is therefore the key issue. After fibrinolysis a 
routine invasive strategy reduces the rate of recurrent ischem ic events as compared to 
an ischem ia driven invasive strategy. W hether the benefit of a routine invasive strategy
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is based on the effect of opening persistently occluded infarct-related arteries (rescue 
angioplasty) or also pertains to patients successfully treated with fibrinolysis remains 
to be determ ined. The impact of a routine invasive strategy after successful fibrinolysis 
is studied in the currently enrolling APRICO T-3 trial with reocclusion, left ventricular 
function and long-term clinical outcome as its endpoints. Although it is expected that 
stenting will reduce the rate of reocclusion, the question remains whether the risk of 
periprocedural events associated with a routine invasive strategy and the risk of stent 
throm bosis outweighs the risk of reocclusion. Therefore left ventricular function and 
long-term clinical outcome are im portant additional endpoints in this study.
After prim ary angioplasty the rate o f reinfarction is 3 %  as compared to 7 %  after fibri­
nolysis. Although, stents reduce the rate of reocclusion from 1 0 %  to 6 % ,  no effect is 
observed on the rate of reinfarction after prim ary angioplasty. Given the low incidence 
of ischem ic events after prim ary angioplasty, angiographic endpoints are often used 
as outcome measure to compare new treatment strategies. As reocclusion is also un­
com m on after stenting the rate of restenosis is the most frequently used angiographic 
endpoint. Restenosis is sensitive in detecting small differences between therapies. 
However, in contrast to reocclusion its association with hard clinical endpoints like 
myocardial infarction en long-term mortality is less established.
The initial introduction of drug-eluting stents in daily clinical practice was mainly 
based on relatively sm all-random ized trials showing lower rates of restenosis with no 
effect on clinical outcome as compared to bare metal stents. These positive findings 
quickly lead to wide spread introduction of drug-eluting stents for both on-label and 
off-label indications. Afterwards safety concerns were raised when large post market­
ing surveys suggested that the use of drug eluting stents was associated with an in­
creased risk of stent throm bosis. This com plication occurs in 1 -5 %  of patients both 
early and late after stent implantation and is associated with a m ortality rate up to 
4 0 % .  As a result, the increase in the use of drug eluting stents has become less prom i­
nent and worldwide a debate has arisen about the safety issues associated with the in­
troduction of new therapies in the absence of hard clinical evidence. Properly designed 
stringent post-m arketing surveys facilitate the early introduction of potential life saving 
new therapies and may detect expected and unexpected clinical events. The lack of a 
control group ham pers the interpretation of these findings. Large scale randomized
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clinical trials therefore remain the best way to study the impact of new coronary inter­
ventions and anti-throm botic strategies in prim ary angioplasty. As stent throm bosis 
occurs both early and late after stent implantation and tends to occur after cessation of 
the anti-throm botic therapy long-term follow-up will be necessary to study the impact 
of this phenomenon.
M echanistic studies
Although new treatment strategies should always be tested in large-scale clinical ran­
domized trials, angiographic/im aging follow-up (sub)studies can provide useful m ech­
anistic insight in the clinical benefit of treatment strategies. The G U ST O  trial is one 
of the most fam ous examples, which combined clinical and angiographic outcome. 
T his trial compared four fibrinolytic strategies in a large-scale randomized clinical trial 
and studied the m echanism s of benefit in an angiographic sub-study. The results of 
this landm ark trial have offered a unique insight in the understanding of treatment 
and several pathophysiolgical concepts in ST-elevation myocardial infarction. Prop­
erly performing an angiographic study requires specialistic knowledge with respect 
to the design and organization of such a study. W hether an angiographic follow-up 
study is the appropriate method to study the impact of an intervention on clinical 
outcome greatly depends on several issues. First and most importantly there should 
be an independent relation between the angiographic measure and clinical endpoints. 
Additionally the angiographic endpoint should be universally defined and follow-up 
angiography performed system atically by an experienced study group. Another im por­
tant issue is the tim ing of the follow-up angiography. In case of a recurrent ischem ic 
event, rethrombosis can be m issed if follow-up angiography is performed at a fixed 
point in time instead of at the time of an intercurrent clinical event. Angiographic TIM I- 
flow rate after reperfusion therapy, reocclusion and left ventricular ejection fraction 
are all useful angiographic measures independently associated with clinical outcome 
and can be used to gain insight in the m echanism s of benefit of new interventions. 
On the other hand, studies on the impact of the more subtle process of progression 
are more difficult to interpret. Progression has not been defined universally and its 
im pact on clinical outcome has not been demonstrated univocally. Medical therapy 
with A CE inhibitors have been shown to reduce the rate of death and ischem ic events 
in secondary prevention but failed to show an effect on coronary artery progression,
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which in part may be related to the tim ing of follow-up angiography. Post-menopausal 
estrogen therapy has been shown prothrombotic in large-scale clinical trial but failed 
to show such an effect in angiographic progression trials. These examples underline 
the im portance of using a validated measure by an experienced study group following 
a strict protocol. These conditions not only apply to angiography but probably to all 
im aging m odalities. Many surrogate endpoint trials have studied new treatment strat­
egies using progression as measured by IVUS as the prim ary outcome. W hile IVUS 
may reliably identify progressing stenoses, it cannot yet, a priori identify a vulnerable 
plaque nor is there a clear correlation between IVU S-m easures and clinical outcome 
data. The prom ising new C E T P  inhibitor torcetrapib, which increased the H D L and 
lowered LDL was associated with regression as measured with IVUS, but a large scale 
clinical trial was ended prematurely because of excessive m ortality of patient in the 
treatment group. In conclusion, m echanistic studies are of invaluable im portance to 
provide insight in the m echanism s of benefit of new treatment strategies but should 
always be performed in conjunction with large clinical outcome studies. If performed 
under the proper conditions m echanistic studies not only provide pathophysiological 
insight in a positive clinical trial but also in clinical trials with a neutral or negative 
result. M echanistic studies can provide a clue to the reason why a therapy has failed 
which fuels the progression of science.
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SAMENVATTING
In Nederland is de incidentie van het eerste hartinfarct 20-30 per duizend inwoners 
per jaar bij mensen ouder dan 60 jaar. Veertig procent van deze mensen overlijdt voor­
dat ze het ziekenhuis bereiken. In de afgelopen decennia is de prognose van mensen 
met een hartinfarct sterk verbeterd. De resultaten van vele grote klinische onderzoe­
ken hebben bijgedragen aan deze vooruitgang. Met name studies gericht op vroege 
reperfusie en de preventie van retrombose hebben de uitkomst sterk verbeterd. Het 
huidige proefschrift heeft betrekking op patiënten die m iddels reperfusietherapie zijn 
behandeld en zowel patiënten behandeld met fibrinolyse als een primaire percutane 
coronaire interventie (PCI) komen aan bod. Hoewel van oudsher fibrinolyse de voor­
keur had, is heden ten dage primaire PCI de therapie van keus in Nederland. Echter, 
door het gebrek aan het tijdig voorhanden zijn van een primaire PCI is fibrinolyse nog 
steeds de meest gebruikte reperfusie strategie in grote delen van de wereld buiten N e­
derland. Het is belangrijk om te realiseren dat het doel van beide therapieën hetzelfde 
is; het vroeg en volledig heropenen van het afgesloten kransslagvat en voorkomen dat 
het geopende vat opnieuw afgesloten raakt (reocclusie). Een centraal thema in het 
huidige proefschrift is de relatie tussen de angiografische en klinische uitkomst in de 
verschillende fases na het acute hartinfarct. In de acute fase zijn de tijdsrelatie tot be­
handeling en de verschillende reperfusie strategieën met elkaar vergeleken. De lange 
termijn gevolgen van reocclusie op de mortaliteit is het onderwerp in de subacute fase 
na een hartinfarct. In de stabielere fase is de invloed van progressie van arteriosclerose 
het onderwerp. In de algemene introductie beschreven in hoofdstuk 1 wordt achter­
grond informatie gegeven over de basisprincipes van reperfusietherapie, reocclusie en 
progressie. In vogelvlucht worden de onderwerpen van de verschillende hoofdstukken 
in dit proefschrift toegelicht.
In hoofdstuk 2 van dit proefschrift wordt de rationale beschreven van de gerandom i­
seerde m ulticentrum  studie “Holland Infarction Study (H IS)”. In deze studie wordt pri­
maire PCI vergeleken met vroege, bijvoorkeur prehospitale fibrinolyse met een liberaal 
rescue beleid. O p het mom ent van initiëren van de studie in 20 0 2 was reeds gebleken 
dat primaire PCI betere resultaten kende dan fibrinolyse in het geval dat patiënten zich 
presenteren in een ziekenhuis met interventie m ogelijkheden. Echter, het merendeel
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van de patiënten met een hartinfarct presenteert zich in een ziekenhuis zonder inter­
ventie capaciteiten of prehospitaal. In deze situatie is het voordelige effect van een 
primaire PCI m inder groot ten opzichte van fibrinolyse. Daar komt nog bij dat in de 
gerandomiseerde studies primaire PCI vaak werd vergeleken met suboptim ale fibrino- 
lytische therapie. Veelal werd niet-fibrinespecifieke fibrinolyse gegeven in plaats van de 
effectievere wel specifieke middelen. Ook kregen patiënten meestal pas fibrinolytische 
therapie in het ziekenhuis in plaats van prehospitaal. Ten slotte werden patiënten na 
fibrinolyse vaak zeer conservatief behandeld, dat wil zeggen dat er niet standaard een 
invasief beleid werd gevoerd in geval van onvoldoende reperfusie na fibrinolyse (res­
cue). In de H IS werd primaire PCI vergeleken met vroege, bijvoorkeur prehospitale 
fibrinolyse met een liberaal rescue beleid. Jammer genoeg werd de HIS voortijdig ge­
staakt in verband met financieringsproblem en. Hierdoor werden er van de geplande 
900 patiënten uiteindelijk slechts 48 geincludeerd. In hoofdstuk 3 staan de resultaten 
beschreven van deze 48 patiënten. Het voorkomen van het gecombineerde eindpunt 
dood, reinfarct en herseninfarct na 1 jaar bedroeg 8 %  voor patiënten behandeld met 
primaire PCI ten opzichte van 2 2 %  in geval van fibrinolyse. Gezien de kleine patiënten 
groepen is het niet mogelijk klinische conclusies te trekken op basis van deze getallen.
Primaire PCI is de reperfusietherapie van voorkeur, indien de procedure verricht 
kan worden binnen negentig minuten na presentatie en wordt uitgevoerd door een 
ervaren interventieteam. In de richtlijnen is deze tijdslim iet geïntroduceerd omdat er 
een sterke relatie bestaat tussen de tijd van presentatie tot het opblazen van de dot­
terballon en de ziekenhuism ortaliteit. Langere tijdsintervallen zijn geassocieerd met 
een verhoogd m ortaliteitsrisico. Het is daarom van wezenlijk belang dat deze tijd sin ­
tervallen zo kort mogelijk worden gehouden. Verschillende strategieën zijn effectief 
gebleken in het reduceren van de tijdsintervallen, zoals het beschikbaar zijn van één 
telefoonnum m er waarmee direct het catheterisatieteam kan worden geactiveerd, het 
activeren van het catheterisatieteam voordat de patiënt wordt getransporteerd en de 
afspraak dat het personeel binnen 20 minuten na een oproep in huis is. In hoofdstuk 4 
van dit proefschrift worden de resultaten beschreven van een prospectieve registratie 
van 581 patiënten die zich prehospitaal presenteerden en verwezen zijn naar het U ni­
versitair Medisch Centrum  St. Radboud voor een primaire PCI van 2005 t/m  2007. We 
laten zien dat er een tijdsw inst valt te behalen van 50 minuten wanneer een patiënt na
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prehospitale diagnose van een acuut hartinfarct direct wordt verwezen naar een inter­
ventie ziekenhuis in plaats van vervoer via een niet interventie ziekenhuis. Bovendien 
laten we zien dat een kortere duur van begin van klachten tot balloninflatie onafhanke­
lijk geassocieerd is met een beter resultaat van de procedure (hoger percentage TIM I- 
3 flow). Deze procedurele parameter is een bekende voorspeller van de mortaliteit. 
O nze resultaten suggereren hiermee dat direct vervoer naar een interventie ziekenhuis 
de mortaliteit kan verlagen.
In hoofdstuk 5 van dit proefschrift onderzoeken we de relatie tussen de verschillende 
tijdsintervallen en de langeterm ijns mortaliteit in patiënten met een prehospitale diag­
nose van ST-elevatie infarct die verwezen zijn voor een primaire PCI. Met de introduc­
tie van prehospitaal geïnitieerde primaire PCI hebben de richtlijnen een tijdsraam  (van 
eerste medisch contact tot het opblazen van de dotterballon) geïntroduceerd w aarbin­
nen een primaire PCI verricht dient te worden. In de prehospitale situatie is de impact 
van dit tijdsinterval op de klinische uitkom st nooit eerder onderzocht. In Hoofdstuk 
5 beschrijven we de impact van de verschillende tijdsintervallen op de mortaliteit in 
547 patiënten uit onze prospectieve registratie waarvan de data met betrekking tot de 
tijdsintervallen kompleet is. De tijd van het begin van klachten tot het opblazen van 
de dotter ballon blijkt een onafhankelijke voorspeller van de mortaliteit; H R 1.07 (9 5 %  
CI: 1.01-1.12, p=0.02) samen met Killip klasse en de leeftijd. Het tijdsinterval van het 
mom ent van eerste medische contact tot het opblazen van de dotterballon is niet 
geassocieerd met de mortaliteit; HR 1.07 (9 5 %  CI: 0.95-1.21, p=0.3). Deze bevindingen 
komen niet overeen met de resultaten uit eerdere am erikaanse studies die een d ui­
delijke relatie laten zien tussen het tijdsinterval van het arriveren in het ziekenhuis tot 
het opblazen van de dotterballon en de ziekenhuism ortaliteit. Het feit dat onze studie 
prehospitale patienten betreft en is verricht in Nederland draagt er aan bij dat zowel de 
totale duur van klachten en de duur van het eerste medisch contact tot het opblazen 
van de ballon aanm erkelijk korter zijn dan in de am erikaanse situatie. Mogelijk door 
de relatief korte duur en geringe spreiding in het tijdsinterval van eerste medische 
presentatie tot het opblazen van de dotterballon is een relatie met mortaliteit niet 
aangetoond. De situatie waarin de tijdsintervallen na presentatie van de patiënt steeds 
korter worden, wordt het belang van de patiënten vertraging steeds groter. Daarom 
verdienen pogingen om dit tijdsinterval te reduceren meer aandacht.
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Het initiële voordeel van reperfusie therapie wordt voor een deel geneutraliseerd door 
het optreden van reinfarcten en reocclusie. Na een primaire PCI met het plaatsen van 
een stent treedt reocclusie weinig frequent op (3 -6 %  na 6-7 maanden). Na fibrinolyse 
treedt reocclusie echter veel frequenter op, namelijk in 3 0 %  van de patiënten na een jaar. 
Hoewel reocclusie is geassocieerd met een verhoogde kans op reinfarcten, revasculari- 
saties en minder herstel van de linkerventrikelfunctie is de impact van reocclusie op de 
lange termijnsmortaliteit niet uitgebreid onderzocht. Hoofdstuk 6 van dit proefschrift be­
schrijft de uitkomst van 10 jaar vervolgonderzoek bij 248 patiënten met gepaard angio- 
grafisch onderzoek uit de APRICOT-1 studie. Patiënten in deze studie hadden een ST- 
elevatie hartinfarct en waren met succes behandeld met fibrinolyse. Na een conservatief 
ischem isch bepaalde revascularisatie strategie trad reocclusie op in 2 9 %  van de patiën­
ten na 3 maanden. Reocclusie was geassocieerd met een cardiale overlevingskans van 
7 3 %  na 10 jaar in vergelijking tot 8 8 %  in patiënten zonder reocclusie. Deze relatie was 
onafhankelijk van de linkerventrikelejectiefractie en werd gezien in zowel patiënten met 
een symptomatische reocclusie als bij patiënten met een reocclusie zonder symptomen.
In stabiele patiënten hebben angiografische follow-up studies laten zien dat m edicij­
nen die het lipiden profiel gunstig beïnvloeden de snelheid van progressie van coro­
naire arteriële stenosen verminderen en dat het optreden van progressie is geasso­
cieerd met een slechtere prognose. Progressie treedt op in fases en meestal zonder 
dat dit klinisch wordt gemerkt. W andstandige niet-occlusieve trom busform atie wordt 
verondersteld onderdeel te zijn van het multifactoriele proces van plaque progressie. 
Hoewel bekend is dat aspirine de kans op ischem ie gerelateerde klinische gebeurte­
nissen verkleint is de rol van aspirine met betrekking tot het meer subtiele proces van 
progressie onbekend. Hoofdstuk 7 beschrijft de resultaten van een gerandomiseerde, 
placebogecontroleerde studie met angiografische follow-up na een jaar. Één maand 
na fibrinolyse werden 154 patiënten met een open infarct gerelateerd vat gerandom i­
seerd naar het doorgaan met dubbele antiplaatjes therapie of placebo. Het effect van 
de com binatie van aspirine en dipyridam ol op progressie in niet infarctgerelateerde 
kransslagaders werd onderzocht. In totaal waren 1436 coronaire segmenten beschik­
baar voor analyse. Verschillende kwantitatieve coronair angiografische maten werden 
gebruikt en er konden geen verschillen worden aangetoond in de gem iddelde verande­
ringen in diameter tussen beide behandelgroepen. Tevens werden er geen verschillen
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gevonden in de proportie van patiënten met progressie wanneer dit sem ikwantitatief 
werd gedefinieerd. Bij lange termijn klinische follow-up kon geen relatie worden aan­
getoond tussen het optreden van progressie en de klinische uitkomst. O nze resultaten 
sluiten aan bij eerder dieronderzoek waarin is aangetoond dat aspirine alleen klinische 
episodes voorkomt die zijn gerelateerd aan (sub) occlusieve trombus formatie en geen 
invloed heeft op niet-occlusieve trom bus formatie.
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Reperfusie therapie
Gezien de superioriteit van primaire PCI als reperfusie therapie bij het acute myo- 
cardinfarct, dient de beschikbaarheid van primaire PCI te worden geoptimaliseerd. 
Uitbreiding van het aantal interventie ziekenhuizen kan gewenst zijn, echter strikte 
regulatie is hierbij noodzakelijk om het volume, de ervaring en de kwaliteit van in­
dividuele centra te waarborgen. In de Nederlandse situatie is complete dekking met 
hoogwaardige kwaliteit relatief eenvoudig te organiseren. Daarentegen kan in dunbe­
volkte landen met lange reistijden adequate dekking problem atischer te realiseren zijn. 
Medicam enteuze voorbehandeling met fibrinolyse, een glycoproteineblokker of een 
com binatie van beide middelen leek een goede oplossing ter overbrugging van de tijd 
tussen het stellen van de diagnose STEM I en een primaire PCI. Grote studies met deze 
behandelstrategie lieten echter geen effect zien op de klinische uitkomst, ondanks een 
toename van het percentage patiënten met een open infarct vat voor de procedure en 
verbeterde ST-segm ent resolutie na de procedure. Wel werd er een trend richting een 
betere klinische uitkomst gezien in patiënten die zich presenteerden binnen twee uur 
na het begin van klachten.
Prehospitale triage voor het ST-elevatie infarct is een andere mogelijkheid om de 
beschikbaarheid van primaire PCI te vergroten. Deze strategie is effectief daar het zo ­
wel de duur van presentatie tot ballon inflatie met 50 tot 60 minuten verkort, als de 
duur van het begin van klachten tot de presentatie met 60 minuten verkort. Hoewel 
prehospitaal geïnitieerde primaire PCI meer en meer de standaard behandeling wordt 
in Europa wordt in de Verenigde Staten de introductie van dit systeem gehinderd door 
beperkende wetgeving. Indien er een prehospitaal systeem aanwezig is, dienen er uni­
forme protocollen te zijn die gericht zijn op het snel stellen van de diagnose en een 
directe verwijzing naar een interventieziekenhuis en deze protocollen dienen strikt te 
worden gehanteerd. Hierbij dient er rekening te worden gehouden met de matige sen­
sitiviteit van het prehospitale com puter algoritme om een ST-elevatie myocard infarct 
te diagnosticeren. Interventiecentra dienen hierop te anticiperen door alle prehospi­
tale patiënten te accepteren, zelfs in geval van twijfel over de diagnose van het ST- 
elevatie myocardinfarct. De vraag of extra scholing van am bulance personeel en/of het 
faxen van het prehospitale ECG naar het ziekenhuis de diagnostische zekerheid in de
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prehospitale situatie vergroot, verdient nader onderzoek. O ndanks de grote tijdswinst 
van een prehospitaal systeem zal voor een deel van de patiënten uit voornam elijk 
dun bevolkte gebieden de beschikbaarheid van primaire PCI problem atisch blijven. 
Voor deze patiënten blijft (prehospitale) fibrinolyse de therapie van eerste keus. Het 
tijdsraam  van 90 minuten waarbinnen een primaire PCI effectiever is dan fibrinolyse 
is recentelijk ter d iscussie gesteld en m ogelijkerwijs zijn zelfs langere tijdsintervallen 
tot primaire PCI acceptabel. Deze bevindingen hebben de vergelijking tussen primaire 
PCI en optim ale fibrinolytische therapie, dat wil zeggen prehospitale fibrinolyse en 
een liberale invasieve vervolg strategie, aangewakkerd voor patiënten met een lange 
wachttijd tot invasieve behandeling. Behandelstrategieën die zich richten op het be­
perken van de infarctgrootte en regeneratie van myocardcellen na reperfusietherapie 
laten geen eenduidig effect op de prognose zien. Vooralsnog blijft snelle en complete 
reperfusie in patiënten met een ST-elevatie infarct het primaire doel van behandeling.
Naast de bovengenoemde maatregelen kan additionele tijdsw inst worden bereikt 
door de tijd van het begin van klachten tot presentatie verder te verkorten. Media cam ­
pagnes met uitleg over het belang van vroege presentatie en uitleg over de symptomen 
die passen bij een hartinfarct zouden dit tijdsinterval kunnen verkorten. Anderzijds 
is het belangrijk om te realiseren dat - 3 0 %  patiënten met een hartinfarct niet wordt 
behandeld met reperfusietherapie, ondanks dat ze wel in aanm erking komen. Deze 
patiënten hebben een matige prognose en de uitkom st zou sterk verbeterd kunnen 
worden wanneer ze wel behandeld zouden worden.
De preventie van het reinfarct en reocclusie
Terwijl vroeg herstel van goede perfusie van het infarct gerelateerde vat het belangrijk­
ste doel is in de acute fase van het hartinfarct, is behoud van goede doorgankelijkheid 
(of preventie van reocclusie) de uitdaging in de subacute fase. Na zowel primaire PCI 
als fibrinolyse is reocclusie geassocieerd met een slechtere prognose, onafhankelijk 
van de linkerventrikelrestfunctie. Het routinematig laat ( >  24  uur) openen van het 
afgesloten infarctgerelateerde vat verbetert de prognose niet. Derhalve is preventie 
van recidief infarct en reocclusie van groot belang. De kans op nieuwe ischem ische 
gebeurtenissen is kleiner na een routinematig invasief beleid dan na een ischem ie 
gestuurd invasief beleid na fibrinolyse. O f  dit voordeel volledig berust op het openen 
van afgesloten vaten bij patiënten die zonder succes zijn behandeld met fibrinolyse
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(rescue) of dat er ook voordeel is bij patiënten die wel succesvol zijn behandeld en 
dus een open infarct gerelateerd vat hebben, is onbekend. Het effect van een routine 
invasief beleid na succesvolle fibrinolyse wordt onderzocht in de APRICO T-3 studie. 
Eindpunten in deze studie zijn reocclusie, linkerventrikelrestfunctie en lange termijn 
prognose. Hoewel de verwachting is dat een invasief beleid, met stentplaatsing, de 
kans op reocclusie verkleint, is het nog de vraag of de kans op het optreden van peri- 
procedurele infarcten en stent trombose opweegt tegen het risico op reocclusie. De 
andere eindpunten, linkerventrikelrestfunctie en langetermijnprognose, zijn derhalve 
van groot belang voor de uitkomsten van deze studie.
Na primaire PCI is de kans op een reinfarct 3 %  in vergelijking tot 7 %  na fibrinolyse. 
Het plaatsen van een stent bij een primaire PCI verlaagt wel de kans op reocclusie, 
maar niet op een recidief infarct. Daar de kans op ischem ische events na primaire PCI 
klein is, worden vaak angiografische eindpunten gebruikt om nieuwe therapieën te 
evalueren. Reocclusie zou hiervoor een geschikt eindpunt zijn, maar komt eveneens 
weinig voor. Derhalve wordt restenose in de meeste studies gebruikt als angiogra- 
fisch eindpunt. Hoewel restenose sensitief is in het detecteren van kleine verschil­
len tussen therapieën, is een associatie tussen restenose en het optreden van harde 
klinische eindpunten, zoals het optreden van een myocardinfarct of mortaliteit, niet 
aangetoond. De introductie van drug eluting stents in de dagelijkse klinische praktijk 
berust voornam elijk kleine gerandomiseerde angiografische studies die m inder re­
stenose lieten zien ten opzichte van bare metal stents. Deze positieve angiografische 
bevindingen hebben geleid tot het wijdverbreide gebruik van drug eluting stents, zowel 
on-label als off-label. Later zijn deze stents in opspraak geraakt, doordat grote post 
marketing surveys een verhoogde kans op stent trombose suggereerden. Stent trom ­
bose als com plicatie na PCI treedt op in 1 -5 %  van de gevallen, zowel vroeg als laat na 
implantatie en is bovendien geassocieerd met een mortaliteit tot 4 0 % .  Als gevolg van 
deze bevindingen is de groei in het gebruik van drug eluting stents teruggelopen en 
is er een wereldwijde d iscussie op gang gekomen over de introductie van nieuwe the­
rapieën zonder bewezen klinische effectiviteit. Goed ontworpen stringente post mar­
keting surveys faciliteren een snelle introductie van potentieel levensreddende nieuwe 
therapieën en kunnen leiden tot detectie van zowel verwachte als onverwachte effec­
ten. Het ontbreken van een controle groep beperkt echter de interpretatie van deze 
surveys. Grootschalige gerandomiseerde studies blijven derhalve de beste methode
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om nieuwe interventies en antitrombotische strategieën te onderzoeken in patiënten 
die worden behandeld m iddels primaire PCI. Daar stent trombose zowel vroeg als laat 
na stent implantatie kan optreden en bovendien vaak pas optreedt na het stoppen van 
antitrom botische therapie, is lange termijn follow-up noodzakelijk om dit fenomeen 
beter in kaart te brengen.
M echanistische studies
Hoewel nieuwe therapieën altijd getest dienen te worden in grote klinische gerando­
miseerde studies, kunnen angiografische/im aging studies inzicht geven in het wer­
kingsm echanism e van bepaalde therapieën. De G U ST O  studie is één van de meest 
bekende voorbeelden hiervan. In deze grote gerandomiseerde klinische studie werden 
vier fibrinolytische strategieën met elkaar vergeleken, het w erkingsm echanism e werd 
onderzocht in een angiografische substudie. De resultaten van de G U ST O  hebben een 
belangrijke bijdrage geleverd aan het begrip van het pathofysiologische concept van 
het ST-elevatie myocard infarct en de behandeling ervan. Het correct uitvoeren van 
een angiografische studie vraagt specialistische kennis met betrekking tot het ontwerp 
en de organisatie van een dergelijke studie. O f  een angiografische studie de juiste 
methode is voor het onderzoeken van een bepaalde interventie is sterk afhankelijk 
van een aantal zaken. Ten eerste dient de m edische interventie die wordt onderzocht 
een te verwachten effect te hebben op het angiografische eindpunt. Ten tweede dient 
er een onafhankelijke relatie te bestaan tussen het angiografische eindpunt en de 
klinische prognose. Vervolgens is het noodzakelijk dat het angiografische eindpunt 
eenduidig gedefinieerd is en dient het onderzoek system atisch plaats te vinden door 
een ervaren onderzoeksgroep. Een belangrijk punt betreft de tim ing van het vervolg 
onderzoek. In het geval van een hernieuwde ischem ische gebeurtenis kan retrombose 
worden gemist, wanneer het vervolgonderzoek niet wordt verricht op het mom ent van 
de klinische gebeurtenis, maar op een standaard mom ent tijdens de studie. Zowel 
TIM I-flow, het optreden van reocclusie als linkerventrikelejectiefractie zijn eenduidig 
gedefinieerde angiografische parameters en onafhankelijke voorspellers van prognose 
in patiënten met een acuut myocard infarct. Derhalve kunnen ze worden gebruikt als 
eindpunten van m echanistische studies. Studies waarin als eindpunt ziekte progressie 
wordt gebruikt, zijn daarentegen m oeilijker te interpreteren. Progressie van ziekte is 
nam elijk niet universeel gedefinieerd en het effect ervan op de prognose is niet ondub­
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belzinnig aangetoond. De bovengenoemde bepalingen zijn w aarschijnlijk niet alleen 
van toepassing op angiografische studies maar gelden ook voor studies met andere 
beeldvorm ende modaliteiten. Intravascular ultrasound (IVUS) kan meer betrouwbaar 
progressie meten dan angiografie. IVUS is niet in staat betrouwbaar een instabiele 
plaque te identificeren en bovendien is een relatie tussen met IVUS gemeten progres­
sie en de prognose nog nooit aangetoond. In een IVUS studie werd de veelbelovende 
C E T P  remmer torcetrapid onderzocht. Dit m edicijn verhoogt het HDL-cholesterol 
en verlaagt het LDL- cholesterol. In het IVUS onderzoek werd in plaats van remming 
van progressie, regressie van coronairlijden gezien met torcetrapid. De desillusie was 
enorm toen bleek dat torcetrapid was geassocieerd met oversterfte in een grote geran­
dom iseerde placebogecontroleerde klinische studie die als gevolg van de bevindingen 
ook voortijdig is gestaakt. Concluderend kan worden gesteld dat m echanistische stu­
dies van groot belang zijn voor het verkrijgen van inzicht in het w erkingsm echanism e 
van nieuwe m edische interventies, maar ze dienen altijd gecombineerd te worden met 
een grote gerandomiseerde klinische studie. Indien een m echanistische studie wordt 
verricht onder de juiste voorwaarden, verschaft dit niet alleen inzicht bij een positieve 
klinische uitkomst, maar ook in het geval van een neutrale of negatieve uitkomst. Dit 
inzicht vergroot onze kennis en draagt bij aan de vooruitgang van de wetenschap.
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Dankwoord
Nu de datum van mijn promotie nadert kijk ik met een mengeling van gevoelens terug 
op de periode van mijn onderzoek. Een waardig promotie onderzoek kenmerkt zich 
door hoge pieken maar som s ook diepe dalen. Het verrichten van onderzoek is een 
confrontatie met je eigen vermogen, maar zeker ook met je eigen tekortkomingen. 
Mijn eigen loopbaan als promovendus voldoet zeer zeker aan deze kenmerken, der­
halve ben ik nu dan ook erg trots op het bereiken van deze m ijlpaal. Het levert me 
niet alleen de titel van doctor op maar ook een enorme persoonlijke ontwikkeling en 
mensenkennis. De ervaring die ik heb opgedaan met het opzetten van een studie, het 
beheren van een database, het tot stand brengen van publicaties en het geven van pre­
sentaties heeft me verrijkt voor de rest van mijn leven. Het voortijdig beëindigen van 
de Holland Infarction Study was voor mij een grote teleurstelling en één van de diepste 
dalen in mijn carrière als promovendus. Tot op de dag van vandaag ben ik van mening 
dat voor de prehospitale situatie de studievraag (met enige aanpassing) van de HIS 
actueel is (zie stellingen). Door de opm ars van de primaire PCI en het bijbehorend po­
litieke klimaat in cardiologisch Nederland ontbrak er draagvlak voor de studie en dit is 
een belangrijke reden waardoor de H IS nooit echt van de grond is gekomen. Met deze 
ervaring rijker en een illusie arm er heb ik mijn promotie onderzoek verder toegespitst 
op de optim alisatie van de logistiek rondom primaire PCI en het effect van progressie 
van atherosclerose en reocclusie op de lange termijn prognose na het myocardinfarct. 
Als promovendus in het algemeen, maar zeker als onderzoeker van een multicentrum 
studie heb ik met heel veel verschillende mensen onder allerlei om standigheden sa­
mengewerkt. Hoewel het onm ogelijk is alle betrokkenen persoonlijk te bedanken ben 
ik ieder erkentelijk voor hun bijdrage aan mijn promotie onderzoek. Zonder jullie was 
dit boekje nooit tot stand gekomen. Een aantal mensen vormt een sleutelrol in mijn 
leven als onderzoeker en bij de tot standkom ing van mijn proefschrift. Deze mensen 
wil ik graag persoonlijk bedanken.
Promotor, Professor F.W.A. Verheugt.
Uw enorme parate kennis van studies en uw gave om complexe problemen eenvoudig 
weer te geven kenmerken u, zowel als clinicus als onderzoeker. Met u als mijn pro­
motor en groot voorstander van prehospitale fibrinolyse ben ik begonnen aan mijn 
promotie onderzoek. Hoewel het niet is gelopen zoals vooraf gepland, is het einddoel, 
de promotie, nu toch bereikt. O p onderzoeksniveau hebben we min of meer samen de
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overstap gemaakt van de prehospitale fibrinolyse naar primaire PCI als voorkeursthe- 
rapie bij het acute myocard infarct. Tijdens het doen van onderzoek heeft u mij altijd 
veel vrijheid gegeven. In het begin was dit voor mij som s lastig, maar naarmate mijn 
onderzoek vorderde en ik mij verder ontwikkelde, ben ik dit erg gaan waarderen en 
heeft het me als onderzoeker ju ist verder gebracht. Ik ben u dankbaar voor het snelle 
correctiewerk, de onderzoeksbesprekingen en de gezellige diners tijdens congressen. 
Bovenal ben ik u dankbaar voor de steun die u mij heeft geboden van het begin tot het 
einde van mijn promotie.
Copromotor, Marc Brouwer, beste Marc
Dankzij jouw enthousiasm e ben ik besmet geraakt met het onderzoeksvirus en heb 
ik besloten promotie onderzoek te gaan doen. Met je toewijding en grenzeloze wil 
om je doel te bereiken heb je laten zien dat “the sky the lim it” is. Ik ben je dankbaar 
voor de vele uren die we samen achter de computer hebt gezeten om de data “echt 
te snappen” en de tijd die we hebben gestoken in het perfectioneren van de inhoud 
van onze manuscripten. Deze intensieve m anier van werken heeft zeker bijgedragen 
aan de grote hoeveel hoogwaardige publicaties die zijn voortgevloeid uit de relatieve 
kleine databases die de experimentele cardiologie tot zijn beschikking heeft. Boven al­
les heb ik bewondering voor je onwrikbaar geloof in mensen waarmee je samenwerkt. 
Na de H IS heb jij geregeld dat ik naar Nieuw Zeeland kon om onderzoek te doen met 
John French om zo mijn promotie onderzoek een doorstart te geven. Door het grote 
succes van je werkwijze is je tijd voor individuele begeleiding schaarser geworden. Ik 
beschouw m ezelf daarom als één van “the lucky few” die zo intensief met je heeft kun­
nen samenwerken. Dank!
Copromotor, W im  Aengevaeren, beste W im ,
Je passie voor de wetenschap en de interventiecardiologie kent geen grenzen. Je bent 
werkelijk onvermoeibaar. Het buiten opwachten van een patiënt met een ST-elevatie 
infarct en de som s intense d iscussies over de inhoud van de manuscripten zijn daar 
typerende voorbeelden van. Hoewel er in het Rijnstate ziekenhuis m inder tijd is voor 
wetenschap dan in het UM C St. Radboud hoop ik dat je het onderzoek een warm hart 
blijft toedragen.
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Professor F. Bär, beste Frits,
De frequente Steering Com m ittee vergaderingen over de HIS bij het ICIN staan me nog 
helder voor de geest. D iscussies over net gepubliceerde resultaten van de D A N AM I-2 
en A SSEN T-3 plus, het gebruik van enoxaparine, het CRF en de uitbreiding van het aan­
tal centra voor deelname, zal ik niet snel vergeten. Jammergenoeg ontbrak er landelijk 
voldoende draagkracht voor de studie en is de HIS voortijdig gestopt. Ik heb van het 
H IS avontuur enorm veel geleerd en onze samenwerking als erg prettig ervaren.
Professor John K. French, dear John,
When I came to New Zealand all alone, you made me feel right at home and I was im ­
pressed how you always managed to squeeze in some time for a study meeting in your 
busy clinical schedule. Angiographic follow-up studies on reocclusion after myocardial 
infarction has linked the Radboud University and Greenlane hospital in Auckland New 
Zealand for a long time. Despite the fact that you moved to Liverpool hospital Sydney 
in Australia our contact remained. Hopefully we can enjoy your creativity and refresh­
ing scientific input and collaborate on new projects in de future.
N ick Clappers en W essel Keuper
Na Marc, Jaap, Peter, Etienne en ik vormen jullie de laatste generatie onderzoekers die 
nog echt in “de kelder” hebben gezeten. Met z'n drieën hebben we enkele jaren de 
experimentele cardiologie bemand. In deze periode hebben we veel geleerd maar ook 
veel plezier gehad. Drie jaar intensieve samenwerking schept een band waar je mijn 
inziens de rest van je leven op kan bouwen. Ik ben daarom erg blij dat jullie mijn para­
nimfen willen zijn. Met veel genoegen denk ik terug aan de discussies die we hebben 
gevoerd over ons eigen onderzoek, over de interpretatie van de grote clinical trials en 
natuurlijk over de andere zaken die het leven de moeite waard maken. Nick, je gevoel 
voor taal is bijzonder en ik heb daar veel van geleerd. Bedankt voor het altijd kritisch 
lezen van mijn m anuscripten. W essel, wanneer er iets geregeld moest worden, vroeg 
ik jou om advies. Je betrouwbaarheid en organisatiekunde maken je een goed collega 
en onderzoeker, al ben je van dat laatste ze lf niet altijd overtuigd. Heren, ik weet hoe 
lastig het is om kliniek en promotie onderzoek te com bineren. O ndanks deze lastige 
omstandigheden ga ik er vanuit dat binnen afzienbare tijd ook jullie boekje ter verde­
diging zal verschijnen.
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Etienne Cram er
Je bent veruit de meest creatieve onderzoeker die ik ken. T ijdens besprekingen weet je 
iedere keer een nieuw licht te laten schijnen op de verschillende vraagstukken en dit 
geeft vaak nieuwe inzichten en altijd stof tot nadenken. Eén van mooiste onderzoeks­
projecten van onze afdeling is jouw kindje de TR A M IC I. Hopelijk volgen binnenkort de 
resultaten. Ik ben erg benieuwd naar je visie op de uitkomsten.
Peter Kievit en Jaap Remmen
Het was voor mij een waar genoegen om met jullie als de oude generatie onderzoekers 
te kunnen samenwerken. Beider jullie kennis op zowel klinisch als onderzoeksniveau 
zie ik als groot voorbeeld. Het verbaast mij dan ook geenszins dat jullie allebei een 
mooie plek als cardioloog hebben gevonden.
Irene Joziasse
O nze samenwerking met betrekking tot het angiografische progressie project in Nieuw 
Zeeland heeft uiteindelijk geleid tot een mooie publicatie. Het was indrukwekkend 
om te zien hoeveel werk je had verzet in de tijd dat je daar zat. Inm iddels ben je ge­
promoveerd maar heb je jam m ergenoeg besloten om de cardiologie te verlaten. In de 
toekomst is Nederland in ieder geval een heel goede huisarts rijker.
De student onderzoekers
Ham za El Aidi: Je gedrevenheid en standvastigheid ten aanzien van alles waarin je ge­
looft leiden som s tot onbegrip, maar hebben zeker ook bijgedragen aan het feit dat je 
als talentvolle onderzoeker verschillende onderzoeksbeursen hebt verkregen. Ik wens 
je heel veel succes met je promotie onderzoek in Utrecht.
Rozemarijn van der V ijver en Noem i Wouters: Jullie zijn en blijven de ladies van het 
onderzoek. Na een stage in Nieuw Zeeland bij John French hebben jullie het onder­
zoek afgerond in Nederland. Dank voor de gezellige tijd en respect voor het doorzet­
tingsvermogen dat jullie hebben getoond bij het afronden van het onderzoek.
Stephan Liem. Wat heb jij ongelooflijk hard gewerkt met het maken van de da­
tabase, grote klasse. Met de d iscussies over de parallellen en verschillen tussen de 
trauma helikopter en de prehospitale triage van het myocard infarct hadden we een
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leerzam e afleiding. Ik heb onze samenwerking enorm  gewaardeerd. Heel veel succes 
in Den Bosch en dat je maar snel in opleiding mag komen voor de cardiologie.
De staf en assistenten Cardiologie van het U M C St. Radboud wil ik bedanken voor het 
includeren van patienten voor de verschillende studies en het bieden van de m ogelijk­
heid om tijdens mijn opleiding enige onderzoekstaken te verrichten.
De leden van de m anuscriptcom m issie, prof. dr. P Sm its, prof. dr. ir. H .A . van Swieten, 
prof. dr. L.J. Schutze Kool, prof. dr. J.L. W altenberger en prof.dr. J.J. Piek wil ik danken 
voor de tijd die zij hebben genomen om het m anuscript kritisch te beoordelen.
Truus, Noortje, Gabe en Rudi, dank voor de IC T  ondersteuning. Het was erg prettig 
dat computer problemen over het algemeen binnen een dag waren opgelost, zodat we 
snel verder konden met het onderzoek. Martijn van O ijen, bedankt voor je positieve 
inbreng. Jij wees ons altijd op de mogelijkheden in plaats van op de onm ogelijkheden. 
Richard Braam wil ik danken voor de gezellige tijd in het C W Z  en vruchtvolle discussies 
over de cardiologie en onderzoek. Pierre van Grunsven, medisch leider van RAV regio 
Gelderland zuid wil ik bedanken voor de prettige samenwerking en het beschikbaar 
stellen van de prehospitale gegevens. Tjerk Kingma en Hans Hillege van het TC C  in 
Groningen wil ik danken voor de tomeloze inzet bij de ondersteuning van de Holland 
infarction studie. De m aatschap cardiologie van het C W Z  wil ik bedanken voor de 
eerste introductie in het vak van de cardiologie en hun bereidwilligheid tot deelname 
aan onze onderzoeksprojecten. Steeds meer bewondering heb ik voor de visie en het 
doorzettingsvermogen van Dr. T .E .H . Hooghoudt en Drs. D.P. Hertzberger om in 1986 
reeds prehospitale thrombolyse te introduceren in N ijm egen. De m aatschap cardiolo­
gie van ziekenhuis Rijnstate wil ik bedanken. Ten eerste omdat ze me de gelegenheid 
hebben geboden mijn promotie onderzoek af te ronden en ten tweede voor de ple­
zierige werksfeer waarin ik op dit mom ent mijn opleiding kan volgen. Mijn dank gaat 
uit naar alle centra die hun medewerking hebben gegeven aan de holland infarction 
studie. Tot slot wil ik alle patiënten bedanken die hebben deelgenomen aan de ver­
schillende studies beschreven in dit proefschrift.
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Mijn O uders en mijn zusje. Lieve Ma, Pa en Maartje jullie onvoorwaardelijke steun 
en liefde vormen de basis voor wie ik ben, de keuzes die ik maak en zal maken in de 
toekomst. O ndanks de puzzels die we hebben gelegd en de hobbels die we hebben 
genomen is onze band uiteindelijk alleen maar sterker geworden. Grenzeloze liefde en 
enorme verdraagzaamheid vormen de hoeksteen van ons gezin. Ik ben dan ook trots 
hiervan deel uit te maken. Ik houd zielsveel van jullie.
Lieve Heidi, ik weet dat je hier een hekel aan hebt en daarom zal ik het kort houden. 
O nze gem eenschappelijke basis houdt ons bijeen. Door de tegenstellingen in onze 
karakters vullen we elkaar aan. Dit maakt ons een superteam. Met jou voel ik me 
compleet.
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Curriculum vitae
De auteur van dit proefschrift werd geboren op 18 april 1974 te Am sterdam . O p 8 jarige 
leeftijd verhuisde hij naar Diepenveen, alwaar hij zijn verdere jeugd doorbracht. In 1993 
werd het eindexamen behaald van het voorbereidend w etenschappelijk onderwijs aan 
de Scholengem eenschap Alexander Hegius te Deventer. In het eerste jaar na het eind­
examen werd hij uitgesloten van deelnam e aan de studie geneeskunde als gevolg van 
een ongunstige loting bij de num erus fixus. In dit jaar werd de propedeuse scheikunde 
gehaald aan de Radboud Universiteit N ijm egen. Na gunstige loting in het jaar daarop 
werd gestart met de studie geneeskunde waarna in 1998 met succes het doctoraal exa­
men werd gehaald aan de Radboud Universiteit N ijm egen. De interesse voor de car­
diologie was op dat mom ent reeds gewekt met als gevolg dat er een wetenschappelijke 
stage werd verricht onder begeleiding van professor dr. T. van der W erf over de polikli­
nische behandeling van atrium fibrilleren. Tijdens deze stage ontmoette hij professor 
dr. F.W.A. Verheugt en dr. M.A. Brouwer die zijn interesse voor de cardiologie en de 
wetenschap verder aanwakkerden. Na het behalen van het arts examen in 2001 werd 
ervaring op gedaan als arts assistent cardiologie niet in opleiding, eerst in het Canisius 
W ilhelm ina Ziekenhuis in Nijm egen onderbegeleiding van dr. A.J.M O ude O phu is en 
dr. T .E .H . Hooghoudt en later aan de Radboud universiteit onder de hoede van profes­
sor dr. F.W.A. Verheugt. Hoewel hij in 2003 werd aangenomen voor de opleiding tot 
cardioloog koos hij ervoor, gezien de eerder beschreven wetenschappelijke interesse, 
zijn carrière te starten met promotie onderzoek. Initieel als één van de arts onderzoe­
kers van de Holland Infarction Study onder de leiding van professor dr. F.W.H.M Bär uit 
het academ isch ziekenhuis Maastricht, later werd het promotie traject vervolgd onder 
de hoede van professor dr. F.W.A. Verheugt. O p 1 oktober 2007 begon de opleiding tot 
cardioloog met de vooropleiding interne geneeskunde in het Jeroen Bosch Ziekenhuis 
in Den Bosch (opleider:dr. P.M. Netten). Inm iddels wordt sinds 1 januari 2010 met veel 
plezier de B-opleiding cardiologie gevolgd in het Rijnstate ziekenhuis in Arnhem  (O p­
leider: dr. H .A. Bosker). O p 1 januari 2013 hoopt hij zich te registreren als cardioloog.
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